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Abstract 
 
During a drug’s lifecycle, evidence must demonstrate that the benefits of the 
product continue to outweigh the risks. Benefit-risk (B-R) assessment is a vital 
stage of the drug approval process and is an important task for regulators. 
Involving patients in B-R assessment is a recent development. Patients may 
view benefits and risks very differently when compared with the views of 
pharmaceutical companies or regulatory assessors.  The aim of this research 
was to investigate this topic to ultimately propose a framework for involving 
patients in this process. The research strategy involved three phases. In phase 
I, a survey was submitted to (1) pharmaceutical companies and regulatory 
agencies and (2) patient advocacy groups across Europe, to obtain their 
opinions on involving patients in B-R assessment. Phase I of the research 
identified several challenges, including: how to ensure adequate 
representation of patients and a lack of an established method. It was also 
identified that to date, only patient advocacy groups were directly involved in 
B-R assessment discussions. However, some companies were developing 
initiatives to involve patients. Based on these findings, phase II was 
implemented, where individuals from regulatory agencies, pharmaceutical 
companies and patient advocacy groups participated in semi-structured 
interviews to identify themes around patient involvement and to establish rich 
data around the current challenges. This data was used to inform the 
development of a novel framework, one element of which was tested in phase 
III of the research; where qualitative focus groups were conducted with 
patients. The framework proposed from this research, therefore, involves 
qualitative focus groups, enabling patients to provide insight into their disease 
and treatment. The information obtained, when presented alongside 
quantitative preference elicitation data, may then be used to contribute to B-R 
discussions by regulators, to ultimately support their decision-making. 
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Glossary of terms and abbreviations 
 
Adverse Event (AE) 
Any untoward medical occurrence in a patient or clinical trial subject 
administered a medicinal product, which does not necessarily have a causal 
relationship with this treatment (Directive 2001/20/EC) 
 
Adverse Drug Reaction (ADR) 
All untoward and unintended responses to a medicinal product at any dose 
administered (Directive 2001/20/EC). 
 
Benefit 
In the context of this thesis, defined as ‘something that promotes wellbeing’ or 
‘a potential favourable effect of a drug on the current state of health’ (Mussen, 
Salek and Walker, 2009). 
 
Benefit-risk (B-R) assessment 
The assessment made after understanding the various benefits of a treatment 
and comparing them against the associated safety issues (Sashegyi, Felli and 
Noel, 2014). 
 
Benefit-risk balance 
A comparison of the benefits of a treatment against the associated safety 
issues (Sashegyi, Felli and Noel, 2014). 
 
Benefit-Risk Action Team (BRAT)  
‘BRAT standardises and supports the decision and communication of a BR 
assessment between pharmaceutical companies and the regulators through a 
6-step process: define decision context, identify outcomes, identify data 
sources, customise framework, assess outcome importance, and display and 
interpret key BR metrics’ (Noel et al., 2012; IMI PROTECT, 2018).  
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Decision-making 
In the context of this thesis, ‘decision-making’ refers to decisions made by 
regulatory agencies which ‘pertains to the approval of new medicines’ 
(Mussen, Salek and Walker, 2009). 
 
European Medicines Agency (EMA) 
‘A decentralised agency of the European Union (EU), located in London, and 
soon to move to Amsterdam once the UK leaves the EU. It began operating in 
1995. The Agency is responsible for the scientific evaluation, supervision and 
safety monitoring of medicines in the EU’ (EMA, 2018). 
 
European Union (EU) 
‘A political and economic union of twenty-eight Member States; located 
primarily in Europe’ (EU, 2018).  
 
European Patients’ Academy on Therapeutic Innovation (EUPATI) 
An EU funded initiative which ‘aimed to trigger a major rethink in the way 
patients and the public understand the medicines development process and 
their own involvement therein’ (EUPATI, 2018). 
 
Food and Drug Administration (FDA) 
The United States agency responsible for ‘protecting the public health by 
ensuring the safety, efficacy, and security of human and veterinary drugs, 
biological products, and medical devices; and by ensuring the safety of our 
nation's food supply, cosmetics, and products that emit radiation’ (FDA, 2018). 
 
Good Clinical Practice (GCP) 
‘An international ethical and scientific quality standard for designing, 
conducting, recording and reporting clinical trials that involve the 
participation of human subjects’ (EMA, 2002, p. 7) 
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Guy’s and St Thomas’ NHS Foundation Trust (GSTT) 
A South London National Health Service Trust composed of Guy’s Hospital at 
London Bridge and St Thomas’ Hospital, Westminster, where this research was 
undertaken. 
 
IMI Pharmacoepidemiological Research on Outcomes of Therapeutics by 
a European Consortium (IMI PROTECT) 
‘A collaborative European project that comprises a programme to address 
limitations of current methods in the field of pharmacoepidemiology and 
pharmacovigilance’ coordinated by the EMA and GlaxoSmithKline (GSK) (IMI 
PROTECT, 2018a).  
 
INVOLVE 
Established in 1996 and funded by, the National Institute for Health Research, 
‘INVOLVE is an initiative to support active public involvement in NHS, public 
health and social care research. It is one of the few government funded 
programmes of its kind in the world’ (INVOLVE, 2018). 
 
Medicines and Healthcare products Regulatory Agency (MHRA) 
An executive agency of the UK Department of Health ‘responsible for ensuring 
that medicines and medical devices work and are acceptably safe’ (MHRA, 
2012) and the UK Competent Authority for oversight of clinical trials that fall 
within the scope of The Medicines for Human Use (Clinical Trials) Regulations 
2004 and amendments.  
 
National Health Service (NHS) 
The UK public sector health care service, free at the point of care and funded 
by national insurance and taxes. 
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Patient and Public Involvement (PPI) 
In the context of this thesis, PPI refers to the involvement of lay people in 
benefit-risk assessment. Their involvement is active participation; being 
carried out ‘with’ or ‘by’ members of the public rather than ‘to,’ ‘about’ or ‘for’ 
them’ (INVOLVE, 2018). 
 
Patient Reported Outcome Measures (PROMs) 
‘A set of standardised measures used to capture patient reported outcomes, 
including symptom status, physical function, mental health, social function, 
and wellbeing’ (Nelson, et al., 2015). 
 
Pharmacovigilance 
‘The science and activities relating to the detection, assessment, 
understanding and prevention of adverse effects or any other possible drug-
related problems’ (WHO, 2018). 
 
PREFER 
‘PREFER will establish recommendations to support development of 
guidelines for industry, Regulatory Authorities and HTA bodies on how and 
when to include patient perspectives on benefits and risks of medicinal 
products’ (PREFER, 2018). 
 
PrOACT-URL Framework 
PrOACT-URL is the EMA’s generic decision-making guide with eight steps: 
Problems, Objectives, Alternatives, Consequences, Trade-offs, Uncertainty, 
Risk attitudes, and Linked decisions. the EMA’s Benefit-Risk Project adapted 
PrOACT-URL is focussed on the decision-making of medicines (IMI PROTECT, 
2018b). 
 
Qualitative research 
‘An approach for exploring and understanding the meaning individuals or 
groups ascribe to a social or human problem. The process of research involves 
emerging questions and procedures, data typically collected in the 
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participant’s setting, data analysis inductively building from particulars to 
general themes, and the researcher making interpretations of the meaning of 
the data’ (Creswell, 2014).  
 
Quantitative research 
‘An approach for testing objective theories by examining the relationship 
among variables. These variables can be measured, typically on instruments, 
so that numbered data can be analysed using statistical procedures’ (Creswell, 
2014).  
 
Research Ethics Committee (REC) 
An independent committee comprised of medical professionals and lay 
members who must ensure the protection of the rights, safety and well-being 
of human subjects by reviewing and providing favourable ethical opinion on a 
proposed trial, often called ‘REC approval’ (Directive 2001/20/EC). 
 
Research and Development (R&D) 
The department within a National Health Service hospital responsible for 
reviewing all research projects to be conducted within the organisation and 
ultimately giving research management approval; often called ‘R&D approval’. 
 
Risk 
In the context of this thesis, the ‘possibility of loss or injury, peril’ (Mussen, 
Salek and Walker, 2009). 
 
Semi-quantitative research 
This term, used regularly by regulatory agencies and pharmaceutical 
companies, refers to a ‘mixed-methods’ approach. ‘This approach to inquiry 
involves collecting both quantitative and qualitative data, integrating the two 
forms of data, and using distinct designs that may involve philosophical 
assumptions and theoretical frameworks’ (Creswell, 2014).  
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Introduction 
 
When considering those personnel involved in developing novel drugs and 
compounds, a list of stakeholders comes to mind. They include pharmaceutical 
companies, who develop and manufacture the molecule. These companies 
invest large amounts of money to enable the product to reach a level of 
development suitable to move to testing; in clinical trials. There are clinical 
teams of doctors, nurses, trial managers and study coordinators, undertaking 
clinical trials within hospitals and clinical research organisations. In addition, 
there are the regulatory agencies, responsible for assessing the drug’s efficacy 
and safety based on clinical trial data often collected over many years, both 
before and after licensing. One of the most important stakeholders, however, 
may be considered last when considering regulatory drug development: i.e., 
the patient. Of course, all stakeholders would agree that ‘patients come first, 
ahead of science and society’ (ICH GCP, 1996, p. 15). Patients’ rights, safety and 
well-being are paramount under the international standard of ICH Good 
Clinical Practice, to which all clinical trials must adhere to.  It goes without 
saying that, clinical researchers, pharmaceutical companies and regulatory 
agencies, inevitably prioritise patients when a clinical trial of a new compound 
is set-up and developed.  
 
Even so, apart from those examples where patient reported outcome measures 
(PROMs) are incorporated into a clinical trial protocol, how often are patients 
asked exactly what they think of the study they are taking part in? Are they 
questioned about the drug they are taking, in the context of what it actually 
means to them on a personal level? They will have undoubtedly been 
questioned about the most obvious effects on their daily living, since taking the 
drug, as well as any side effects they may have experienced. To reiterate the 
point, this matter is not merely about patient safety or the list of adverse 
events a patient may or may not have experienced over the previous month. It 
is argued that the general questions asked of patients participating in clinical 
trials do not adequately take into consideration what patients actually think 
about the trial, or their treatment. 
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As patient and public involvement becomes central to policy development 
across a range of industries, the general trend is that it is now time to include 
patients in all aspects of a clinical trial.  This encompasses trial design through 
to the conduct and subsequent data analysis and hopefully, if the study is 
positive, drug licencing. Surely, in today’s world of democratic devolution it is 
essential that patients are also included in regulatory decision-making 
regarding new drugs. It would be predictably advantageous that patients 
should have a voice on this topic and as such, they should contribute to 
decisions on drug licensing.  
 
Nevertheless, how do we know that including patients in this vital process will 
enhance an already clearly defined and robust process? Can we be sure that 
patients are not being exposed to greater risk by involving those patients who 
may lack the experience and understanding necessary in essential decision-
making? These are questions that must be posed, and it is for these reasons 
that further research into the topic of patient inclusion in benefit-risk 
assessment is essential. The crucial question is, however, should patients be 
involved in this process at all?  
 
It is clear that involving patients directly in benefit-risk assessment during 
drug development is becoming increasingly important. It has been widely 
recognised that patients may view benefits and risks differently when 
compared with the views of pharmaceutical company representatives or 
regulatory assessors (Mussen, Salek and Walker, 2009). Several regulators and 
pharmaceutical companies have already implemented strategies to engage 
patients directly in their benefit-risk assessment activities, including the Food 
and Drug Administration in the US and the European Medicines Agency (FDA, 
2013; EMA, 2014). The involvement of patient advocacy groups and patient 
representatives has also been shown to be valuable not only in benefit-risk 
considerations, especially from the standpoint of risk tolerability, but it has 
also aided the decision-making process (Bernabe et al., 2014).  
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The inclusion of patients has particular relevance to the risk management plan 
of a clinical study, which is an important requirement of the new Clinical Trials 
Regulation (EU) No 536/2014 (European Commission, 2014). Indeed, the level 
of risk that an individual is willing to accept may be higher or lower than 
anticipated, depending on the degree of benefit delivered by their medication. 
This information may inevitably have a useful impact throughout the pre-
authorisation phases of clinical development and it is also important 
subsequent to the drug’s authorisation, during post-marketing surveillance.  
 
The question now is not whether patients should be involved, as this is 
unequivocal, but how they can be incorporated into a benefit-risk assessment 
framework. Several potential methods have been considered and investigated 
by the IMI PROTECT consortium (IMI PROTECT, 2015) although a validated 
method for including patients has not yet been forthcoming. 
 
Quantitative benefit-risk preference-elicitation methods include discrete 
choice experiments, rating scales, threshold technique, standard gamble and 
conjoint-analysis (Hauber et al. 2013; Hiligsman et al., 2014). In the context of 
benefit-risk assessment, these methods could be greatly enhanced when 
combined with a qualitative element, which would be essential in allowing 
patients the opportunity to communicate what is most important to them. This 
tactic can generate significantly richer data than a quantitative approach 
alone. Some participation has already occurred, via patient advocacy groups, 
whom, in collaboration with pharmaceutical companies and academia have 
completed several benefit-risk preference studies (Wolka, et al., 2017).   
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One proposed ‘semi-quantitative’ methodology would be to undertake 
qualitative focus groups enabling patients to provide insight into their disease 
and treatment. The information obtained, when presented alongside 
quantitative preference elicitation study data, may then be used to contribute 
to B-R discussions by regulators, to ultimately support their decision-making. 
Any method developed would need to be appraised by key stakeholders 
involved in benefit-risk assessment, including regulators and pharmaceutical 
companies, to ensure it is fit for purpose. Patient representatives and patient 
advocacy groups would need to be consulted to confirm that the method 
proposed was pragmatic and retained patient acceptability. Several challenges 
would need to be overcome during this process.  
 
Thus, patient identification and selection must be considered to verify that 
those patients to be included were drawn from a range of backgrounds. In 
addition, demographic characteristics, disease severity and prognosis would 
all need to be taken into account, so that the patient groups were as 
representative as possible. Although challenges remain, further research on 
this topic presents a genuine opportunity to significantly enhance the current 
regulatory framework, which ultimately has real potential to benefit patients. 
 
Study rationale 
 
It is clear from recent initiatives that patient-focused drug development will 
continue to gain in popularity and will be undoubtedly be used more widely. 
The FDA’s project aimed to address how to use the patient perspective not only 
to inform their decision-making but to also include their views in a benefit-risk 
assessment process. Mullard (2013) states that once patient opinions have 
been collected, using a variety of means (from meetings or from surveys), the 
next challenge is turning this information into a format suitable for inclusion 
in a structured and meaningful assessment framework (Mullard, 2013; FDA, 
2013b).  
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This area of research received investment over several years (2013-2017, in 
particular), however, regulatory agencies and pharmaceutical companies are 
still yet to publish a standard methodology of incorporating patients in a 
benefit-risk assessment model or framework. Therefore, this thesis addresses 
this novel area. It is known that involving patients in regulatory decision-
making could greatly improve and enhance the benefit-risk assessment 
process.  It is clear from the literature that the existing benefit-risk assessment 
models have their strengths and weaknesses. These quantitative models could 
be substantially enhanced by incorporation of a qualitative element obtained 
directly from the patients themselves.  
 
This research, accomplished over a similar time period to those projects 
completed by the regulatory agencies of the US and Europe, has produced a 
distinctive contribution to information in this area of research. It may not 
however, be the outcome the reader would initially expect. The general 
consensus published by the FDA and EMA was that patients must be 
incorporated in the B-R decision-making process. However, the current study 
has generated findings some of which may well throw doubt on this 
assumption.  
 
Research focus 
 
It is clear from the literature, which will be described and critically evaluated 
further in Chapter II, that involving patients in benefit-risk assessment 
decision-making was a current topic that required further investigation. This 
is an issue of international importance, though such a sizeable topic cannot be 
fully addressed by a single PhD thesis.  Be that as it may, this research study 
has unveiled a number of interesting findings which may possibly contribute 
to this vital topic. The study employed mixed methods; comprising 
quantitative surveys, and qualitative semi-structured interviews and focus 
groups; using a grounded theory approach to generate a novel framework. 
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The reasons for this research approach were twofold. Firstly, current opinion 
on whether or not patients should be included in benefit-risk assessment 
decision-making was probed by surveying pharmaceutical companies, 
regulatory agencies and patient advocacy groups. This was important to not 
only identify current opinion but to also identify the actual methods already 
used to include patients in benefit-risk assessment, if any.  
 
Secondly, qualitative semi-structured interviews and focus groups were 
selected as an appropriate methodology to include patients. With reagrds to 
the framework development, a grounded theory approach was deemed most 
suitable, as it was expected that novel concepts and themes would be 
important to contribute to fulfilling the study’s aim. In order to achieve the 
overall aim, several individual research objectives were developed, which are 
summarised on Page 8. 
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Research aim and objectives 
 
The aim of this research was to propose a semi-quantitative framework for 
involving patients in the benefit-risk assessment of medicines.  
 
Specifically, the objectives of this research were to: 
 
(1) Survey pharmaceutical companies and regulatory agencies to discover the 
degree that patients were already included in benefit-risk assessment within 
their organisation. 
 
(2) Survey patient advocacy groups to discover their current knowledge on the 
topic of regulatory benefit-risk assessment of medicines. 
 
(3) Using qualitative semi-structured interviews, establish the opinions of 
representatives from pharmaceutical companies, regulatory agencies and 
patient advocacy groups, by undertaking thematic analysis of their views and 
opinions.  
 
(4) Using focus groups to disclose the views of patients, identify the patient’s 
perspective; to include an insight into their condition and their opinions on 
patient involvement in benefit-risk assessment discussions. 
 
(5) Using a Grounded Theory (GT) approach, describe, analyse and synthesise 
these data and ultimately propose a semi-quantitative framework for 
involving patients in the benefit-risk assessment of medicines. 
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The study was important to highlight issues related to patient involvement in 
B-R assessment, already described in Chapter I, and this is an important topic 
globally. By investigating these objectives, it was anticipated that best practice 
might one day be developed. This would support the ultimate aim that any 
novel framework could subsequently be communicated to regulators and 
pharmaceutical companies. Accordingly, this had the potential to improve 
current processes around involving patients in B-R assessment.  
 
In Chapter II (Review of Literature), an analysis is presented of the previous 
projects and studies undertaken within this field. Several international 
projects, described subsequently, have contributed to knowledge within this 
topic area. They also investigated a number of key challenges around the 
involvement of patients in B-R assessment. This was essential to understand 
during the study design phase, as these challenges would inevitably impact 
this programme of PhD research. 
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Chapter II: Review of literature 
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Introduction 
 
This Review of Literature introduces the following topics: B-R assessment as a 
general topic, the various stakeholders involved, science communication to lay 
audiences (which also considers risk communication and risk perception) and 
patient and public involvement in research. The concept of the ‘expert patient’ 
will be fully investigated and a detailed analysis of patient involvement in B-R 
assessment will be reported. Finally, several international projects currently 
in progress will be presented, all of which have contributed to the topic of 
patient involvement in B-R assessment. 
 
Benefit-risk assessment of medicines 
 
Before a new medicine is approved for marketing, and throughout the 
medicinal product’s lifecycle, both before and after licensing, data must be 
available to demonstrate the safety and efficacy of the drug. A detailed 
assessment is completed using all available pre-clinical and clinical data; to 
ensure the benefits of the product are carefully balanced against the risks. B-R 
assessment is a pivotal stage of the drug approval process and is integral to the 
activities of regulatory agencies (ICH, 2012). ‘The assessment of the benefit-
risk in the context of a new drug application is a central element of the 
scientific assessment of a marketing authorisation’ (EMA, 2007, p. 2).  B-R 
assessment has even been transposed into law. As an example, in Europe, 
Article 26 of Directive 2001/83 as amended states that ‘a marketing 
authorisation shall be refused if the benefit-risk balance is not considered to 
be favourable or if therapeutic efficacy is insufficiently substantiated’ (EMA, 
2007, p. 3).  An example that demonstrates the complexity of B-R analysis is 
the treatment of severe combined immunodeficiency (SCID) using gene 
therapy. SCID is a genetic condition where patients are unable to produce 
certain immune cells, consequently, they are at extreme risk of infection. 
Unfortunately, this group of patients do not often survive longer than a few 
years from birth.  
 
 
- 12 - 
The condition has previously been termed ‘the boy in the bubble’ as one 
patient became famous in the media for having to remain in a sterile 
environment in order to prevent infection (Hacein-Bey-Abina et al., 2008).  
Several Phase I clinical trials have been completed to date on a small group of 
patients in London and Paris. However, there was a high incidence of adverse 
events that were later defined as suspected unexpected serious adverse 
reactions (SUSARs). The SUSARs that occurred in four patients involved 
‘insertional oncogenesis,’ the incorporation of a cancer-causing gene resulting 
in leukaemia (Hacein-Bey-Abina et al., 2008).   
 
Based on this information alone, it would be fair to assume that the risk is too 
great and the treatment should no longer be used. Notwithstanding this, the 
leukaemia was treatable using chemotherapy and after treatment three of the 
patients continued to ‘benefit from the gene transfer’ although one patient 
died (Hacein-Bey-Abina et al., 2008). The risks of the gene therapy were 
worthwhile in the majority of cases as the patients survived, whereas without 
the treatment they would have died. Three of the four patients were cured of 
their genetic condition and continue to do well. However, in the absence of 
long-term safety data risks still remain.  
 
Although this research was undertaken for clinical care and there was no 
intention to submit a marketing authorisation, it is still useful in 
demonstrating the challenges faced by regulators and pharmaceutical 
companies when assessing treatments for benefit-risk; as it not always 
straight-forward. As with many orphan drugs and rare treatments, the B-R 
balance after reviewing all of this information is perhaps obvious. On the other 
hand, the benefit-risk balance of the majority of treatments is often not so easy 
to determine.  
 
The benefit-risk assessment process has been an area of focus in recent years 
and is a field that is changing rapidly. The Council for International 
Organisations of Medical Sciences (CIOMS) publicly highlighted the issue in 
1998 when they released the following statement:  
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‘It is a frustrating aspect of benefit-risk evaluation that there is no defined and 
tested algorithm or summary metric that combines benefit and risk data and 
that might permit straightforward quantitative comparisons of different 
treatment options, which in turn might aid in decision-making’ (CIOMS, 1998, 
p. 13).  
 
In response to this, the regulatory agencies of the US, Europe and Japan, who 
had only up to that juncture issued a list of benefit-risk criteria, recognised that 
guidance on the various methods for benefit-risk analysis was urgently 
required, yet it was several years before further literature was published on 
the subject (EMA, 2007). The Committee for Medicinal Products for Human 
Use (CHMP) at the European Medicines Agency undertook an audit in 2004 
examining exactly how the agency completed benefit-risk analysis. The group 
appraised the currently available models of benefit-risk assessment, which 
they confirmed could be placed into two groups: ‘models used for individual 
clinical trials, and general models’ (EMA, 2007, p. 3).  
 
Models for benefit-risk assessment 
 
Quantitative models 
There are a number of different quantitative models used for benefit-risk 
analysis. Data from clinical trials are analysed and a decision is made based on 
the outcome. One popular model used for individual clinical trials is the 
‘Number Needed to Treat/Number Needed to Harm (NNT/NNH)’ (EMA, 2007, 
p. 3). The NNT is the number of patients who need to be treated to obtain a 
benefit (defined as ‘preventing one additional adverse outcome’) whereas 
‘NNH is the number of patients needed to be treated to identify one adverse 
treatment related outcome’ (EMA, 2007, p. 3). Although this model is simple to 
use, the CHMP report states that ‘the method has essentially been adapted for 
one clinical trial with binary endpoints. It is unclear how it would account for 
multiple benefit-risk variables and multiple adverse events of different 
seriousness’ (EMA, 2007, p. 4).  
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The general models include ‘the Principle of three’ and the ‘Transparent 
Uniform Risk Benefit Overview (TURBO)’ models. The benefit-risk assessment 
at the time of licensing a novel drug is almost always based on data from a 
limited number of patients and therefore the benefit-risk assessment process 
is continuous and ongoing (ICH, 2012). ‘In assessing the altered benefit/risk 
ratio of drugs which appear to be causing clinical toxicity, spontaneous 
reporting schemes, such as the Yellow Card System in the UK, play a crucial 
part’ (Mann, 2007, p. 705). As accumulating data is collected post-marketing, 
the status of a drug’s marketing authorisation may change depending on the 
acquisition of additional safety data, to ensure that the benefits continue to 
outweigh the risks. These general models were therefore developed for the 
reassessment of marketed medicines in the event that new safety issues arise 
(EMA, 2007).  
 
The ‘principle of three’ is a model ‘based around the concept of seriousness, 
duration, and incidence as related to disease indication’ (EMA, 2007, p. 4).  A 
grading system is used with each parameter being rated as low, medium or 
high. This method is based on ‘visible weighting of the scores for the level of 
improvement produced by the medicine against the scores for the adverse 
effects criteria’ (EMA, 2007, p. 4). The TURBO model conversely, is a 
‘quantitative and graphical approach to benefit-risk analysis’ (EMA, 2007, p. 
4). The model ‘tries to quantify the benefit and risks of a medicine in a given 
indication and then both factors are displayed in a TURBO diagram’ (EMA, 
2007, p. 4).  
 
There are several limitations to both these types of general model, in that many 
of the criteria used are not well defined. In addition, the scores that are used 
in the analysis are also not defined in comparison to the criteria; opening them 
up to subjective differences when different assessors undertake the 
assessment. Both models were developed for medicines that had already been 
marketed and had not been validated for the B-R analysis of novel medicines 
(EMA, 2007).  
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The multi criteria decision analysis (MCDA) model ‘uses an algorithm that 
combines value judgements along multiple dimensions’ (EMA, 2007, p. 4). 
‘Decision-analysis’ is widely used throughout the world of business as well as 
within various government departments. This decision-making is used in 
areas such as managing R&D programmes, for new product launches, or 
responding to environmental risks (EMA, 2007, p. 4).  This MCDA model 
involves developing a list of relevant benefit and risk criteria that can then be 
used for determining a benefit-risk profile. These criteria are then organised 
depending on their importance in the overall decision (termed ‘weighting’). 
Each criterion can be scored, weighted and then a calculation can be 
undertaken using computer software (EMA, 2007, p. 5). This model has been 
accepted by a number of organisations as best practice.  
 
This particular quantitative model is useful in that it can be used to evaluate 
benefit-risk between different treatment arms, against placebo or an active 
control as it uses numerical values and scoring to make the decisions. On the 
other hand, ‘there is a danger that decision over relies on the numerical 
outcome analysis of the model’ (EMA, 2007, p. 5). In addition, developing this 
model for a single drug is time consuming due to the list of criteria that need 
to be developed. However, it does allow for the subjective discussion between 
clinicians who act as assessors; which can be a useful training tool (EMA, 2007, 
p. 5).  
 
In their book, ‘Benefit-Risk Appraisal of Medicines, A systematic approach to 
decision-making’ published in 2009, Mussen, Salek and Walker presented a 
detailed case for the reasons why a standardised model for benefit-risk 
assessment of medicines is required. Previously there was no standardised 
model for such an assessment and therefore regulatory agencies and industry 
conducted the benefit-risk assessment process using a variety of models as 
described previously (Mussen, Salek and Walker, 2007a, 2007b).  
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By developing a standardised framework, it was hoped that a more 
reproducible system could be implemented, which would may one day become 
the industry standard. This quantitative model, based around multi-criteria 
decision analysis, was devised and validated by the authors. The development 
of this model was lengthy and time-consuming, involving several years of 
work. It was essential that the authors collaborated with all relevant 
stakeholders involved in benefit-risk assessment, to ensure that the 
requirements of each stakeholder were considered and integrated into their 
model. The authors described how newer models not based around MCDA had 
also been published in recent years, although it was clear that they had similar 
weaknesses to those described previously, since they were often based on the 
general models (Mussen, Salek and Walker, 2009). 
 
Qualitative models 
Qualitative models are created around the concept that experts make 
decisions based mostly on their experience and after a thorough review of 
data. They often use ‘gut feeling’ to make decisions, and this is obviously 
difficult to replicate. ‘The current process of benefit-risk assessment of 
medicines relies primality on intuitive expert judgement’ (Coplan et al., 2011, 
p. 312). The literature shows that regulators still rely heavily on qualitative 
decision-making, centred on a review of data. Regulators agree that there is a 
great deal of work to be done with regards to standardising benefit-risk 
analysis. In addition to the work undertaken by the CHMP in Europe, the 
United States Food and Drug Administration (FDA) are also working on this 
issue and are in fact leading the way at the present time. In their recent 
publication ‘Structured Approach to Benefit-Risk Assessment in Drug 
Regulatory Decision-Making’ (FDA, 2013) they outline their case for a 
complete review of their current systems and processes. Once fully qualitative, 
the authors stated that ‘in the past, some FDA stakeholders have indicated that 
there is room for improvement in the clarity and transparency of FDA’s 
benefit-risk assessment in human drug review (FDA, 2013). Consequently, the 
FDA accepted that work was needed to develop processes internally, and this 
review was completed by 2017.  
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Semi-quantitative models 
The fact that several different models exist, some adopting a quantitative 
approach only and others fully qualitative, divulged from the literature that 
that a standardised method for B-R assessment was required. In spite of this, 
regulators and pharmaceutical companies did not formally follow a universal 
procedure. Thus, by implementing a semi-quantitative approach, it would be 
possible to utilise the strengths of both type of assessment; established upon 
expert decisions concerning a quantitative analysis of the clinical trial data. 
Nowadays, a semi-quantitative approach emerges more often in the literature, 
indicating it is the preferred method by most. The need for a universal B-R 
framework has been well described by a number of research groups. Mussen, 
Salek and Walker (2009) stressed this need and several papers also discuss 
the concept as a whole (Coplan et al., 2011; Brass, Lofstedt and Renn, 2011; 
Colopy et al., 2015).  
 
Coplan et al. (2011, p. 312) described the need to development a framework 
which ‘enhances transparency, reproducibility and communication of the 
benefit-risk balance of medicines.’ In reality, this has been a common theme 
throughout the literature. Without a universal framework, how are companies 
able to understand how regulators assess B-R? This is a difference in 
perspective compared to the actual model implemented, but these elements 
are equally important. This highlights the difficulty of implementing a 
universal process as there are multiple elements to consider.  
 
Although the FDA publish documentation related to their decision-making 
online, they also point out that ‘while the FDA takes great care to clearly 
explain the reasoning behind a regulatory decision in these documents, the 
clinical analysis may not always be readily understood by a broad audience 
who may wish to understand FDA’s thinking’ (FDA, 2013, p. 1).  This is because 
their previous methods essentially followed a qualitative approach, heavily 
reliant on expert judgement and it was difficult to reproduce.  
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The authors also describe how many stakeholders have also highlighted the 
need for ‘regulatory decisions to be based more on a formalised and 
quantitative approach to benefit-risk assessment, including the assignment of 
weights to benefit and risk considerations’ (FDA, 2013, p. 1). This is interesting 
as it is this type of approach that has been proposed by Mussen, Salek and 
Walker in their book (2009). The FDA began to develop their own framework 
in 2012. The initial project aimed to identify relevant stakeholders. They also 
piloted the new framework, including the use of MCDA, alongside their current 
processes in order to compare the outcomes. This project was part of a long-
term strategy commenced in 2013 and completed in 2017.  
 
BRAT framework 
Around 2009 it appeared that a standardised approach was finally going to be 
accepted by regulatory agencies and industry. Those in the industry eventually 
became dissatisfied with this lack of established best practice. Several 
organisations collaborated to set up the ‘Benefit-risk Action Team’ to address 
the problem, and together they eventually developed the ‘BRAT framework.’ 
Through the development of a 6-step process, BRAT aimed to standardise the 
decision-making and communication surrounding benefit-risk assessments. 
The 6-stages developed were: define decision context, identify outcomes, 
identify data sources, customise framework, assess outcome importance, and 
display and interpret key BR metrics (IMI PROTECT, 2018). The development 
of this semi-quantitative framework was a step forward in the ultimate goal of 
developing a standardised approach to B-R assessment. Levitan et al. (2014) 
described how the use of this framework could be greatly enhanced by inviting 
patients into B-R discussions. 
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PrOACT-URL framework 
Zafiropoulos et al., (2012) expanded work in this area and they eventually 
developed the PrOACT-URL framework. PrOACT-URL is now the EMA’s 
generic decision-making guide with eight designated steps. The steps are: 
Problems, Objectives, Alternatives, Consequences, Trade-offs, Uncertainty, 
Risk attitudes, and Linked decisions. The framework covers the important 
aspects for structuring a decision-making problem. The framework itself is 
generic and can be applied to any decision-making problem, but the EMA’s 
Benefit-Risk Project adapted PrOACT-URL is focussed on the decision-making 
of medicines (IMI PROTECT, 2018b).  
 
However, even with the development of process at the regulatory agency level, 
recent publications (Wolka et al., 2016; Smith et al., 2017) suggest that some 
companies have still decided to take a different route with regards to the 
processes they implement. Wolka et al. (2016) described a process which was 
implemented within Eli Lilly, which involved submitting B-R documentation 
as part of marketing authorisations. Whereas Smith et al. (2017), from Amgen, 
describe their methodology for B-R across the product lifecycle.  
 
It is a positive development that companies are publishing these methods and 
adding to the literature, however, it is still evidence of a lack of a universal 
framework which all regulators and pharmaceutical companies adhere to. This 
is substantiated by the fact that companies still implement their own 
methodologies, even with standard processes being developed by regulators. 
Although there has been progression and clear developments, there is still 
work to do.  
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Stakeholders involved in benefit-risk assessment  
 
The stakeholders involved in benefit-risk analysis include pharmaceutical 
companies, regulatory agencies as well as healthcare professionals such as 
prescribers (Mussen, Salek and Walker, 2009, p. 6). One key area that is 
addressed by Mussen, Salek and Walker (2009) is the different perspectives of 
professionals involved in benefit-risk analysis (2009, p. 6-8). Stakeholders 
have both diverse viewpoints and various priorities depending on the nature 
of their work. ‘Since benefit-risk assessment is essentially a value judgement, 
it will inevitably be prone to a number of biases’ (Mussen, Salek and Walker, 
2009, p. 8).  These biases are informed by the nature of the work of the 
individual making the assessment. In addition, different individuals may give 
different views at different times, even when presented with the same data; 
which demonstrates the subjective nature of the assessment process (Mussen, 
Salek and Walker, 2009, p. 8).   
 
McAuslane et al. (2017) describe how the Centre for Innovation in Regulatory 
Science (CIRS) evaluated the models used for the B-R assessment of medicines. 
This work involved evaluating current practice and included a programme of 
workshops; ‘bringing together members of the pharmaceutical industry, 
regulators, academia, patients, and other stakeholders as well as supervising 
doctoral research and surveying stakeholders’ (McAuslane et al., 2017, p. 635). 
 
Pharmaceutical companies 
The primary objective of pharmaceutical companies is to demonstrate 
sufficient efficacy of a product to receive regulatory approval. In addition, the 
company would hope that healthcare professionals prescribe the medicine 
(Mussen, Salek and Walker, 2009, p. 7). A particular company may accept a risk 
depending on how likely that risk will affect the chance of the product 
receiving a licence. They also consider the possibility of legal liability in the 
event of serious adverse events (Mussen, Salek and Walker, 2009, p. 7).   
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Regulatory agencies 
Regulatory agencies take a population approach when assessing benefits and 
risks, in that they view the nation as a whole rather than focussing on 
individuals (Spilker, 1994; Cromie, 1997). They require evidence for an 
established and favourable safety profile. They will also consider the cost of a 
treatment by comparing it to treatment alternatives because the 
pharmacoeconomics of medicines also influences their decision-making. 
Regulators ‘usually focus on risks more than benefits due to their 
responsibility for ensuring public health’ (Mussen, Salek and Walker, 2009, p. 
8).  
 
Healthcare professionals 
Prescribers have their own unique perspective with regards to benefits. ‘They 
assess or guess whether other doses, other medicines or a non-medicine 
treatment will enhance or reduce the degree or type of benefit obtained’ 
(Spilker, 1994, p. 53). Risks and benefits may ‘offset each other’, for example a 
small risk may be cancelled out by an even greater benefit. In fact, sometimes 
risks ‘are given greater emphasis by prescribers when compared to the risks 
of the disease being treated’ (Mussen, Salek and Walker, 2009, p. 8). In some 
cases, prescribers may focus on benefits or risks depending on research data 
they have reviewed. This is often ‘strongly influenced by the way data is 
presented in scientific journals and advertisements’ (Skolbekkan, 1998, p. 
1958). 
 
Patient advocacy groups 
As the need to involve patients in B-R assessment was recognised, methods for 
including patients within company and regulatory processes were developed. 
One of the biggest challenges faced by pharmaceutical companies and 
regulatory agencies is accessing patients directly. There are of course the 
logistical challenges of meeting patients face-to-face but there are also ethical 
considerations too. Therefore, one successful method of linking in with 
patients has been for companies and regulatory agencies to collaborate with 
patient advocacy groups (IMI PROTECT, 2018). Often, these groups are 
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managed and run by patients themselves, but they may also be volunteers or 
healthcare professionals who work closely with the patient group of interest.  
Patient advocacy groups therefore act as a useful gatekeeper for 
pharmaceutical companies and regulatory agencies to gain direct access to 
patients. As such, their involvement in B-R assessment has become popular in 
recent years (IMI PROTECT, 2018).  
 
Patients 
In general, ‘regulators tend to view patients as incompetent to judge risks and 
benefits,’ (Mussen, Salek and Walker, 2009, p. 8). However, times are changing. 
Patient-Public Involvement (PPI) has become increasingly important in recent 
years. As patients become more informed, due to increased access to 
information such as via the internet, their well-informed opinions are 
increasingly important. The National Institute of Health Research (NIHR) 
explain that PPI leads to higher-quality, patient-focussed research which 
speeds up the transfer of evidence into clinical practice (NIHR, 2013, p. 4).   
 
Patients and the public can participate in research in a number of ways. Most 
often, their participation involves working with researchers, clinicians, 
research managers and health economists. Patients are now often involved in 
‘setting research priorities, identifying research questions, influencing 
research design, assessing protocols, being active partners in the research 
process itself, ensuring results are published and speaking about the value of 
research’ (NIHR, 2013, p. 4). Although patients are now involved in many 
different aspects of research design and management, this PhD thesis focuses 
on the involvement of patients in benefit-risk assessment. 
 
Different perspectives 
One key aspect of clearly defining the stakeholders involved in B-R assessment 
is the variety of perspectives that these stakeholders will ultimately exhibit. 
This is the reasoning why involving patients in B-R assessment is key, mainly 
because they will view benefits and risks differently to the views of 
pharmaceutical companies and regulatory assessors.  
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Arnardottir et al., (2012) explored this very question and revealed that 
patients would be willing to accept greater risks when compared to the 
opinions of healthcare professionals.  This was also verified later when it was 
highlighted that ‘regulators may value major benefits and risks of drugs for an 
individual patient mostly in the same way as doctors and patients, but 
differences may exist regarding the value of minor or short-term drug effects’ 
(Mol et al., 2014, p. 979). These findings are evidence of why patient 
involvement is so important, as the acceptance of risk may very well determine 
the decision of a regulator who way well have been unsure of their decision. 
However, Arnardottir et al., (2012) also ascertained how risk communication 
is so important to ensure that patients fully understand what is being 
presented to them.  
 
Science communication and risk perception 
 
Science communication is now an academic discipline of its own, which 
developed from the idea that the approaches taken to present science to lay 
audiences should follow a standardised methodology. Bjornson (2004) 
described how a lack of understanding of risk is an issue. Also, the patients’ 
need for an effective treatment may in fact allow them to take risks which are 
inappropriate. Bjornson (2004) focussed on the interpretation of risk which 
can be different between individuals and the wider population. More recently, 
it was elucidated how involving patients in their risk management is an 
effective tool in reducing overall risks associated with their condition 
(Coleman and Muir, 2015). The FDA advises patients in their guidance 
documentation regarding use of medicines that they must accept certain risks 
in order to benefit from a drug.  For example, a patient may accept greater risk 
in a life-threatening disease ‘in the hope of getting the benefits of a cure or a 
longer life’ (Mussen, Salek and Walker, 2009, p. 8). In the case of a minor 
illness, a patient may only accept a limited risk of adverse events. This concept 
appears many times in the literature and is clearly a concern for stakeholders. 
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Nair et al. (2002, p. 105) also came to a similar conclusion. They found that 
‘patients and clinicians each appear to have a different understanding of what 
and how much information patients should receive about medications,’ 
including information related to drug risks. This indicates that the patient and 
clinician have different priorities; which would ultimately affect their decision-
making. However, Nair et al. (2002, p. 105) did highlight that ‘feedback from 
patients can be used to develop patient-oriented treatment information,’ 
therefore, patient involvement is a useful undertaking. What is essential, 
however, is the understanding of risk and the communication of that risk. Risk 
perception changes depending on how an idea is presented, so this is clearly 
an area of importance when involving patients in B-R assessment. 
 
Patient and public involvement (PPI) 
 
McKevitt et al. (2015, p. 3248) stated that ‘increasingly, patients are being 
repositioned as active partners in the production and maintenance of health, 
rather than as passive recipients of health care.’ It was also identified that 
‘there is now an international body of evidence to demonstrate the benefit of 
patient and public engagement in health’ (Corrie and Finch, 2015, p. 9). This 
research group emphasised that ‘shared decision-making programmes 
encourage clinicians and patients to collaboratively select a course of action 
based on both clinical evidence and the patients’ informed preferences’ (Corrie 
and Finch, 2015, p. 10).  
 
Their comments are mainly in reference to research around PPI in healthcare, 
though the latter statement in particular has specific relevance to the topic of 
patient involvement in B-R assessment. Foot et al. (2014) go further, by 
describing how caregivers and family members should also be involved, 
especially in situations where the patient may require additional support 
when making treatment decisions.  
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The UK’s National Institute of Health Research (NIHR) implemented a detailed 
strategy of patient and public involvement in research in 2013. This strategy 
contributed greatly to real change within the UK’s research environment.  
Not only did researchers gain awareness and understanding of the importance 
of PPI, but they also began the process of including patients within their 
research design. This would ultimately result in studies which are more 
appealing to patients and increase patient recruitment and retention. This 
strategy included development of the INVOLVE initiative. ‘INVOLVE is an 
initiative to support active public involvement in NHS, public health and social 
care research. It is one of the few government funded programmes of its kind 
in the world’ (INVOLVE, 2018). 
 
However, there are also challenges with implementing PPI effectively. Gibson 
et al. (2012, p. 1) ‘identified some of the major inherent weaknesses of a 
monolithic, single-track model of patient and public involvement in the 
management and running of health and social care systems.’ A one-size-fits-all 
methodology does not work in practice, as some social groups do not involve 
themselves as much as others, whether by choice or by situation, therefore 
there is a risk that PPI is not fully representative. Williamson (2013) describes 
how some marginalised groups are often excluded from PPI initiatives. In 
addition, Komporozos et al. (2016) and Martin (2008) highlight how PPI 
initiatives can be hindered by the ‘power and knowledge differentials between 
patients and clinical professionals’ (Martin, 2008, p. 1757).   
 
There is also another risk, highlighted by the findings from the Public 
Involvement Impact Assessment Framework Study Group, who stated that 
there is a risk that some researchers may only take a tokenistic approach to 
PPI. In their paper, the group state that when PPI is undervalued, it ‘leads to 
tokenism in research practice. Tokenism fails to demonstrate value; thus, PI is 
perceived as not adding value to health and social care research’ (PiiAF, 2013, 
2014). Staniszewska (2015) may provide evidence of why a tokenism 
approach is sometimes taken. It may be down to a lack of experience or 
understanding of PPI itself.  
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It was identified that researchers need greater training and support with 
regards to how to undertake patient and public involvement initiatives 
adequately. In addition to the process itself, researchers also need assistance 
in developing the relevant competencies they need, such as ‘collaboration 
skills, listening skills, insight, empathy and an understanding of how different 
values and motivations can influence patient and public involvement in 
research’ (Staniszewska, 2015). This is a valid point and without adequate 
education there is a risk that PPI will not be implemented effectively. 
 
The concept of the ‘expert patient’ 
 
In addition to the general principles of PPI, Corrie and Finch (2015) also 
present a new concept, specified as the ‘expert patient,’ which has been 
emerging in the literature in recent years. The expert patient is defined as a 
patient who fully understands their condition and the treatments available to 
them. They often participate in initiatives to assist in educating others about 
their condition, from patients through to clinicians and other healthcare 
providers. This different perspective can be useful as it enables a deeper 
understanding of a patient’s condition, particularly with respect to how it 
affects them on a personal level.  
 
Corrie and Finch (2015, p. 20) explain that ‘while patients have traditionally 
been regarded as passive users of the NHS, patients are engaging with their 
health in different ways outside of NHS services.’ Surveys within the NHS 
‘consistently show that patients want more information about their health 
conditions and treatment options and the skills to self-manage their condition’ 
(Corrie and Finch, 2015, p. 10). Patients also now expect to be involved in their 
treatment decisions and interestingly, they are not only engaging more with 
clinicians, they are also engaging with each other. For example, in recent years 
several ‘online peer-to-peer support networks to enable patients to share their 
experiences and learn from each other’s experiences have emerged’; such as 
‘Patients Like Me’ (Corrie and Finch, 2015, p. 26). 
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Involving patients in benefit-risk assessment 
 
Involving patients in the research process is not a new concept; however, 
involving patients in the area of benefit-risk analysis is without a doubt a 
recent development. It has been identified by several parties that patients have 
a vital role to play as they can offer a different and unique point of view. This 
is because patients, who are taking medications for their various conditions, 
may view benefits and risks very differently when compared against the views 
of pharmaceutical companies or regulatory assessors.  
 
Patients tend to ‘view benefits in terms of how their symptoms improve, by 
how much and for how long’ (Mussen, Salek and Walker, 2009, p. 9). In 
addition, patients view risks with respect to their chance of having an adverse 
reaction or a lack of effect resulting in a relapse of their underlying disease 
(Mussen, Salek and Walker, 2009, p. 9). It is important to note that patients 
may sometimes ‘focus excessively on any risks to which their attention is 
drawn’ so the ‘perception of risk may therefore be different from actual risk’ 
(Mussen, Salek and Walker, 2009, p. 9).  
 
In essence, patients’ opinions are ‘often very personal, subjective value 
judgements that can only be based on religious, philosophical, and social 
values’ (Veatch, 1993). It is therefore essential that an individual is given all 
the information and not only material on the benefits or side-effects, so that 
they can make an unbiased decision. Many factors influence how a patient 
views the benefit and risks of a particular treatment. They are ‘influenced by 
the media, by healthcare professionals and by friends and family’ (Mussen, 
Salek and Walker, 2009, p. 10). This makes for a very complex picture, which 
can be unique to every individual. In addition, the way in which a patient 
makes their assessment is strongly influenced by the way in which the data is 
presented.  
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For example, if side effects have been emphasised by a healthcare professional, 
when in fact the risk is low, the patient may still be influenced negatively. 
However, even with these challenges, one key statement made by Mussen, 
Salek and Walker (2009, p. 10) is of particular importance and interest:  
 
‘Research has demonstrated that, despite the fact that lay people sometimes 
lack certain information about hazards, their basic conceptualisation of risk is 
much ‘richer’ than that of the experts and reflects legitimate concerns that are 
typically omitted from expert risk assessments.’ 
 
In their book entitled ‘Benefit-Risk Assessment in Pharmaceutical Research 
and Development,’ Sashegyi, Felli and Noel (2014, p. 39) have described the 
importance of the patient’s perspective. These authors drew attention to how 
‘the FDA and industry have inherent biases regarding drug approval 
processes. Hence, the FDA worries foremost about risk while industry focuses 
on benefit profiles.’ The authors discuss how having two ends of a spectrum is 
not an adequate tactic to the problem. Patients can be the ‘voice of reason in 
decision-making processes, tempering industry and regulatory 
predispositions to ensure progress’ (Sashegyi, Felli and Noel, 2014, p. 39). This 
is a valid approach as there are multiple places in between. They state that ‘no 
party is better able to assess a drug’s acceptable risk than those living with the 
illness the drug is designed to address’ (Sashegyi, Felli and Noel, 2014, p. 39). 
Although this is a valid opinion, it is not fair to state that only the FDA and 
industry have their intrinsic biases. It is inevitable that patients have their 
inherent biases too. The fact that several international stakeholders are now 
implementing projects to include the patient’s perspective in drug 
development and benefit-risk demonstrates it is highly topical and requires 
further research. These initiatives are described subsequently.   
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Current initiatives to involve patients in benefit-risk assessment 
 
FDA 
The FDA was one of the first regulatory agencies to include the patient’s 
perspective in their programme for developing the benefit-risk assessment 
process. They initiated a project entitled ‘Patient-Focused Drug Development’ 
in 2012, which has since been incorporated into their long-term strategy. 
 
The FDA makes it clear that patients have a unique perspective with regards 
to a drug’s benefit and risk profile and they understand how patients can offer 
valuable contributions to the drug development and subsequent review 
process. However, they recognise the need for a systematic approach of 
obtaining patient views and opinions (FDA, 2013a).  The authors describe how 
several programmes exist to facilitate patient representation in other ways, 
sometimes accessing patient advocacy groups, but the focus has not previously 
been on benefit-risk assessment.  
 
The programme, which has been published on the FDA’s web site, described 
how a series of workshops were undertaken with patients suffering from 
various diseases so they could be questioned on their condition and current 
drug therapy. The ultimate aim was to not only to gain the patient’s 
perspective on the condition and their current therapy, but to also help 
identify an unmet medical need, which could help with drug development 
programmes (Mullen, 2012).  
 
This approach was very much qualitative in nature. The workshops were 
facilitated by experts in B-R assessment in combination with patient 
representatives. The methods utilised open forums where patients, and in 
some cases, family members and carers, could all contribute to the discussion. 
The meetings were recorded and transcribed, and the transcripts are available 
for public review. Thematic Analysis was undertaken and the themes of most 
importance to patients were documented. Mullard (2013) reviews the first 
meetings of the FDA’s ‘Patient-focused drug development’ programme.  
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The FDA aimed to facilitate up to twenty meetings with patients and patient 
advocacy groups over the five-year programme. They selected a range of 
patient groups for inclusion within the programme, which are displayed in 
Table 2.1 (as listed in Box 1, page 652, Mullard, 2013). The range of conditions 
which were included is interesting as many focussed on rare diseases, which, 
the FDA, had concluded is where the patient’s perspective can be most 
valuable.  
 
It should also be noted that in some cases parents were invited to speak on 
behalf of their children who had a rare condition. For example, during the 
‘Neurological manifestations of inborn errors of metabolism’ workshop, 
parents of children with Batten’s Disease offered their contributions (FDA, 
2014a). 
 
Table 2.1: Patient-Focused Drug Development – Conditions included in 
the FDA’s programme (in order of meeting date, FDA, 2013b) 
 
Year and patient group / condition 
2013: Narcolepsy; HIV, Lung Cancer, Chronic Fatigue Syndrome 
 
2014: Sickle Cell Disease, Fibromyalgia, Pulmonary Arterial Hypertension, 
Neurological Manifestations of Inborn Errors of Metabolism, Haemophilia A 
and B, Idiopathic Pulmonary Fibrosis 
 
2015: Female Sexual Dysfunction, Breast Cancer, Chagas Disease, Functional 
GI Disorders, Parkinson’s and Huntington’s Disease, Alpha-1 Antitrypsin 
Deficiency 
 
2016: Non-tuberculous mycobacterial infections, Psoriasis, Neuropathic 
pain associated with peripheral neuropathy, patients who have received 
organ transplant, Sarcopenia, Autism, Alopecia, Hereditary Angioedema  
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The first three meetings involved patients with myalgic encephalomyelitis 
(ME) and chronic fatigue syndrome (CFS), lung cancer and HIV and the 
opportunities plus challenges associated with systematically integrating the 
patient perspective into drug reviews were emphasised (Mullard, 2013, FDA, 
2013b).  
 
One of the aims of these meetings was to inform the FDA’s benefit-risk 
framework. ‘While developing the framework, the FDA recognized [sic] that 
two key factors – analysis of the condition and current treatment options – 
required more patient input’ (Mullard, 2013, p. 652). It was clear that there 
were currently limited opportunities for patients to voice their opinions with 
regards to drug development. The FDA therefore hoped to ‘fill this gap’ and 
ultimately improve other policies throughout the agency as a result (Mullard, 
2013, p. 652). Mullard also describes how the National Health Council (NHC) 
‘participated in early discussions around the need for both the benefit-risk 
framework and the patient-focused drug development programme’ (Mullard, 
2013, p. 652; FDA, 2013b).  
 
The NHC could also appreciate the benefit of incorporating patient views in 
this context. The meetings were conducted in a manner which ‘allowed both 
patients and patient advocates to discuss their disease symptoms, treatment 
options and the side effects they endure’ (Mullard, 2013, p. 652). One 
interesting point to note was how the meetings developed differently 
depending on the indication under discussion. For example, the ME and CFS 
meeting involved detailed discussion on how pain and fatigue affect the 
patient’s lives on a daily basis, as these are possibly the major issues that this 
patient group endures. The HIV group, however, focused on their difficulties 
around drug side effects and drug-drug interactions (Mullard, 2013, p. 652; 
FDA, 2013b).  
 
This is interesting as it demonstrates how different patient groups may focus 
on very different issues when it comes to their condition and treatment, 
depending on how it affects their daily lives. Mullard recognised ‘the challenge 
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of capturing a sufficiently diverse set of patient perspectives from brief 
meetings, especially when sub-populations have different needs and views’ 
(Mullard, 2013, p. 652). For example, the lung cancer meeting was only 
comprised of patients who were well enough to travel. This could have 
signified that their disease and therefore experiences were not the same as 
those patients unable to travel due to the severity of their illness.  
 
The views described may therefore not have been truly reflective of the entire 
patient group. This is a challenge and something that must be addressed. The 
HIV patient group also flagged up additional challenges since the meeting did 
not include many patients who were recently diagnosed with the disease. It 
was of note that during this meeting, the discussion turned towards 
participation in clinical trials. ‘It is now evident that recruitment into HIV 
clinical trials is becoming increasingly difficult, due to the advances and 
success that drug developers have achieved with antiretroviral therapy’ 
(Mullard, 2013, p. 652).  Thus, it was concluded that ‘the patients most likely 
to enrol and experiment with new regimens could not discuss their concerns’ 
(Mullard, 2013, p. 652) as they were not present at the meeting. Mullen later 
described how it was clear from the early meetings of the programme ‘just how 
important it is to ensure a broad a group of patients are represented at the 
meetings as possible’ (Mullard, 2013, p. 652).  
 
To assist with this matter, the NHC has developed a ‘Patient Stratification Tool’ 
to ‘help identify patient sub-populations, differences in disease impact and 
variations among the population in terms of treatment and management 
options’ (Mullard, 2013, p. 652). The goal of the tool was to ‘provide a way for 
patient groups to systematically organize [sic] issues, stratify their patient 
population, and identify key topics of focus in preparation for meetings’ (NHC, 
2013). This tool could also be used to ‘ensure that patient input was stratified 
and applied appropriately during benefit-risk decision-making’ (Mullard, 
2013, p. 652; FDA, 2013b). Another key requirement of the project that the 
FDA was keen to implement was to allow patients unable to attend meetings 
in person the opportunity to give their opinions. This was essential to ensure 
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that a range of views were obtained. It may be that some patients were too 
unwell to attend the meeting in person, however, their views may well have 
been some of the most important to obtain; especially if the reason they were 
unable to attend the meeting was due to the severity of their disease or 
perhaps even due to drug side effects. The FDA therefore ‘explored alternative 
ways of engaging remote participants in real-time’ (Mullard, 2013, p. 652).  For 
example, the use of online questionnaires (Mullard, 2013, p. 652). 
 
European Medicines Agency 
Like the FDA, the EMA’s approach to patient involvement in B-R assessment 
has also been qualitative in nature. Individual Member States, such as France, 
began work on their own projects (Affsaps, 2006), before collaborating at the 
European level. ‘In addition to the Benefit-Risk Methodology Project, the EMA 
supported the evaluation of methodologies for the inclusion of the patient 
voice in the decision-making process’ and created a road map to do this, 
commencing in 2014 (Muhlbacher et al. 2016, p. 735).  
 
The EMA’s remit is to ‘help ensure that over 500 million European citizens, 
from very varied environments and cultures, are provided with safe and 
effective medicines.’ The EMA, therefore, ‘has been at the forefront of efforts 
to involve patients as critical stakeholders in the regulatory process and works 
extensively with patient and consumer representatives’ (EMA, 2018).  
 
At the EMA, benefit-risk evaluation is performed primarily by the Committee 
for Medicinal Products for Human Use (CHMP) and the Pharmacovigilance 
Risk Assessment Committee (PRAC). The EMA note in their reports (EMA, 
2014a, 2014b, 2014c, 2014d) that ‘patient representatives are also involved in 
the work of other EMA scientific committees and working parties’ (EMA, 
2014a, 2014b). As such, the EMA argued that ‘patients should be consulted in 
all cases where their involvement can bring added value to the benefit/risk 
discussion’ (EMA, 2014c, p. 1).  
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In this context, the EMA states that ‘patients’ representatives already 
participate within the EMA scientific committees as: members, who act in the 
same way as all other members or ‘experts’, who advise the committee on 
specific issues and are selected for their relevant expertise, experience or 
knowledge; they bring a real-life experience of the disease and its current 
therapeutic environment.’  
 
Therefore, the EMA are one of the first examples of a regulatory agency 
employing an ‘expert patient’ within their committee meetings. These expert 
patients ‘usually only attend part of a meeting to answer specific questions 
raised by the committee and do not take part in committee conclusions or 
decisions’ (EMA, 2014a, p. 1). 
 
They must maintain confidentiality, declare any conflict of interest and abide 
by the EMA code of conduct’ (EMA, 2014a, p. 2).  In addition, the EMA also 
‘invites representatives of an organisation(s), who express the views of a 
patient organisation(s) related to a specific issue when requested by a 
committee,’ therefore, the use of patient advocacy groups by the EMA is well 
documented (EMA, 2014a, p. 2). It is now a long-term objective of the EMA to 
interact with patients in more effective ways (CRF Advisor, 2015). 
 
Bernabe et al. (2014) completed a study examining patient representatives’ 
contributions to the B-R assessment tasks at the EMA. This was a well-
executed study; however, some interesting elements of the publication stand 
out. The first is the population sampled: fifteen participants were regulatory 
staff and only five were patient representatives. In addition, it was interesting 
how knowledgeable the patient representatives were; quoting 
pharmacovigilance terminology and other terms associated with B-R 
assessment. It is fair to say that the majority of patients would not have the 
understanding or background to comment on B-R assessment at this level. 
Therefore, are these patient representatives’ truly representative of patients? 
It is argued that they are not. 
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Table 2.2 – Summary of the contributions of patient representatives in 
the benefit-risk assessment task of scientific communities (adapted from 
Bernabe et al. 2014).  
 
Benefit-risk 
tasks 
Contributions of patient representatives 
Benefit-risk 
analysis 
 
 
Additional inputs in the benefit-risk picture, such as 
experiential information regarding the pathology or some 
other aspects that regulators might find negligible but may 
in fact be important from a patient’s perspective. 
 
Benefit-risk 
evaluation 
 
Providing a concrete basis for the values and weights given 
to specific benefits and risks by concretizing and making 
explicit the significance of these benefits and risks (by 
providing real-life impact of certain interventions on 
patients, for example. 
 
Decision-
making 
 
Especially within areas where the patient perspective is 
necessary or pressing, validating that the risks of an 
indication are indeed acceptable for the patients considering 
the benefits (i.e., provide extra confidence on the decision). 
 
 
Lilly’s MEET Initiative 
It is not only regulators that have initiated projects related to patient 
involvement. The pharmaceutical company Lilly commenced a series of 
workshops entitled ‘Medicine Evaluation Educational Training’ or ‘MEET’ 
workshops. This programme aimed to involve patients at all stages of 
medicines development including drug evaluation and assessment. The 
programme was divided into several modules including how health 
technology assessment (HTA) is undertaken in the UK as well as how patient 
advocacy groups can be involved not only in HTA but also in regulatory 
decision-making regarding drug evaluation.  
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IMI PROTECT 
As the FDA’s project gained more exposure, and as companies such as Lilly 
communicated their findings, more and more collaborations began to develop 
over the period of 2013-present. Wolka et al. (2017) stressed that the most 
effective partnering in B-R discussions are those which involve patient 
advocacy groups, pharmaceutical companies and regulatory agencies; all 
working together. The IMI PROTECT consortium is a ‘collaborative European 
project that comprises a programme to address limitations of current methods 
in the field of pharmacoepidemiology and pharmacovigilance.’ This large 
initiative is coordinated by the EMA and GSK (IMI PROTECT, 2018a). The EMA 
observed the FDA’s project carefully, and after undertaking their own patient 
involvement projects, they identified that the best way forward was through a 
collaboration with the pharmaceutical industry and academia. Focusing very 
much on B-R methodology, IMI PROTECT highlighted the need to involve other 
organisations in the process; namely patient advocacy groups as well as 
patients themselves. 
 
PREFER 
PREFER is one of the most recent projects that has been established. The 
project is in its early stages of development however it aims to ‘establish 
recommendations to support development of guidelines for industry, 
regulatory authorities and HTA bodies on how and when to include patient 
perspectives on benefits and risks of medicinal products’ (PREFER, 2018). This 
is an area of the literature that is covered in great depth: the development of 
patient preference studies.  
 
A patient preference study is a quantitative study where patients are able to 
make choices based on their preference. Quantitative benefit-risk preference-
elicitation methods include discrete choice experiments, rating scales, 
threshold technique, standard gamble and conjoint-analysis (Hauber et al., 
2013; Hiligsmann et al., 2014).  
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Bowling and Ebrahim (2001) and Acquadro et al. (2003) explored different 
ways in which patient preferences could be incorporated into a B-R 
assessment framework. Their research focussed on patient reported outcome 
measures (PROMs), an effective way of obtaining information directly from 
patients (Nelson et al, 2015). Further work was undertaken by Egbrink and 
IJerman (2014) and van Til and IJerman (2014) who drew attention to the 
value of quantitative patient preferences directly in regulatory decision-
making.  Johnson and Hauber (2008) and Danner et al. (2011) also presented 
their methods of undertaking quantitative patient preference studies. The 
study completed by Danner et al. (2011), however, looked at their use with 
regards to Health Technology Assessment. In addition, Wolka et al. (2017) 
presented an example where patient advocacy groups representing psoriasis 
patients were able to contribute effectively, when undertaking a preference 
elicitation study. 
 
Improved patient involvement has the potential to drive medicines 
development, as more relevant and impactful patient outcomes will increase 
efficiency, whilst make the drug lifecycle more productive (Hoos et al., 2015, 
p. 929). It will also contribute to a better prioritisation of candidate molecules, 
‘and by addressing barriers to patient participation, enhanced recruitment and 
retention in clinical trials’ (Hoos et al., 2015, p. 929). If a universal framework 
for patient involvement is ever to be adopted, a unique partnership will be 
required between all relevant stakeholders; who will need to implement a 
change of culture within their organisations (Smith et al., 2016) 
 
Using the knowledge gained from the existing literature, the research study 
employed during this programme of PhD research was developed. Chapter III 
describes the research strategy which was employed for this research study 
and the justification for the approach taken. 
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Chapter III: Research strategy 
and methodological framework 
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Introduction 
 
Chapter III commences with the overall research strategy which was employed 
for this study. The chapter describes how the research methods were selected, 
the justification for these decisions, and a critical analysis of each research 
method which was utilised. Chapter III focusses on the justification for 
selection and the theory behind these research methods, however, the 
practical details of exactly how they were implemented within this study are 
included at the start of each individual results chapter (Chapters IV, V and VI). 
 
Research strategy 
 
Biggam (2015) explained how a clear research strategy is essential for 
undertaking a successful research study. A research strategy is defined as ‘a 
description of how the research study is implemented; the strategy taken to 
complete the empirical study’ (Biggam, 2015, p. 150). The research strategy 
for this research study involved a semi-quantitative approach, described by 
Creswell (2014) as ‘mixed-methods;’ utilising both quantitative and 
qualitative methods. The decision to describe this study as ‘semi-quantitative’ 
rather than ‘mixed methods’ was attributed to the fact that this is the standard 
terminology used within industry (in the context of the B-R assessment of 
medicines).  
 
Strategy for the review of literature 
 
The research strategy must be clearly defined and it must be justified. Once the 
strategy has been decided, it is essential that a thorough investigation is 
completed into the current literature around the topic of the research study.  
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Creswell (2014) asserted that a review of literature must be completed 
throughout the period of research and must be focussed around the topic 
under investigation. It is important to undertake the literature review on 
commencement of a period of research, however, this is not an individual 
exercise.  The literature review, is by necessity, an ongoing process. This is to 
ensure that new literature was identified and any recent research findings 
which may be relevant to the study were incorporated. Thus, a literature 
review was commenced in March 2013 and an annual review of the literature 
was undertaken throughout the period of the research study (2013-2018). 
Initially, the literature review focussed on the benefit-risk assessment of 
medicines. The following key words were searched: benefit-risk, benefit-risk 
assessment, benefit-risk assessment of medicines. The literature identified 
from these search terms was very much focussed on the quantitative 
methodology around benefit-risk assessment. Therefore, the next stage 
involved modifying the search criteria to include ‘qualitative’ and ‘mixed-
methods.’ Although this did identify some literature relevant to the research 
study, it was still not sufficiently focussed.  
 
Mussen, Salek and Walker (2009, p. 8) describe the key stakeholders involved 
in benefit-risk assessment of medicines. The search terms were therefore 
modified again to include the following terms: ‘stakeholders involved in 
benefit-risk assessment,’ and ‘stakeholders benefit-risk’. This search produced 
relevant literature which included those studies described in Chapter II 
(Review of Literature) involving pharmaceutical companies and regulatory 
agencies, as well as patient advocacy groups.  
 
Finally, the literature review search criteria focussed on patient involvement 
by using the following terms: patient public involvement, patient participation, 
patient’s perspective and patient preferences. In addition to the topic of 
patient participation in the benefit-risk assessment of medicines, literature 
about the following related topics were also reviewed: science communication, 
risk communication and risk perception and patient and public involvement 
in clinical research. 
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Methodological framework 
 
When developing the research proposal, it was important to identify the 
different approaches that could be adopted in the research. In this connection, 
Creswell (2014) delineated the three difference approaches to research: (a) 
qualitative, (b) quantitative, and (c) mixed methods, or semi-quantitative as 
portrayed in this thesis. ‘The three approaches are not as discrete as they first 
appear’ (Creswell, 2014). This statement is interesting as it did not become 
clear until late into the research process. When designing the research 
proposal, with limited experience in qualitative research in particular, the 
study design appeared to be clear. However, it was only after starting the 
research and experiencing the differences in the available approaches that this 
was understood. There were multiple examples of where both quantitative 
and qualitative elements were relevant within this programme of PhD 
research, and sometimes these methods were not clearly segregated. 
 
Qualitative research is described as ‘an approach for exploring and 
understanding the meaning individuals or groups ascribe to a social or human 
problem. The process of research involves emerging questions and 
procedures, data typically collected in the participant’s setting, data analysis 
inductively building from particulars to general themes, and the researcher 
making interpretations of the meaning of the data’ (Creswell, 2014, p. 4). 
Quantitative research is described as ‘an approach for testing objective 
theories by examining the relationship among variables. These variables can 
be measured, typically on instruments, so that numbered data can be analysed 
using statistical procedures’ (Creswell, 2014, p. 4). Semi-quantitative 
methodology refers to a combination of these approaches. This term, used 
regularly by regulatory agencies and pharmaceutical companies, refers to a 
‘mixed-methods’ approach. ‘This approach to inquiry involves collecting both 
quantitative and qualitative data, integrating the two forms of data, and using 
distinct designs that may involve philosophical assumptions and theoretical 
frameworks’ (Creswell, 2014, p. 4).  
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With a focus on qualitative methods, it was also important to recognise how 
theory relates to practice. Gray (2013) described how the choice of method 
used to gather data is not only influenced by the research methodology 
employed, but also the theoretical stance of the researcher. Braun and Clarke 
(2013, p. 27) underline how, ‘in setting out a framework for research practice, 
methodology relies on ontology and epistemology’. Firstly, qualitative 
research is ‘underpinned by ontological assumptions.’ Ontological positions 
describe the ‘relationship between the world and our human interpretations 
and practices’ (Braun and Clarke, 2013, p. 27). There are many variations 
which can be placed along ‘the ontology continuum’, ranging from ‘relativism’ 
on one side, ‘realism’ on the other and ‘critical realism’ placed centrally (Braun 
and Clarke, 2013, p. 27). With that in mind, the research strategy employed for 
this programme of PhD research, from the perspective of developing a 
framework for involving patients in B-R, was from a critical realist position. 
‘Realism assumes a ‘knowable world,’ which is comprehensible through 
research’ (Braun and Clarke, 2013, p. 27).  
 
Furthermore, Braun and Clarke (2013, p. 27) also explained how qualitative 
research is also ‘underpinned by epistemological assumptions.’ The 
fundamentals of epistemology are based around the ‘nature of knowledge’ and 
primarily refer to ‘what counts as legitimate knowledge’ (Braun and Clarke, 
2013, p. 27). There are a number of epistemological stances, including 
positivism, post-positivism, constructionism, and contextualism. ‘Positivism 
assumes a straightforward relationship between the world and our perception 
of it’ and ‘requires demonstration of reality through objective (unbiased) 
collection of data.’ Post-positivism, however, views the search for the ‘truth’ as 
achievable, but ‘acknowledges that researchers are influenced by their 
contexts’ and therefore influence their research (Braun and Clarke, 2013, p. 
27). Interpretivist research ‘is guided by the researcher’s set of beliefs and 
feelings about the world and how it should have been understood and studied’ 
(Denzin and Lincoln, 2005; Levers, 2013). 
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Yet, the very nature of qualitative research means that ontological and 
epistemological positions can inevitability change, depending on the situation 
and the findings which are identified from within the data. This, with regards 
to this programme of PhD research, the philosophical position of the 
researcher was that of constructionist. The constructionist paradigm ‘is 
conceptualised by having aspects of both the postpositivist and interpretivist 
paradigms – ontological critical realism with epistemological subjectivism.’ 
Levers (2013) described how in a constructionist paradigm, ‘meaning is 
created through an interaction of the interpreter and the interpreted’ 
therefore, ‘knowledge of the observed is constructed rather than discovered’ 
(Levers, 2013). 
 
It was clear that patient involvement in B-R assessment was a new area of 
investigation. The FDA and EMA were taking a qualitative approach to patient 
involvement, although, with an ever-increasing volume of literature on 
quantitative patient elicitation and patient preference studies, a combination 
of these approaches would be an appropriate strategy to employ. With this in 
mind, when considering a framework for involving patients in B-R assessment, 
it was proposed that a mixed-methods or ‘semi-quantitative’ approach could 
potentially be most effective. The focus of this thesis, however, was to test and 
validate one element of the proposed framework: using qualitative focus 
groups to obtain rich data on the patients’ experience, their disease and their 
treatment. 
 
Data collection techniques and analysis 
 
Phase I: Surveys  
Braun and Clarke (2013, p.  134) describe how ‘qualitative surveys, at their 
most basic, consist of a series of open-ended questions about a topic, and 
participants type or hand-write their responses.’ This form of qualitative 
research is self-administered, meaning that it is important that participants 
are given enough information in advance of the survey for them to understand 
how to complete it.  
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There are three main types of survey: hard copy, email and online (Braun and 
Clarke, 2013). Due to the population that would be surveyed, the strategy 
undertaken for phase I was by using online surveys. ‘Online surveys require 
the use of specialist software, such as SurveyMonkey’ (Braun and Clarke, 2013), 
therefore, this software was used for phase I of the research. This was the most 
convenient option, as it was known in advance that it was likely that 
participants would span multiple organisations across a range of countries. 
Details of the exact methodology used for phase I of the research will be 
described in Chapter IV. 
 
Phase II: Semi-structured interviews 
During phase I of the research, participants were invited to participate in 
phase II, involving semi-structured interviews. With this approach, an 
interview guide is prepared in advance of the interview, hence the name ‘semi-
structured,’ however, this guide is not strictly adhered to, enabling the 
interview to take a natural course (Braun and Clarke, 2013). This approach 
enabled richer data to be collected; giving the participants the opportunity to 
build upon themes in their own words. Details of the exact methodology used 
for phase II of the research will be described in Chapter V. 
 
Phase III: Focus Groups 
Braun and Clarke (2013) describe how ‘using a group discussion format has 
become increasingly popular way to collect data from participants.’ The 
difference between semi-structured interviews and focus groups is that the 
latter collects data from ‘multiple participants at the same time’ (Braun and 
Clarke, 2013). They often involve a ‘relatively unstructured, but guided, 
discussion focussed around a topic of interest’ (Braun and Clarke, 2013). The 
researcher leading the discussion is called a ‘moderator’, rather than an 
‘interviewer’ (Braun and Clarke, 2013). This is because the moderator is not 
asking direct questions as with an interview, although some questions of 
course in involved, but rather they lead a discussion; which is hopefully 
generated between participants (Braun and Clarke, 2013).   
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It was decided that this would be the most appropriate method of collecting 
data from patients directly. Details of the exact methodology used for phase III 
will be described in Chapter VI. 
 
Sample size and saturation 
Qualitative research tends to use much smaller sample sizes when compared 
to quantitative research (Braun and Clarke, 2013). Nevertheless, although the 
sample size is of less importance, for example, research has been previously 
undertaken with only a single participant, the concept of ‘saturation’ is 
paramount. Saturation, an important aspect of GT, ‘typically refers to the point 
when additional data fails to generate new information’ Braun and Clarke, 
2013). This concept was, therefore, applied to all phases of this programme of 
PhD research. 
 
Coding and the generation of themes using TA and GT 
Another reason why SurveyMonkey was selected as the software of choice for 
the online surveys was the ease at which qualitative textual data can be coded 
and analysed (Braun and Clarke, 2013). The textual data was coded and 
analysed used ‘thematic analysis’ and the themes generated were used to 
influence decision-making in the later phases of the research study. To meet 
the ultimate aim of developing a semi-quantitative framework for involving 
patients in B-R assessment, it was decided a Grounded Theory approach would 
be most suitable. TA allows for the generation of themes within a topic, 
however GT goes further. By using the data to generate theories. GT focuses on 
‘social and social psychological processes within particular social settings’ 
(Charmaz, 2006), and allows the researcher to ‘construct theories’ based on 
the data generated, rather than by searching for theories within the data’ 
(Charmaz, 2006). GT can be viewed as a methodological approach utilising a 
series of methods, one of which is TA. There is a risk, however, that GT is 
frequently misunderstood.  
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Timonen, Foley and Conlon (2018) describe the essential elements in 
undertaking GT: ‘(1) taking the word ‘grounded’ seriously, (2) capturing and 
explaining context-related social processes, (3) pursuing theory through 
engagement with data and (4) pursuing theory through theoretical sampling.’ 
This research group noted the importance of remaining objective while 
recognising reflexivity: how the researcher influences the creation of data by 
being an active participant in its creation.  
 
Finally, Bringer (2004) described how ‘most authors agree that transparency 
is essential when communicating the findings of qualitative research.’ Using a 
standardised approach is essential, therefore, the use of software such as 
QSR*NVIVO is recommended. Therefore, this software was used for the 
qualitative data analysis throughout all phases of the research study. 
 
Study plan and data collection 
 
The research strategy involved three phases. In phase I, a survey was 
submitted to (1) pharmaceutical companies and regulatory agencies and (2) 
patient advocacy groups and charities across Europe, to obtain their opinions 
on involving patients in B-R assessment. The qualitative survey data was 
analysed using Thematic Analysis (TA). Based on the findings, phase II was 
implemented, where individuals from regulatory agencies, pharmaceutical 
companies and patient advocacy groups participated in semi-structured 
interviews, to identify themes around patient involvement and to establish 
rich data around the current challenges. This data was used to inform the 
development of a novel framework, which was tested in phase III; where 
qualitative focus groups were conducted with patients. The semi-structured 
interview and focus group data were investigated using a Grounded Theory 
(GT) approach. The research strategy involved three phases, shown in Figure 
3.1 – Study flowchart on Page 47. 
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Figure 3.1: The study flowchart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phase I 
 
Chapter IV: Evaluation of the current perspectives of regulatory agencies, 
pharmaceutical companies and patient advocacy groups on the 
involvement of patients in the benefit-risk assessment of medicines 
 
 
 
Phase II 
 
Chapter V: A Thematic Analysis of the current perspectives of regulatory 
agencies, pharmaceutical companies and patient advocacy groups on the 
involvement of patients in the benefit-risk assessment of medicines 
 
 
 
Phase III 
 
Chapter VI: Evaluation of the patient’s perspective on their involvement in 
the benefit-risk assessment of medicines. 
 
 
 
Research into a proposed benefit-risk assessment framework 
 
 
 
 
 
Chapter VII: General discussion and the development of a semi-
quantitative framework to incorporate patient views as key criteria in 
decision-making  
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Research training 
 
It was important to undertake training to be fully equipped to undertake this 
research study. The first course undertaken was that of ‘qualitative research 
methods,’ which focused on how to undertake semi-structured interviews and 
focus groups, the process for undertaking thematic analysis and how to report 
qualitative research. The second course was about the use of the ‘QRS*NVIVO 
software program.’ This training described the software, how to initiate a 
project and how to use the software to code and subsequently analyse a 
qualitative dataset. And finally, training was received in how to work with 
patients who were undergoing difficult times; important when interviewing 
patients about their conditions, some of which are serious in nature. Evidence 
of research training is filed in Appendix I. 
 
Peer review 
 
As part of the research ethics application, evidence of peer review was 
required. After attending research training in qualitative research, the 
researcher identified a qualitative researcher who would be appropriate to act 
as an independent peer reviewer of the study design and study set-up. The 
letter of peer review is filed in Appendix II.  
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Researcher’s perspective and reflexivity 
An important consideration for the design and completion of this programme 
of PhD research was the researcher’s own background and perspective related 
to the subject under investigation. Braun and Clarke (2013, p. 307) describe 
the importance of ‘owning your perspective’ as a researcher – known as 
‘reflexivity’ – in that it is essential to reflect on how a researcher’s values and 
interests can influence the process of collecting and analysing data within a 
research study (Braun and Clarke, 2013, p. 307).  
 
With that in mind, it was important to note that the researcher completing this 
programme of PhD research has over fifteen years’ experience of designing, 
setting up, project managing and auditing clinical trials. He is well versed in 
research ethics and has been involved in reviewing over one hundred ethics 
applications for a range of study types; from early phase clinical trials in 
oncology and rare diseases requiring treatment with gene and cell therapy – 
through to later phase studies in a range of clinical indications.  However, the 
researcher’s experience regarding clinical trials is not only related to his 
professional life. His interest in the topic of patient and public involvement 
stems from personal experience of having a chronic condition: psoriatic 
arthritis. After receiving treatment with methotrexate, the researcher 
discontinued due to unacceptable adverse events. The opportunity to 
participate in a clinical trial of a new biologic called secukinumab then arose, 
which had an incredibly positive impact on the researcher’s clinical outcomes. 
Therefore, the researcher has a positive approach to both undertaking and 
participating in research, based on their own experiences. 
 
In addition, as a white, middle-class gay man, it is important to note how their 
own personal experiences and background may have affected the way in which 
they approached the study conduct - including their analysis of participants’ 
perspectives. As a member of the LGBT+ community, the topic of diversity is 
important to the researcher; therefore, diversity played an integral aspect in 
the way in which the researcher approached to the study.  
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The combination of professional and personal experiences have therefore 
influenced the general approach to this programme of PhD research.  In 
summary, the researcher’s original perspective was that a diverse group of 
patients must immediately be recruited to participate in the benefit-risk 
assessment of medicines; however, this perspective changed during the 
conduct of the research – which will be further described in Chapter VII 
(General discussion). 
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Chapter IV: Evaluation of the 
current perspectives of 
regulatory agencies, 
pharmaceutical companies and 
patient advocacy groups on the 
involvement of patients in the 
benefit-risk assessment of 
medicines 
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Introduction 
 
Chapter II described the current initiatives which involved patients in B-R 
assessment. Several stakeholders had implemented strategies to engage 
patients directly in their benefit-risk assessment activities including the Food 
and Drug Administration in the US and the European Medicines Agency (FDA, 
2013; EMA, 2014).  Nonetheless, it could not be assured that the initial review 
of literature captured everything, as some organisations may not have felt the 
need to publicise their patient involvement projects. In addition, some 
organisations, especially pharmaceutical companies, may not have considered 
it appropriate to communicate information about their ongoing projects, 
perhaps because they were in an early stage of completion. It was therefore 
important to gain information on the level of involvement of patients from as 
many pharmaceutical companies and regulatory agencies as possible. 
Therefore, Chapter IV describes phase I of the research, where regulatory 
agencies and pharmaceutical companies were surveyed with regard to the 
current involvement of patients in B-R assessment within their organisations. 
 
As limited research had already been completed within this area, for example 
the project undertaken by Bernabe et al. (2014), in the research plan it was 
decided to expand the types of organisations involved, not only focusing on 
European organisations but also involving several international stakeholders. 
Bernabe et al. (2014) reported how patient advocacy groups and patient 
representatives were involved at the EMA. However, there was no distinction 
between patient advocacy groups, charities or any examples of direct contact 
with patients. Nonetheless this was clear from the FDA’s ‘Patient Focused Drug 
Development’, as patients, caregivers and family members were invited to 
participate directly. An important point which has been noted from these 
previous projects, however, is how differently the organisations approached 
their patient selection. Some, like the FDA, clearly defined ‘patients’, and used 
a stratification tool to differentiate patients with different severities of disease.  
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Conversely, the EMA projects did not appear to take these aspects into 
consideration and adopted the approach that a ‘patient representative’ and a 
‘patient’ were interchangeable terms and these individuals had no tangible 
differences. However, this thesis argues that this is not the case. The objectives 
of phase I of the research study were to (1) survey pharmaceutical companies 
and regulatory agencies to discover the degree that patients were already 
included in benefit-risk assessment within their organisation and (2) survey 
patient advocacy groups to discover their current knowledge on the topic of 
regulatory benefit-risk assessment of medicines. In order to achieve these 
objectives, the following sub-objectives were identified. 
 
Sub-objectives 
 
• Identify the current involvement of patients in B-R assessment of 
regulatory agencies and pharmaceutical companies. 
 
• Ascertain the challenges of involving patients in B-R assessment. 
 
• Pinpoint possible solutions to the challenges of involving patients in B-R 
assessment. 
 
• Perceive the current knowledge of patient advocacy groups on the subject 
of B-R assessment of medicines. 
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Methods 
 
Sponsorship and study set-up 
To commence the research application process, sponsorship was requested 
from Cardiff University. One of the requirements of sponsorship was that a 
scientific review of the protocol was completed. Cardiff University Research 
Ethics Committee was therefore contacted and a member of the panel 
completed a scientific review of the protocol.  Once sponsorship was agreed, 
the study setup could commence. Once the draft study protocol was developed, 
the study essential documentation was created in line with the Research 
Governance Framework for Health and Social Care. This included the 
participant invitation letter, a participant information sheet and consent form 
plus a demographic questionnaire. 
 
Development of the surveys  
To satisfy the requirements of objectives 1 and 2 of this study, two surveys 
were developed, the first was prepared for pharmaceutical companies and 
regulatory agencies, the second being intended for patient advocacy groups. 
Surveying pharmaceutical companies, regulatory and patient advocate groups 
in a single survey was not appropriate due to the different levels of awareness 
of the concepts involved. Consequently, two separate surveys were developed. 
The survey aimed at pharmaceutical companies and regulatory agencies 
(Survey P-R) included questions regarding the involvement of patient 
advocacy groups and patients in different stages of B-R assessment, from the 
initial discussions through to B-R decision-making. The language was 
developed so that it would be easy to understand by participants. The survey 
for patient advocacy groups (Survey PAG), however, required additional 
information within it which described B-R assessment, as there was potential 
that participants would not have encountered the concept of B-R assessment 
previously. An example ‘Survey P-R’ can be found on page 53 and an example 
‘Survey PAG’ can be found on page 63.
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Benefit-risk assessment incorporating patient views 
 
QUESTIONNAIRE for REPRESENTATIVES FROM THE PHARMACEUTICAL INDUSTRY OR REGULATORY AGENCIES (Survey P-R) 
 
Thank you for completing this questionnaire. The questionnaire should take approximately 15-20 minutes to complete. 
 
1) Which type of organisation do you work for? Please circle 
 
Pharmaceutical Company 
 
 
Regulatory Agency 
 
Name of organisation (optional)  
 
Job Title (optional)  
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2) Which of the following options best describes the system used by your organisation for assessing the benefit-risk (BR) of a new medicine and who is involved?  
 
 Who is involved? 
Please tick all that apply / comment 
Internal Experts Patient Representatives and/or 
Patient Advocate Groups 
 
Patients 
W
h
at
 t
y
p
e 
o
f 
sy
st
em
 d
o
 y
o
u
 u
se
? 
Qualitative 
System 
   
Semi-
quantitative 
system 
   
Quantitative 
System 
 
   
Other 
Please state 
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3) Patient Representatives and Patient Advocate Groups 
Please read the following statements and give us your own personal opinion by circling the appropriate response below. 
 
There is a need to incorporate the views of patient representatives and or/patient advocate groups into benefit-risk analysis (i.e. they can answer questions, 
provide general information on conditions and treatments, state their opinions, but not to do anything more than this) 
 
Strongly disagree 
 
 
Disagree 
 
Neutral 
 
Agree 
 
Strongly Agree 
 
Please provide reasons for your response 
 
 
 
 
There is a need to incorporate the views of patient representatives and/or patient advocate groups into benefit-risk evaluation and decision-making (i.e. they 
should receive voting rights in the overall decision) 
 
Strongly disagree 
 
 
Disagree 
 
Neutral 
 
Agree 
 
Strongly Agree 
 
 Please provide reasons for your response 
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4) Patients 
Please read the following statements and give us your own personal opinion by circling the appropriate response below  
 
There is a need to incorporate the views of patients into benefit-risk analysis (i.e. they can answer questions, provide information on how their condition and 
treatment affects them, state their opinions, but not to do anything more than this) 
 
Strongly disagree 
 
 
Disagree 
 
Neutral 
 
Agree 
 
Strongly Agree 
 
Please provide reasons for your response 
 
 
 
 
There is a need to need to incorporate the views of patients into benefit-risk evaluation and decision-making (i.e. they should receive voting rights in the overall 
decision) 
 
Strongly disagree 
 
 
Disagree 
 
Neutral 
 
Agree 
 
Strongly Agree 
 
 Please provide reasons for your response 
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5) What is your personal opinion on the perceived benefits/positives of incorporating patient views in benefit-risk assessment? Please provide reasons for your 
answer 
 
 
 
 
 
 
 
 
6) What is your personal opinion on the perceived risks/negatives of incorporating patient views in benefit-risk assessment? Please provide reasons for your 
answer 
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7) What do you perceive are the barriers to involving patients in the benefit-risk assessment process? Please provide reasons for your answer 
 
 
 
 
 
 
8) Can you suggest any possible solutions to overcoming these barriers? Please provide reasons for your answer 
 
 
 
 
 
 
 
9) Has your organisation developed a model/method for communicating benefit-risk balance to patients? Please comment or provide examples 
 
 
 
If your organisation does not involve patient representatives, patient advocate groups or patients in benefit-risk assessment please answer question 10 and then 
go to Question 15 on Page 8. 
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10) Does your organisation have any plans to incorporate patients into benefit-risk assessment?  (Please comment or provide examples) 
 
 
 
 
 
Now go to Question 15 
 
If your organisation does involve patient representatives, patient advocate groups or patients in benefit-risk assessment please answer questions 11-15: 
 
11) Who is involved? Please circle all that apply 
Patient representatives Patient Advocate Groups Patients 
 
12) If what context are they involved? 
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13) What criteria do you use when selecting patient representatives/patient advocates/patients?  
 
Patient representatives / patient advocates: 
 
 
Patients: 
 
 
 
14) How do you ensure the patient representatives/patient advocates/patients involved in the benefit-risk assessment of a new medicine are representative of 
the patients who will end up receiving the drug? 
 
Patient representatives / patient advocates: 
 
 
Patients: 
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15) Would you or another representative from your organisation be interested in taking part in a semi-structured interview about involving patients in benefit-
risk assessment? Please circle 
Yes No 
If yes, please provide contact details below: 
Name  
Telephone Number  
E-Mail Address  
 
16) Do you have any other comments? 
 
 
 
 
 
 
 
 
 
 
We are also collecting some limited demographic data to help with the analysis of this research. If you are happy to complete this information, please go to page 
8  
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DEMOGRAPHICS 
Please circle the relevant option 
 
What is your age group? 
 
18-24 25-34 35-44 45-44 55-64 65-74 75-84 85+ 
How would you describe 
your ethnicity? 
 
How would you describe 
your gender? 
 
What is your highest level of 
education completed to 
date? 
 
No school High school 
 
Trade / 
technical / 
vocational 
qualification 
Bachelor’s 
Degree 
 
Master’s 
Degree / 
Professional 
Degree 
Doctorate 
Degree 
Prefer not to 
answer 
 
 
Many thanks for completing this questionnaire 
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Benefit-risk assessment incorporating patient views 
QUESTIONNAIRE for PATIENT REPRESENTATIVES and PATIENT ADVOCATE GROUPS (Survey PAG) 
Thank you for completing this questionnaire. The questionnaire should take approximately 15-20 minutes to complete. 
 
1) Which type of organisation are you involved with? Please circle 
 
Patient Advocate Group 
 
 
Charity 
 
Other, please state: 
 
 
Name of organisation (optional)  
Job/Role Title (optional)  
 
Background Information 
Before a new medicine is approved for marketing, evidence must be available to demonstrate the safety, quality and effect of the drug. A 
detailed assessment is completed using all available clinical trial data; to ensure the benefits of the product are carefully balanced against the 
risks. Benefit-risk assessment is a vital stage of the drug approval process and is an important task for regulatory agencies and pharmaceutical 
companies. There are a number of different methods used for benefit-risk assessment and different regulators and pharmaceutical companies 
use a variety of different ways. This sometimes involves developing a list of benefit and risk criteria (for example, a benefit could be ‘less pain’ 
and a risk could be ‘increased side effects’) and then ranking the criteria in order of importance. Involving patients in benefit-risk assessment 
is a new development. Patients, who are taking medications for their various conditions, may view benefits and risks very differently when 
compared with the views of pharmaceutical companies or regulatory assessors; however there has been limited research in this area.  The aim 
of this questionnaire is to obtain your personal views on the matter. 
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2) Are you aware of any initiatives involving patients in the benefit-risk assessment of medicines? Please comment 
 
 
 
 
 
 
 
3) Do you feel there is a need to incorporate patient views into benefit-risk assessment? Please provide reasons for your answer. 
 
 
 
 
 
 
 
4) What is your personal opinion on the perceived benefits/positives of incorporating patient views in benefit-risk assessment? Please provide reasons for your 
answer. 
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5) What is your personal opinion on the perceived risks/negatives of incorporating patient views in benefit-risk assessment? Please provide reasons for your 
answer. 
 
 
 
 
 
 
6) Would you or another representative from your organisation be interested in taking part in a semi-structured interview about involving patients in benefit-
risk assessment? Please circle 
Yes No 
If yes, please provide contact details below: 
Name  
Telephone Number  
E-Mail Address  
 
7) Do you have any other comments? 
 
 
 
 
We are also collecting some limited demographic data to help with the analysis of this research. If you are happy to complete this information, please go to page 
4  
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DEMOGRAPHICS 
Please circle the relevant option 
 
What is your age group? 
 
18-24 25-34 35-44 45-44 55-64 65-74 75-84 85+ 
How would you describe 
your ethnicity? 
 
How would you describe 
your gender? 
 
What is your highest level of 
education completed to 
date? 
 
No school High school 
 
Trade / 
technical / 
vocational 
qualification 
Bachelor’s 
Degree 
 
Master’s 
Degree / 
Professional 
Degree 
Doctorate 
Degree 
Prefer not to 
answer 
 
Many thanks for completing this questionnaire 
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Testing and validation of the surveys 
The draft Survey P-R was tested by an individual who had previously worked 
in B-R assessment within a pharmaceutical company. Feedback was received 
and this was incorporated into the final approved version. The tester 
commented on readability, understanding of the concepts involved and the 
flow of the survey. 
 
The draft Survey PAG was tested by two patient representatives from the Guy’s 
and St Thomas’ patient advocacy group. They commented on the readability 
and also on the understanding of the concepts involved. Corrections were 
made to the final version based on the feedback received.  
 
Cardiff University Ethics Application 
For the surveys, an ethics application was developed for submission to Cardiff 
School of Pharmaceutical Sciences Ethics Committee.  The letter of approval is 
filed in Appendix VIII. 
 
Activation of surveys on SurveyMonkey 
Once approved, the paper surveys were transcribed to SurveyMonkey where 
they were tested online. The individual who advised on the content of Survey 
P-R undertook a mock survey which was tested and validated. Once it was 
evident that the surveys were functioning as expected, they were activated on 
SurveyMonkey and recruitment could be commenced. 
 
Recruitment  
Regulatory agencies, pharmaceutical companies, patient advocacy groups and 
patient charities were identified from Google searches and organisation’s main 
contact email address were located. Various online groups related to B-R 
assessment on the social networking website LinkedIn were also searched for 
individuals involved in B-R assessment, and messages (using the REC 
approved template) were sent via the internal messaging system. 
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There is a consistent problem with obtaining key expert opinions due to the 
representativeness of sample populations. Against this background, 
investigation of small populations of expert opinion in particular, there can be 
ensuing confidence of surveying a sizable proportion of that population 
(Christopoulos, 2009). A number of expert professionals possess knowledge 
or can make assessments that are not available in the public domain. This 
knowledge is often considered confidential, sensitive or privileged 
(Christopoulos, 2009).  
 
A snowballing approach was taken to recruitment, in that colleagues passed 
on details of the survey and further participants were identified from 
participants’ existing networks. 
 
Descriptive statistics 
Once participants had completed the survey, and the survey was closed to 
recruitment, data was displayed using descriptive statistics. Centre weighted 
Likert scales were used for several questions in Survey P-R where participants 
could rate their level of agreement to various statements (Strongly agree, 
agree, neutral, disagree, strongly disagree), and participants were also given 
the opportunity to comment on the reasons for their answer. Their comments 
were used within the subsequent thematic analysis of qualitative data, to 
support the codes and eventual themes that were to be identified from the data 
set. 
 
Thematic analysis and generation of codes / themes 
Braun and Clarke (2013) described the stages of coding and analysis which 
make up thematic analysis. After the participants had answered the questions, 
it was important to read and to become familiar with the data, making note of 
items of potential interest. The next stage was to undertake coding, or 
organising the data into themes, before deciding upon which themes and sub-
themes were prevalent across the dataset and which were of most importance. 
The themes identified would later be used to develop theory in phases II and 
III of the research study. 
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Results and thematic analysis 
 
Braun and Clarke (2013) described how the results and thematic analysis 
sections of a qualitative report are often combined, as qualitative data analysis 
inevitably involves discussion of those data in order to be able analyse it 
appropriately. Therefore, the descriptive statistics are presented where 
applicable, however, as the majority of the dataset from the surveys was 
qualitative in nature, the thematic analyses were incorporated into a combined 
results and analysis section. The results from the two surveys were separated 
into two sections, though, the different perspectives were compared and 
contrasted as part of the thematic analysis. 
 
During the analysis of the data collected during research phase I, the 
opportunity arose to submit the preliminary results to a conference. As such, 
a poster abstract was submitted to the UK Clinical Research Facility 
Conference (July 2015). Not only was the abstract accepted, the conference 
organisers requested an oral presentation as part of the conference’s closing 
plenary session (Appendix III). After the success of the first submission, a 
second abstract was submitted to the European Conference of the Research 
Quality Association, Nice, France in April 2016. The poster abstract was also 
accepted (Appendix IV). 
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Survey to regulatory agencies and pharmaceutical companies (Survey 
P-R) 
 
Survey email requests were sent to 77 organisations (39 regulatory agencies 
and 38 pharmaceutical companies). Of the 36 individuals that responded 
positively and commenced the survey, 23 participants completed it in full and 
were therefore included within the analysis. 
 
Figure 4.1 – Type of organisation 
 
 
Question 1 of the survey asked participants about the type of organisation for 
whom they worked. It can be seen that just over half of participants (52%) 
worked for pharmaceutical companies and just under half (48%) worked for 
regulatory agencies. It was voluntary to answer Question 2, which requested 
the organisation’s name. This was important to ensure that there were not 
multiple participants taking part from the same organisation which would 
have skewed the data. It was imperative to protect the confidentiality of 
participants; therefore, participants were the given the opportunity to share 
their organisation’s name if they felt comfortable to do so. Only those 
participants who consented to the sharing of this information have been 
included in Table 4.1.  
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Table 4.1 – Participant’s organisations 
Organisation 
Regulatory agencies 
• European Medicines Agency (EU) 
• Federal Agency for Medicines and Health Products (Belgium) 
• Health Sciences Authority (Singapore) 
• State Agency of Medicines (Estonia) 
• Therapeutic Goods Administration (Australia) 
Pharmaceutical companies 
• GlaxoSmithKline 
• Novartis  
• Merck Serono 
 
Question 3 was voluntary and inquired about the participant’s job title, 
position or role. It was crucial to protect the confidentiality of participants; 
therefore, only those participants who consented to the sharing of this 
information have been included in Table 4.2.  
 
Table 4.2 – Participant’s job title / position / role 
Job title / position / role 
Regulatory agencies 
• Senior Regulatory Specialist 
• Head of Bureau of Pharmacovigilance 
• Member, Advisory Committee of Pharmacovigilance 
• Clinical Epidemiologist 
Pharmaceutical companies 
• Senior Director, Benefit-Risk Evaluation 
• Medical Director, Global Drug Safety Medicine 
• Drug Safety Product Lead 
• Chief Medical Officer 
• Medical Writer 
• Statistical Methodologist (Benefit-Risk) 
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Question 4 asked participants which of the following best described the system 
used to undertake their B-R assessment: qualitative, semi-quantitative or 
quantitative and the data obtained is displayed in Figure 4.2. 
 
Figure 4.2 – Type of system used by organisation 
 
 
Interestingly, as shown in the literature, the majority used a semi-quantitative 
system, though, there remained examples of both fully qualitative and fully 
quantitative still in use by both regulatory agencies and pharmaceutical 
companies. 
 
Question 4 asked participants which individuals within the organisation were 
involved in B-R assessment and analysis. 
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Figure 4.3 – Individuals involved in B-R assessment within the 
organisation 
 
 
All participants stated that their organisations had internal experts who 
participated in B-R assessment. However, just over a quarter of organisations 
(26%) involved patient advocacy groups or patient representatives. Only 9% 
involved patients at the time of undertaking the survey. 
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Figure 4.4 – Participants’ level of agreement on incorporating the views 
of patient representatives and/or patient advocate groups into benefit-
risk analysis 
 
 
Question 6/7 surveyed the participants’ level of agreement with this 
statement, as well providing the opportunity to give reasons for their opinion 
as shown in Figure 4.4. The majority of participants (74%) agreed that patients 
should be involved in B-R assessment, however, several participants stressed 
the challenges which must be overcome.  
 
Strongly agree 
Participants who strongly agreed had similar opinions as to why patient 
advocates should be included in B-R assessment. For example, Participant 03 
stated that ‘It's important to understand which endpoints are important to 
patients.’ This is vital and it highlights the need for ‘insight into the patient 
experience’.  
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Participant 07 emphasised how patients view conditions differently to 
regulators when they stated that ‘I do support patient's involvement as risks 
(side effects) can be differently be judged by them than in the expert’s opinion. 
For example, alopecia is clinically less severe than myelosuppression, but a 
patient may feel the reverse. This situation can be reflected (statistically) in 
benefit-risk tools weighting efficacy and any single side effect’ This also 
supports the emerging theme of ‘insight into the patient’s experience.’ 
 
Participant 10 highlighted that ‘patients and caregivers views are crucial in 
helping us to understand the wide definitions of benefit and risk from the point 
of views of those who receive the treatment with or without choice of other 
treatment options.’ This was supported by Participant 17 who stated that 
‘patient’s subjective views on benefit-risk tradeoffs are a prerequisite to 
making a decision that is for their best interests.’  
 
Participant 22 was the first to underscore the role of patients in ‘enhancing 
decision-making’ when they stated that patient involvement ‘adds robustness 
to decision-making, and to consider various perspectives to make a relevant 
decision that matters to the patients and their healthcare. Increasingly it is 
difficult to act as proxies for patients in regulatory decision-making, and it is 
better to engage their views directly.’ 
 
Agree 
Participant 04 stated that ‘it needs to be more than simply participating, they 
need to be part of decision.’ This is interesting as it draws attention to another 
emerging theme of ‘equality’ and how all stakeholders should perhaps have 
equal rights within the process.  
 
Participant 09 stated that the ‘patient receives the medicine and own the 
experience. Their view points are therefore vital. If they can be fed through a 
group/rep that is great, however that person would be a filter which I 
personally would prefer to avoid.’ This is an interesting perspective as this was 
the exact reasoning behind the structure of the survey, separating patient 
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representatives and patient advocates from patients. This participant 
understood the difference between these two groups whereas other 
participants perhaps did not. The use of the term ‘filter’ shows up this 
difference perfectly. The patient’s experience becomes less when it is seen 
through the eyes of another and presented by someone who did not ‘live the 
experience.’  
 
Participant 19 stated that ‘without a doubt, all stakeholders should have a 
hearing but not all stakeholders should carry equal weight.  Desperate patients 
may have one view which would be, arguably, contrary to the public health 
view for example.’ This is the opposing view of Participant 04 who, although 
they both agreed that patient representatives should be involved, they 
disagreed on the imposition of equal rights within decision-making. 
 
Neutral 
More participants took a neutral stance on this question, indicating that the 
patient representatives’ involvement in benefit-risk decision-making was less 
acceptable than the actual participation in B-R assessment. This is an 
important distinction. Participant 06 stated that ‘the patient's view should be 
evaluated for setting up a study as this might increase the compliance with the 
study cons for such a procedure may be the lack of time or making the process 
more complex; […] the input/feedback from patients can be dependent on 
their educational background.’ This highlights an emerging theme of 
‘understanding, training and education.’ Participant 08 stated that ‘patients 
and patient groups can be different sets of people. I believe both need to be 
involved in information give and take and decision-making, and this should be 
done in the context of the same principles of shared information and shared 
goals as the other stakeholders involved.’  
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Participant 12 highlighted that the ‘analysis should be objective, patient 
views likely to be subjective. In principal it could be a good idea to consult 
patients on some matters for example what kind of risk they consider 
acceptable/unacceptable.’ The objectively of patients is a challenge raised by 
participants which must be addressed. 
 
Disagree 
Participant 01 indicated how ‘patients are able to provide clear insight into 
patient reported outcomes and endpoints that can be utilised for this purpose.’ 
This indicates that this participant did not feel that increased patient 
involvement, other than via the use of PROMS, was required. This opinion was 
not in line with the opinions of the majority.  
 
Figure 4.5 - Participants’ level of agreement on incorporating the views 
of patient representatives and/or patient advocate groups into benefit-
risk evaluation and decision-making  
 
 
 
Question 8/9 surveyed the participants’ level of agreement with this 
statement, as well as imparting the opportunity to give reasons for their 
opinion as shown in Figure 4.5.  
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The majority of participants (61%) agreed that patients should be involved in 
B-R evaluation and decision-making, however this outcome was markedly 
lower than the previous question about their general involvement (decrease 
of 17%). Again, several participants highlighted the challenges which must be 
overcome.  
 
Strongly agree 
Participant 02 stated that ‘they have an overview of patient needs,’ indicating 
that this participant felt that patient representatives do in fact reflect the needs 
of patients. Participant 18 asserted that ‘democracy’ was important, as was 
‘the respect of all stakeholders.’ These indicated themes of ‘insight into the 
patient’s experience,’ ‘democracy’ and ‘equality’ which have emerged from the 
data so far. 
 
Agree 
Participant 07 thought that ‘voting rights can only be done in collaboration 
with regulatory agencies e.g. for submission purposes, marketed products. 
During development, the decision-making bodies are within the company 
driven by their goals.’  Participant 09 stated that ‘It depends on the decision, 
if it’s based on whether the risk outweighs the benefit and therefore the 
medicine is removed from market - no. Patients for the most part will focus 
subjectively and on themselves, not considering the patient population as 
whole.’ Participant 10 believed that ‘the decision-making process should 
ensure the input if patients groups is not neglected. To involve them in 
discussion is one, but to take their wish list into account is another.’ This again 
underscores the concern that patients may not be objective. The use the term 
‘their wish list’ is interesting, as it has negative connotations, for example, 
suggesting the patient may have ulterior motives. An emerging theme of 
‘motives’ appeared when coding this dataset. 
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Neutral 
Participant 03 stated that ‘I think it depends: some regulatory decisions will 
depend on benefit-risk (where patient input is important); some may depend 
on other issues (e.g. stability of the product) where the patient input may be 
less relevant.’ Participant 19 stated that ‘I'd insist on transparency regarding 
the representatives.  My long-term experience has made me rather cynical and 
many stakeholders have secondary and even tertiary agendas which are not 
always consistent with the best outcome for patients and public health.’ This 
supports the emerging theme of ‘motives’ as it also indicates that stakeholders, 
including patient representatives and perhaps even patients, have ulterior 
motives. This is an important theme to highlight. Participant 21 stated that 
‘this is interesting. I've [heard] about being influenced by patient group 
assessments of the impact of risks, and I am aware that patient advocacy 
groups attend FDA advisory committee meetings, but I had never considered 
the possibility of regulatory bodies and patient advocacy groups forging an 
official collaboration for aspects of the decision whether to approve.’ This was 
interesting as this participant was not aware of the official collaborations 
which were developing within this field. 
 
Participant 22 stated that ‘for patients and advocacy groups to make a 
meaningful contribution, they must first understand the regulatory processes, 
our basis of decision-making and the full implication of their decision. Thus, I 
believe with time and effort from regulators to educate the patients, we can 
look forward to incorporating patients views in an official approach like 
voting.’ This was the first evidence of the emerging theme of ‘understanding 
based on education’ which was an important concern for several participants. 
 
Disagree 
Participant 06 stated that ‘if there is no established procedure I would refrain 
from inclusion of the patient representatives.’ The lack of an established 
process for involving patients directly was a concern, and one which will be 
addressed by this thesis. 
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Participant 11 stated that ‘patients should not be empowered. Their views 
are valued, but nothing more than that. Furthermore, in case patients are 
allowed a vote, who is to blame if the decision is wrong?’ This is a valid concern, 
as responsibility is an important aspect of regulatory decision-making, 
although, to suggest that patients should not be empowered is an unacceptable 
position. Patient empowerment within the management of their own 
condition is essential to improve health and reduce overall healthcare costs. 
This is a given. 
 
Strongly disagree 
Participant 12 stated that ‘the assessment should be data driven.’ This 
participant’s previous position about involving patient representatives and 
patient advocates was neutral. It was therefore first assumed that this 
participant came from a fully quantitative background based on these 
comments. However, on checking their previous responses, they used a semi-
quantitative approach to B-R assessment, so this position conflicted with their 
opinion on involving patient representatives. 
 
Figure 4.6 - Participants’ level of agreement on incorporating the views 
of patients into benefit-risk analysis 
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Question 10/11 surveyed the participants’ level of agreement with this 
statement, as well as affording them the opportunity to give reasons for their 
opinion, as shown in Figure 4.6. The majority of participants (74%) agreed that 
patients should be involved in B-R assessment, an identical value to Question 
6/7 about involving patient representatives and patient advocates. However, 
as with previous responses, several participants disclosed the challenges 
which must be overcome.  
 
Strongly agree 
Participant 09 responded that ‘the patient owns the experience and with 
unfiltered voice, they can have a powerful message.’ They used the term ‘filter’ 
for the second time, to refer to the relationship between patient 
representatives/patient advocates and patients.  
 
Participant 17 stated that ‘patient’s subjective views on benefit-risk tradeoffs 
are a prerequisite to making a decision that is for their best interests.’ This is 
interesting as the participant may have been noting that patients are not 
objective and was accentuating their subjectivity as a positive element rather 
than a negative one.  
 
Participant 21 stated that ‘I have not pondered the distinction between direct 
patient representation and patient representation via advocacy groups.’ Again, 
this was noted from the dataset whereas some participants saw patient 
representatives and patient advocates as the same as patients. 
 
Neutral 
Participant 15 stated that ‘it is difficult to provide complex information, in 
ways that can be properly understood.’ This is another example of the 
emerging theme of ‘understanding.’ In addition, Participant 22 also used the 
term ‘filter’ when describing patient advocates, however, this time it was used 
positively. They stated that ‘representatives or advocacy groups may be useful 
to filter the unnecessary emotions behind the opinions, and also allow a 
collation of views to make the opinions more moderated and fair.’  
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This links in with the patient’s objectively so it is an interesting point and 
reflects the other side of the argument. 
 
Disagree 
Participant 12 again reaffirmed that ‘information from patients could be 
taken into account but the analysis should be made by specialists and be data 
driven.’ 
 
Figure 4.7 - Participants’ level of agreement on incorporating the views 
of patients into benefit-risk evaluation and decision-making 
 
 
Question 12/13 surveyed the participants’ level of agreement with this 
statement, as well as affording them the opportunity to provide reasons for 
their opinion, as shown in Figure 4.7. The majority of participants (61%) 
agreed that patients should be involved in B-R evaluation and decision-
making, however this response level was markedly lower than the previous 
question about their general involvement (decrease of 17%). Again, several 
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Agree 
Participant 09 stated that ‘I agree because the decision pendulum swings 
both ways, patients could provide compelling testimony to keep a drug on 
market which they feel is worth the risk. Quantitatively it may not be.’ This is 
important as they affirm that just because something may not be data driven, 
does not mean it isn’t important. They also declared that ‘on the flip side, 
patients consider their experience the only experience and therefore be 
biased.’ This participant also maintains that patients may not be objective and 
can also have an inherent bias, like all stakeholders involved. However, the 
statement that they consider ‘their own experience the only experience’ is 
perhaps unfair and unlikely to be true. Many patients participate in clinical 
trials to help society and for ‘the greater good’ therefore patients most 
definitely do consider the needs of others.  
 
Participant 10 indicated that patient inclusion in decision-making should 
‘depend on the conditions (e.g. cognition issues, terminal state etc.), patients 
may be unable to exercise their rights, hence their caregivers should always be 
able to stand in for them. The difficulty would present on the incorporation of 
this into national laws and regulations.’ The fact that caregivers should be 
included is also another consideration within the process. Participant 13 
pronounced that ‘there are instances where questions have been posed that 
have changed policy, advocated by the consumer representative alone.’ This 
highlights the impact some patient representatives previously had on 
decision-making. Their unique insight affected policy change which is 
important. 
 
Neutral 
Participant 15 communicated that it is ‘difficult to provide appropriate 
information,’ referring to the data which should be presented to patients. This 
is a challenge that must be raised and addressed. The exact technique of 
presenting clinical trial data to patients in a way in which they understand was 
an emerging theme within the dataset.  
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Participant 16 was clear in their reasoning for a neutral stance to this 
question. They stated that ‘incorporate their view, yes. Voting, not so sure. This 
may be biased.’  This indicated that the participant was concerned that there 
was a risk that patients would not remain objective, a common emerging 
theme within the dataset.  
 
Disagree 
Participant 06 reiterated their view that ‘if there is no ‘validated’ process how 
to deal with such a voting, I would refrain from this’ indicating that the 
methods of patient inclusion is an important emerging theme. 
 
Strongly disagree  
Participant 12 stated that the ‘decision should be data driven and objective, 
patient views likely to be subjective.’ The patient’s objectively in decision-
making was again called into question by this participant. 
 
The perceived benefits of incorporating patient views in B-R assessment 
Question 14 invited participants to draw attention to the perceived benefits of 
incorporating patients in B-R assessment. Participant 04 replied that ‘we 
develop drugs to address unmet patient needs, they are central to defining the 
benefit-risk proposition, should be closely involved and vote on the matter, the 
challenge will be to ensure the correct patient representation and training so 
they are on an equal footing.’ This participant also highlighted several 
emerging themes: insight, democracy, equality, understanding, education and 
also the difference between patient representatives/advocates and patients. 
 
Participant 09 specified that the following are benefits of patient inclusion: 
‘understanding of the medicine in real life settings, unfiltered experience 
report, real time feedback.’ Participant 10 highlighted that in some situations, 
the patient’s perspective is a necessity, when they stated that ‘in case such as 
orphan diseases, benefit-risk assessment can be a matter of one person of a 
few individuals and no assessment model can replace the individual personal 
assessment.’  
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Moreover, Participant 11 noted that ‘patients may be less risk averse than 
regulators. Thus, in situations where the benefit-risk balance is uncertain, 
their input would be of value.’ Risk communication was a common point 
throughout the literature, therefore this is a key point.  In addition, 
Participant 12 acknowledge the theme of ‘insight’ when they stated that 
‘patient views could give more insight in the risks that are acceptable to 
patients.’ 
 
Participant 19 identified that patient involvement would be ‘marginally 
useful for major diseases that are well characterized and understood by the 
companies, regulators and physicians.  More useful and often very valuable for 
orphan diseases or strange forms of more common diseases.  Having lived 
through some of the RU486 (Mifepristone) debates some years ago, this 
became political, social and religious far more than medical.  I see virtue where 
the issue is not too political (new anemia treatment perhaps) rather than on 
the controversial issues (psychiatric, abortion, Ebola etc.) where the decision 
is often made by others than the direct stakeholders.’  This is interesting as 
IMI-PROTECT also disclosed that the patient’s perspective may in fact be most 
valuable for orphan diseases. 
 
Participant 21 stated that ‘the overall science of drug development will 
improve as a result of patient views being incorporated into benefit-risk 
assessments. I believe it will help improve trial designs (choosing endpoints 
that matter most to patients). I believe it will improve the quality of signal 
detection (since the severity/impact of a risk on patients can play an iterative 
role in the holistic safety assessment of an emerging drug).’ This was an 
interesting perspective, as this was the first time that signal detection was 
mentioned.  
 
Participant 23 indicated ‘that users' views are taken into consideration - so 
that the level of risk individuals are willing to take and the level of benefit 
patients are seeking is considered. The decision-making will be more balanced 
with this "holistic" view.’ 
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The perceived risks / negatives of incorporating patient views in B-R assessment 
Question 15 asked participants to focus on the perceived risks or negatives of 
incorporating patients in B-R assessment. Participant 02 signified that ‘the 
methodology for eliciting patient preferences was developed in other fields, 
and it not well enough understood how well these methods work in a medical 
context.’ What is more, Participant 04 specified that ‘incorrect training, and 
politicisation of the process’ could result from patient participation, ‘where 
opinions matter more than science.’ 
 
Participant 05 stated that patients may have the ‘inability to understand the 
concepts of risk and harm.’ Whilst Participant 06 declared that there is ‘no 
"monetary value" for a company’ which was the first-time financial aspects had 
been raised by a participant. This was supported by Participant 07 who stated 
that ‘companies are private institutions and […] carry the full financial risk 
during development,’ therefore increased costs are a concern for industry. 
Participant 06 also noted that ‘patient aspects might not reflect the overall 
value but may be very individual and therefore not ‘neutral.’ Participant 09 
supported the emerging theme of ‘motivation and ulterior motives’ as they 
could present ‘self-serving opinions’ as this is ‘human nature.’ They also 
commented that the opinions may be subjective rather than objective. 
 
Participant 10 highlighted that patients may not be representative. They 
stated that ‘the risk is the difficulty in ensuring ethical issues are addressed 
when it comes to those who are not able to speak for themselves (e.g., terminal 
patients etc.), you would need a very efficient way of ensuring the right people 
are being listened to. Hence, an implementation problem.’ The second aspect 
of the statement also touched on the selection of patients which is another 
methodological issue. Participant 11 also touched upon this when they stated 
that ‘it may be very difficult to involve patients. The obvious question is who, 
how and when?’  
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Participant 13 flagged up the theme of ‘understanding’ when they denoted 
that ‘this depends on a willingness of the consumer working to understand the 
complex issues under discussion and appreciating the limits of the role.’ 
 
Participant 15 also raised the issue of ‘understanding’ when they highlighted 
that a risk could be ‘providing information that can be appropriately 
understood.’ Additionally, Participant 16 raised the issue of objectivity when 
they stated that ‘patients views maybe biased, especially in case media interest 
is involved.’ This was the first example of where the media was mentioned yet 
it is a valid and interesting point for consideration. There were examples in the 
literature around risk communication which pinpointed the challenge of 
adequately communicating risk without sensationalising it. 
 
Participant 19 also mentioned financial challenges when they responded that 
‘money, politics and secondary agendas will overcome the medical and public 
health aspects.’ The term ‘secondary agendas’ was interesting and it supports 
the emerging theme of ‘motivations of stakeholders.’  
 
Participant 20 emphasised the topic of objectivity when they stated that 
patients ‘may provide too emotional comments’ [sic]. Participant 22 also 
unveiled the issue of subjectivity in that ‘there potentially introduces more 
subjectivity into this process of decision-making. As fast as the medical science 
evolves, patient’s views do change accordingly and their contribution must 
take into account of this as well. Typically, patients' views are more affected by 
many social and cultural influences as compared to the scientific rigor 
established in a good benefit-risk assessment.’ 
 
The barriers to involving patient views in B-R assessment 
Participants were able to suggest a range of potential barriers to involving 
patients in B-R assessment.  Many focused on the emerging theme of ‘adequate 
methods for including patients.’ In this context, Participant 01 replied that 
the ‘methodology of obtaining patient views for the incorporation of benefit-
risk assessments’ is a barrier.  
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Participant 02 had a similar opinion when they stated that ‘structural and 
logistical challenges in doing something new.’ They also commented that a 
‘lack of internal expertise in preference elicitation methods and application’ is 
a barrier. Participant 03 also mentioned that a ‘lack of established best-
practice on how to do this.’ Participant 05 stated that ‘better methods to 
capture patient input and creating a regulatory pathway to incorporate it.’ 
 
Patient representation was also a strong emerging theme. Participants 05, 06 
and 07 also commented on patient selection. Participant 13 mentioned 
patient selection but commented from an educational perspective, in that 
‘health literacy’ is important. Furthermore, Participant 15 listed several 
barriers: ‘complexity of information, health and scientific literacy and interest 
groups/lobbies with pre-existing agenda.’ The latter was yet another example 
of ‘motivation and ulterior motives.’ 
 
Participant 17 raised the potential ‘arrogance of some physicians’ which, in 
combination with Participant 13’s comment about the ‘the daunting nature 
of the social interactions of the committee work’ highlights a potentially 
emerging theme of ‘strong personalities.’ In light of this, Participant 19 listed 
the following challenges: ‘language, sophistication, emotion, medical and 
public health awareness, quantitative thinking (how many know the difference 
between absolute and relative risk for example).’ 
 
Possible solutions to these barriers 
Question 17 asked participants to comment on possible solutions to the 
barrier that they reported in their answer to question 16. Solutions included 
‘improved training of experts’ (Participant 01), ‘training and broad 
representation’ (Participant 04), ‘development of a structured methodology 
and the inclusion of patients in licensing activities’ (Participant 09), ‘stronger, 
more active patient organisations’ (Participant 16), ‘improved transparency’ 
(Participant 19) and ‘potential use of social media to mobilise patient views’ 
(Participant 21).  
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Figure 4.8 - Organisation’s current involvement of patient 
representatives, patient advocate groups or patients in benefit-risk 
assessment 
 
 
Questions 20 surveyed participants about the current involvement of patient 
representatives, advocates and patients in B-R assessment within their 
organisations and the data is displayed in Figure 4.8.  
 
Ten participants confirmed that they were aware of initiatives within their 
organisations and continued to answer the remaining questions, displayed in 
Figures 4.9 and 4.10. 
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Figure 4.9 – Participant’s knowledge of future plans to incorporate 
patients into benefit-risk assessment within their organisation 
 
 
Of the ten organisation that were aware of future initiatives, the range of 
stakeholders involved varied as shown in Figure 4.10. 
 
Figure 4.10 – Types of stakeholder involved in initiatives involving 
patients in benefit-risk assessment within their organisation 
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It was anticipated during the development of this research element that 
themes such as ‘education,’ ‘understanding’ and ‘equality’ may arise. 
Therefore, it was deemed important to collect some demographic 
characteristics from participants which may have been of use during the 
analysis of the research. 
 
Demographic characteristics of study participants  
 
Figure 4.11 – Age range of participants who completed Survey P-R 
 
 
Ethnicity of participants who completed Survey P-R 
 
When asked to describe their ethnicity, 1 person described themselves as 
‘Chinese’ and all other participants stated they were ‘Caucasian’ (n=19). Three 
participants chose not to answer. 
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Figure 4.12 – Gender of participants who completed Survey P-R 
 
 
Figure 4.13 – Highest level of education of participants who completed 
Survey P-R 
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Chapter IV (II) – Survey to patient advocacy groups, described as ‘Survey 
PAG’ 
 
Survey email requests were sent to 192 organisations. Of the 46 individuals 
that responded positively and commenced the survey, 29 participants 
completed it in full and were therefore included within the analysis. 
 
It should be noted that participants were asked to ‘tick all that apply’ to 
question 1 about their organisation type, as some organisations described 
themselves as both ‘patient advocacy groups’ and they may also have been 
identified as ‘charities’, hence, the total value of all groups combined exceeds 
100%.  
 
Figure 4.14 – Type of organisation (Survey PAG) 
 
 
Question 2 was voluntary and asked for the organisation name. This was 
important to ensure that there were not multiple participants taking part from 
the same organisation which would have skewed the data.  
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Only those participants who consented to the sharing of this information have 
been included in Table 4.3.  
 
Table 4.3 – Participant’s job title / position / role 
Organisation 
Patient advocacy groups and charities 
• NF Kinder Swiss "Positivrat" for HIV and HCV patient  
• Myeloma UK  
• Urostomy Association  
• British Liver Trust 
• Histamine Intolerance Awareness  
• SJS Awareness UK  
• Stevens Johnson Syndrome Awareness UK  
• Fibromyalgia Association UK  
• Epilepsy Society 
• Lupus Patients Understanding & Support (LUPUS)  
• National Ankylosing Spondylitis Society (NASS)  
• HIV/AIDS Carers & Family Service Provider Scotland  
• Polycystic Kidney Disease Charity  
• PNH Support  
• British Kidney Patient Association  
• FOFLEKKREFTFORENINGEN Norway  
• HTAP Belgique 
 
Question 3 was voluntary and asked for the participant’s job title / position / 
role. It was important to protect the confidentiality of participants; therefore, 
participants were the given the opportunity to share their job title / position / 
role. Only those participants who consented to the sharing of this information 
have been included in Table 4.4.  
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Table 4.4 – Examples of participant’s job title / position / role 
Job title / position / role 
• Board member 
• Director 
• CEO 
• Chair of Trustees 
• Chief Executive 
• Coordinator 
• Epilepsy Information Manager 
• Founder / Head of organisation 
• Health Services Research Manager 
• Information and Communications Manager 
• Involvement coordinator 
• National Secretary 
• Patient 
• Policy Director  
• President 
• Senior Policy Advisor 
• Trustee 
• Vice president 
• Visiting Researcher 
• Volunteer 
 
 
Question 4 surveyed participants on if they know of any initiatives about 
involving patients in the B-R assessment of medicines. The majority of 
participants were unaware of any initiatives and for most, this was the first 
time they had come across the concept of patient involvement in B-R 
assessment. Three participants, however, mentioned the EUPATI initiative and 
some were actually a member and had actively participated in the 
development of this project. Three also mentioned the EMA.  
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Participant 08 had an interesting perspective when they stated that ‘NICE 
uses lay members to offer commentary and advice in its technology 
assessments and guideline development work, also the MHRA have a patient 
group which looks at devices and medicines from a safety viewpoint; the EMA 
regularly contacts us to link them with patients with a particular condition 
who can comment on a new medicine.’ This participant had a noteworthy 
viewpoint on the subject of B-R. The most knowledgeable participant, however 
stated that the ‘IMI work package due to start soon, which is a multi-
stakeholder collaborative program examining this topic. EMA and FDA 
initiatives in this area are also underway. Myeloma UK is also undertaking 
collaborative projects in this field’ (Participant 26). 
 
The need to involve patients in B-R assessment 
When participants were surveyed about the whether they felt that patients 
should be involved in B-R assessment, 100% of the 29 participants who 
completed the survey agreed that they should be. Participant 01 was positive 
and commented that they should be involved ‘especially for rare diseases 
without any treatment.’  
 
Participant 11 affirmed that ‘patient empowerment is important in all areas 
of medical care. Empowered patients are demonstrated to be more compliant 
with their treatment regimes. Exclusion of this user group from any point of 
the evaluation is a waste of resource.’ This is an interesting perspective when 
compared to that of Participant 11 (Survey P-R) who did not agree that 
patients should be empowered. Participant 14 also added that ‘I think 
involving patients is important and necessary. There is little point in 
developing an 'intervention' if it is intolerable to the patient and patients are 
usually the best individuals to know what is an appropriate balance of risk and 
benefit.’ The last statement, in particular, demonstrates the risk that some 
patients may overstep the mark with regards to patient empowerment, which 
is possibly the exact point that Participant 11 (Survey P-R) was warning 
against.  
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It is argued that clinicians and regulatory scientists are the ‘best people’ to 
undertake this assessment, of course, in collaboration with other stakeholders. 
 
Participant 21 had strong opinions on this matter, which supports the 
development of the emerging theme around ‘strong personalities’ which may 
take the discussion away from healthcare and politicise it. They stated that ‘a 
lot of information on the internet is highly speculative, spiked with personal 
opinion and sometimes patients are targeted by drug companies who attempt 
to sell products promising them that this is "the solution" to their problem.’ 
This appeared to demonstrate a cynical view of pharmaceutical companies 
which would be a challenging position to moderate during B-R discussions.  
 
Participant 27 had an interesting point where they stated that ‘many studies 
have shown that patients tend to go for a higher risk than a scientific panel, so 
it is important the assessment committee is balanced, including patients, 
doctors, scientists and regulators.’ 
 
The perceived benefits of incorporating patient views in B-R assessment 
Interestingly, a common theme that emerged from the patient advocacy 
group’s statements about the perceived benefits of involving patients was 
around the acceptance of risk. Participant 01 acknowledged that regulators 
will have a ‘better understanding of the amount of risk patients are ready to 
take’ by involving patients. Correspondingly, Participant 06 stated that 
‘patients are the ones that can describe in a more accurate way the benefits 
and side effects of medicines.’ This was supported by Participant 08 who 
highlighted that ‘being able to demonstrate and understand more accurately 
the benefits and value to a person or their family, perhaps where the value of 
treatment will have been over or under-anticipated by the researchers […] is 
helpful.’  
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Participant 14 stated that ‘patients can give valuable insights into the lived 
experience of disease/conditions. They bring more than just a 'medical' 
experience and have valuable insights. Also, in the UK, pharmaceutical 
companies can have very little/no contact with the patients that they are 
developing drugs/interventions for. I also think patients will value something 
more if they know that other patients have been meaningfully consulted. I 
think they will believe the views and experiences of other patients, with lived 
experiences, over the possibly-hypothetical views of researchers, developers 
and healthcare professionals.’  
 
Participant 24 also agreed with these concepts when they stated that 
‘patients are the ones living with the disease and therefore the ones that know 
better what it means in practical terms, they know better than anyone else 
what they are willing to accept (risks) to have benefits in exchange. Having 
their voice heard will make them feel empowered to make better decisions 
even in other aspects of the management of their diseases.’ 
 
The perceived risks / negatives of incorporating patient views in B-R assessment 
Participants also understood that there was a possibility that patients would 
be willing to accept too much risk if they are in need of a viable treatment. 
Thus, Participant 01 stated ‘that patients want a cure so they can be not 
cautious enough and want things going on too fast.’ This was supported by 
Participant 06 who divulged that ‘there is a possibility that patients could 
accept medicines with lower level of benefits due to the absence of 
alternatives.’ 
 
Participant 07 touched upon the challenge of method and logistics in 
particular: ‘I imagine it will be difficult to include patients.’ Likewise, 
Participant 13 fully appreciated the logistical issues when they stated that 
‘views could be lengthy leaving the need to interpret responses.’ This is 
particularly apt when undertaking a PhD research study involving large 
volumes of qualitative interview and focus group transcripts.  
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The theme of ‘adequate representation’ was also evident. Hence, Participant 
08 noted that ‘some patient views will be very personal and subjective - their 
experience may outweigh a perception of possible benefits to others from a 
treatment if theirs was inappropriately delivered and their experience was 
poor.’ In addition to this, Participant 10 brought to light issues related to 
‘emotional and political bias.’ 
 
Participant 12 noted that there is a need to ensure sufficient patients are 
involved to avoid skewed results.’ Interestingly, confidentiality was mentioned 
twice by two different participants (Participant 14 and 24), whereas it wasn’t 
mentioned at all in Survey P-R. This indicates patients’ concern about the 
sharing of information about themselves and of the possibility of needing to 
divulge sensitive information to other stakeholders during B-R discussions. 
 
As a consequence, Participant 14 stated that ‘I imagine that there is a risk 
around confidentiality/sensitivity in new drug developments.’ They also 
commented that ‘while many individuals can well represent their own views 
and experiences, unless they have a lot of contact with others living with the 
same condition/disability they may not be able to represent a wider 
experience. This is a limitation’ indicating an understanding of the adequate 
representation issue. They described how ‘patient experiences can vary 
widely, so again this will only give you a 'snapshot' of possible insights. This is 
why involving patient representative groups/advocates/charities can be of 
benefit as they can often represent the views of many more people living with 
the condition/disease,’ which is a good example of the patient’s insight. 
 
Participant 15 also mentioned the identification of relevant patients as ‘the 
patient must be someone who can assess the relevant population concerned. 
A one-person view could be very biased.’ Participant 20 also mentioned that 
it ‘could be challenging to get target patient groups involved.’ 
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Participant 18 commented on finances, the only participant from Survey PAG 
to do so. They observed that there was ‘potential to make the drug more 
expensive as another layer is added to the development process.’ 
 
Participant 25 noted that ‘sometimes, and especially for some patients with 
specific diseases (e.g., final stage cancers), their decisions might be influenced 
by the hope of living longer or with less pain. They might also not fully 
understand the benefits and risks and make a scientific assessment. This is 
why education and health literacy are paramount.’ Participant 28 used the 
term ‘guinea-pig’ which was interesting. They did not wish ‘to be misused as a 
guinea-pig; to be involved in an experiment where you don't know the 
outcome; to take the risk, that the drug to be tested does not work or does 
impair your health or cause severe side effects; to replace a working treatment 
by a new drug with an unknown outcome.’ This does highlight the need for 
adequate training and education to assist the patient’s understanding of the 
process. 
 
Demographics characteristics of the participants 
 
Figure 4.15 – Age range of participants who completed Survey PAG 
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Ethnicity of participants who completed Survey PAG 
 
When asked to describe their ethnicity, all participants stated they were 
‘Caucasian’ (n=25). Four participants chose not to answer. 
 
Figure 4.16 – Gender of participants who completed Survey PAG 
 
 
Figure 4.17 – Highest level of education (Participants of Survey PAG) 
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Discussion 
 
Phase I of the research presented in Chapter IV identified that patient 
involvement in B-R assessment was more widely implemented than the 
literature indicated.  In addition, the awareness of patient advocacy groups on 
this topic was greater than originally anticipated, indicating recent initiatives 
had been successful in raising awareness. The objectives of phase I of the 
research study were to (1) survey pharmaceutical companies and regulatory 
agencies to discover the degree that patients were already included in benefit-
risk assessment within their organisation, and (2) survey patient advocacy 
groups to discover their current knowledge on the topic of regulatory benefit-
risk assessment of medicines. To achieve the overall aims, Chapter IV had four 
sub-objectives.  
 
The first sub-objective was to identify the current involvement of patients in 
B-R assessment of regulatory agencies and pharmaceutical companies. The 
results confirmed that several stakeholders were in the process of developing 
initiatives to engage patients directly in their B-R assessment activities, in 
addition to the FDA and the EMA.  Nonetheless, the organisations undertaking 
this type of work were in the minority. It should be noted that it cannot be 
assured that the data in Chapter VI covers all activities and initiatives across 
industry, due to the fact that many organisations did not respond to the survey. 
Thus, this was a limitation of this research element. Nevertheless, a range of 
organisations did participate including the European Medicines Agency and 
several large multinational pharmaceutical companies. The fact that 26% of 
organisations involved patient advocacy groups and 9% of organisations 
involved patients in their B-R activities, tends to the hypothesis that this was 
an untapped area for many organisations. Overall, the inclusion of patients in 
B-R assessment was seen as a positive development by the majority of 
participants. Generally, their involvement was advocated because of the 
benefits offered in providing an insight into the patient experience. 
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Whilst limited research had already been completed within this area, for 
example the project undertaken by Bernabe et al. (2014), it was decided in the 
current research plan to expand the types of organisations involved, not only 
focusing on European organisations but also involving several international 
stakeholders. Bernabe et al. (2014) reported how patient advocacy groups and 
patient representatives were involved at the EMA. However, there was no 
distinction between patient advocacy groups, charities or any examples of 
direct contact with patients. This was verified during the research, when direct 
telephone contact was made between the thesis author and the lead 
researcher of the study. It was confirmed that only patient advocacy groups 
who were existing members of the EMA’s network were involved. It is 
understood that using pre-existing links and networks is essential for initial 
engagement, however, there was a risk of potential bias arising from pre-
selection of this type. Participants emphasised how patient views were 
important, and, although patient advocacy groups were significant, there was 
a need to prevent them acting as a ‘filter’ to the patients’ perspective.  
 
When analysing the data, the job titles of participants who completed Survey 
PAG was of particular interest. Many of the participants had a range of roles 
and positions. Some were in fact patients, whereas others were senior staff 
within the patient advocacy organisation. This underscores the diverse nature 
of patient advocacy organisations and charities. By engaging with these 
organisations, it is not possible to be assured that the patient voice is always 
the one which is heard. This is largely because these organisations can be 
complex due to the variety of participants ranging from chief executives, 
directors, chairs, and committee members through to volunteers, patient 
representatives and patients. 
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The second sub-objective was to ascertain the challenges of involving patients 
in B-R assessment. A theme which emerged from the qualitative data was that 
of the patient’s ability to remain objective. Participants from both Survey P-R 
and Survey PAG displayed this point. The fact that patient advocates also 
recognise this objectivity risk indicates their ability to understand the 
challenges involved, which further supports the case for their involvement. A 
number of participants identified the need for training and education, but this 
applies to all stakeholders. In addition, the logistics of involving patients was 
raised as an area needing further work. Another important theme was the 
underlying motivation behind the of involvement of different stakeholders, 
including patient advocates. Thus, several participants described how 
individuals’ can have ulterior motives, which may not always be patient-
centric and may, in fact, be self-serving. Therefore, this is a risk factor that must 
be considered when identifying appropriate potential participants. 
 
Participants were able to suggest a range of potential barriers to involving 
patients in B-R assessment, including a lack of established best-practice on 
how to do this, covering both the methodology of obtaining patient views and 
the structural and logistical challenges. They also commented that a lack of 
internal expertise in preference elicitation methods and application, better 
methods to capture patient input and creating a regulatory pathway to 
incorporate it. Patient representation was also a strong emerging theme, with 
regards to patient selection but also from an educational perspective. Health 
literacy was illuminated. When participants were surveyed about pinpointing 
possible solutions to the challenges of involving patients in B-R assessment 
(the third sub-objective), a range of solutions were suggested. The 
development of a standardised process was acknowledged above all, which 
also underscored the need to ensure any participating patients were as 
representative as possible. This indeed was a challenge which has still to be 
adequately addressed. Other solutions included the improved training of 
experts, training and broad representation and the inclusion of patients in 
licensing activities. Stronger, more active patient organisations was also 
considered an important factor. 
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The final sub-objective of Chapter IV was to recognise the current knowledge 
of patient advocacy groups concerning the subject of B-R assessment of 
medicines. The data outcomes were surprising in that the majority of 
participants, whatever their educational background and knowledge of B-R, all 
understood the principles and the concept well enough to comment. Almost all 
responses from Survey PAG showed at least some understanding of B-R 
assessment, without ever having discussed the topic previously. Therefore, 
with the right education and training, it is fair to concur that patients would be 
able to contribute effectively. Demographics were a topic which required 
further review and investigation. An important point regarding the previously 
published literature was that demographic characteristics were not described. 
This was true of the data obtained by Bernabe et al. (2014), so it was not 
possible to determine the diversity of the population who participated in the 
study.  
 
In essence the research element presented within Chapter IV offers a unique 
contribution. It is argued that adequate patient involvement must consider the 
diversity of the population who are invited to participate. It should be noted 
that the work by Bernabe et al. (2014) was one of the first publications on the 
topic of patient involvement in B-R assessment, so it was leading the field at 
the time. Still, the addition of demographic information would have greatly 
enhanced that specific study. Phase I of the present research collected 
demographic information on all participants from both surveys. When 
reviewing these data, it can be seen that all participants from Survey P-R were 
Caucasian with a high level of education (the majority at Master’s or Doctorate 
level). The participants who completed Survey PAG, however, had more varied 
educational backgrounds. This highlights the need for education and training, 
another emerging theme, yet it also demonstrates that a range of views are 
essential.  
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Summary 
 
• The fact that 26% of organisations involved patient advocacy groups and 
9% of organisations involved patients in their B-R activities, supports the 
hypothesis that this was an untapped area for many organisations. Overall, 
the inclusion of patients in B-R assessment was seen as a positive 
development by the majority of participants. Generally, their involvement 
was supported because of the benefits it offered in providing to an insight 
into the patient experience. 
 
• Participants were able to suggest a range of potential barriers to involving 
patients in B-R assessment, including a lack of established best-practice on 
how to do this, covering both the methodology of obtaining patient views 
and the structural and logistical challenges. They also commented that a 
lack of internal expertise in preference elicitation methods and application, 
better methods to capture patient input and creating a regulatory pathway 
to incorporate it. 
 
• Solutions to increase patient involvement included improved training of 
experts, training and broad representation, development of a structured 
methodology and the inclusion of patients in licensing activities. Stronger, 
more active patient organisations were also considered an important step. 
 
• Patient advocacy groups were relatively knowledgeable on the subject of 
B-R assessment of medicines. Therefore, with the right education and 
training, it is fair to concur that patients would be able to contribute 
effectively. 
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After analysing the qualitative data collected from Survey P-R and Survey PAG, 
and subsequent to the coding and thematic analysis using QRS*NVIVO, several 
emerging candidate themes were identified. The candidate themes identified 
were: 
 
• Adequate methods for involving patients in B-R assessment 
• Adequate representation of patients 
• Objectivity of patients 
• Understanding and education 
• Insight into the patient’s experience  
• Motivation and ulterior motives of stakeholders 
 
At the end of both surveys, participants were offered the chance to continue to 
phase II of the research by participating in a semi-structured interview. The 
candidate themes were further investigated with these participants, and the 
findings are presented and discussed in Chapter V of this thesis. 
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Chapter V: A thematic analysis of 
the current perspectives of 
regulatory agencies, 
pharmaceutical companies and 
patient advocacy groups on the 
involvement of patients in the 
benefit-risk assessment of 
medicines 
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Introduction 
 
Chapter IV was integral to the overall aims of this research. It was imperative 
not only to understand the current level of involvement of patients in B-R 
assessment, but also the challenges that regulatory agencies and 
pharmaceutical companies had to encounter. This was essential if the aim of 
developing a framework for including patients in B-R assessment which would 
meet the expectations and requirements of all stakeholders was to be 
achieved. Phase I of the research presented in Chapter IV identified that 
patient involvement in B-R assessment was more widely implemented than 
the literature suggested.  Challenges which were identified included a lack of a 
standardised method of including patients, as well as issues around ensuring 
the patients who were included remained objective and that they adequately 
represented others. Their motives were also considered, as was the risk that 
they may have ulterior motives, which may not be patient-centric and may, in 
fact, be self-serving. 
 
The awareness of patient advocacy groups on this topic was greater than 
anticipated, as was their understanding on the concepts involved. To further 
develop the concepts and themes which were identified from the survey data, 
semi-structured interviews were completed with those participants who 
wished to take part in phase II of the research. The objective of phase II of the 
research study was (3) using qualitative semi-structured interviews, establish 
the opinions of representatives from pharmaceutical companies, regulatory 
agencies and patient advocacy groups, by undertaking thematic analysis of 
their views and opinions. In order to achieve this overall objective, several sub-
objectives were established in phase II.  
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Sub-objectives 
 
• Discuss the challenges of involving patients in B-R assessment with 
stakeholders. 
 
• Develop solutions to the challenges of involving patients in B-R 
assessment. 
  
• Obtain rich data on the emerging themes from phase I of the research. 
 
• Propose a framework for involving patients in B-R assessment and 
receive feedback from relevant stakeholders. 
 
Methods 
 
Protocol development 
A research protocol was developed in line with good clinical practice and 
research governance requirements (Appendix V). Before the empirical 
component of this study element could commence, appropriate approvals 
were obtained.  
 
Development of the semi-structured interview schedule  
A schedule of questions was prepared (Appendix VI). Questions were based 
around existing methods of including patients in B-R assessment as well as the 
challenges of involving patients and potential solutions to these challenges. 
The questions were divided into three topics: 
 
• Topic 1: Benefit-risk methodology 
• Topic 2: Patient identification and selection 
• Topic 3: Possible barriers to involving patients 
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Cardiff University Ethics Application 
In addition to the surveys, the ethics application submitted to Cardiff School of 
Pharmacy and Pharmaceutical Sciences Ethics Committee also described 
phase II of the research and included the schedule to be used within the semi-
structured interviews.  The letter of approval is filed in Appendix VIII. 
 
Recruitment  
At the end of both surveys used in research phase I, participants were offered 
the chance to continue to phase II by participating in a semi-structured 
interview. There is a consistent problem with obtaining key expert opinions 
due to the representativeness of sample populations (Christopoulos, 2009). 
There was a risk of positive selection for this research phase, conceivably 
because only those participants with an interest in patient involvement would 
move forward into phase II. However, this was a risk that had to be assessed 
and accepted. If a participant expressed interest in taking part in phase II, they 
provided their contact details within the survey.  The researcher then 
contacted the participant directly and a mutually convenient date and time 
were arranged to undertake the interview, either at the participant’s 
workplace or online, via Skype. 
 
Semi-structured interviews 
Meeting individuals at their place of work was most interesting as it was 
possible to see the participant within their own environment. The participant 
signed a consent form on commencement of the interview, consenting to the 
fact that their interview would be recorded, transcribed and analysed. A 
standard schedule was followed for all interviews and they were recorded 
using an audio recorder. The interviews conducted over Skype were most 
challenging, particularly in the case of one participant who had an intermittent 
internet connection.  
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In any event, adequate recordings were obtained for all interviews. The 
candidate themes were further investigated with these participants and this 
information is presented and discussed in the current thesis chapter. Semi-
structured interviews for participants from regulatory agencies and 
pharmaceutical companies were undertaken in London and Basel, 
Switzerland. Semi-structured interviews for patient advocacy groups were 
undertaken in London, Essex and also online using Skype.  
 
Recordings and transcription 
After data was collected via audio recordings and all interviews were 
complete, data was prepared for analysis. This was performed by the process 
of transcription. Transcription involved ‘playing the recording in very short 
bursts’ before ‘typing up what you hear’ (Braun and Clarke, 2013). At first, this 
seemed like a simple process, however, on commencing the transcription 
process it was quickly realised that this would become a lengthy and 
challenging process to undertake. The method utilised was that of 
‘orthographic’ transcription, also known as ‘verbatim’ (Braun and Clarke, 
2006). This style focussed on ‘spoken words, other than sounds, in recorded 
data’ (Braun and Clarke, 2013). It was noted that most qualitative research 
uses transcripts rather than coding directly from the audio recordings 
(however, some research does focus on audio or video recordings). 
Consequently, it was essential that the transcripts were of the highest standard 
possible.  
 
A transcript of an audio recording ‘is not a facsimile; it’s a representation’ 
(Braun and Clarke, 2013). So, in essence, it was expected that the transcript 
would not be an exact representation of the recording, it just needed to be as 
precise as possible. In order to ensure quality, ‘a transcript needs to signal 
what is said and who is speaking’ (Braun and Clarke, 2013). An orthographic 
transcript of high quality also ‘needs to contain both actual words and non-
semantic sounds, such as erm, er, and uhuh’ (Braun and Clarke, 2013).  
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The primary reason for this is because changes to the way in which people 
speak can affect the meaning of what they actually said. Therefore, this method 
of transcription was adopted. Participants were given the opportunity to 
review their transcript and the emerging themes, to ensure the data was an 
adequate representation of their opinions. This process, known as ‘member 
checking’ is a form of quality control. 
  
Coding of themes using QRS*NVIVO 
The transcripts were uploaded to QRS*NIVO and the qualitative data were 
coded and the data allocated to ‘nodes’: a method of analysis to assist in the 
generation and clarification of themes. 
 
Figure 5.1 - Screenshot of coding using QRS*NIVO 
 
 
Thematic analysis and generation of themes 
Thematic analysis, coding and the further validation of themes already 
identified was completed. After the transcription, it was important to read and 
to become familiar with the data, making note of items of potential interest. 
The next stage was to undertake coding, or organising the data into themes, 
before deciding upon which themes and sub-themes were prevalent across the 
dataset and which were of most importance. The themes identified were used 
to develop theory in phase III of the research study. 
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Results and thematic analysis 
 
Once the coding and analysis was complete, the data held on QRS*NIVO was 
reviewed and compared against those data collected in phase I of the research. 
Several emerging candidate themes were identified during phase I, and these 
were verified and clarified during phase II. The candidate themes identified 
during phase I were as follows: 
 
• Adequate representation of patients 
• Adequate methods for involving patients in B-R assessment 
• Objectivity of patients 
• Understanding and education 
• Insight into the patient’s experience  
• Motivation and ulterior motives of stakeholders 
 
The data obtained during phase II verified these themes and the information 
collected during the semi-structured interviews added depth of meaning to 
them. The material collected in phase II was rich and aided the analysis of the 
research. 
 
Participants 
Of the 23 participants who completed Survey P-R, 8 participants (35%) 
consented to be approached to participate in phase II of the study. In spite of 
this, after contact was made, only 4 participants moved forward into phase II 
(17%). Of the 29 participants who completed Survey PAG, 18 participants 
consented to be approached to participate in phase II (62%). Though, after 
contact was made, 8 participants (28%) moved forward into phase II.  
 
Of the 12 participants whom participated in semi-structured interviews and 
completed phase II of the research, 1 participant (8%) represented a 
regulatory agency, 3 participants (25%) worked for pharmaceutical 
companies and 8 participants (67%) were patient representatives, patient 
advocates or worked for patient advocacy groups or charities. 
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The participants who participated in the semi-structured interviews are 
displayed in Table 5.1  
 
Table 5.1 – Participants, their role and association 
Participant Job title, role Association 
SSI01 Pharmacovigilance expert Regulatory agency 
SSI02 Patient advocate PAG 
SSI03 Patient advocate PAG 
SSI04 Patient advocate PAG 
SSI05 Patient advocate PAG 
SSI06 Patient advocate PAG 
SSI07 Patient advocate PAG 
SSI08 Patient advocate PAG 
SSI09 Director of B-R  Pharmaceutical company 
SSI10 Statistician Pharmaceutical company 
SSI11 Medical writer Pharmaceutical company 
SSI12 Patient advocate PAG 
 
 
Thematic analysis and the clarification of emerging themes 
After analysis, the six candidate themes previously identified were confirmed 
and verified. Throughout the interviews, similar themes arose and also new 
information was identified. In addition to those candidate themes which were 
identified in research phase I, any new themes or concepts which emerged 
during phase II were also documented and investigated. The themes which 
were identified and verified during the semi-structured interviews are 
described in detail. In addition, a description of each theme will be presented 
along with examples of how the theme emerged from the data, by quoting 
participants with respect to what they said and how they said it. Themes which 
were most prevalent are described first and any sub-themes which were 
identified are also described. 
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Theme I: Adequate representation of patients 
Theme I was prevalent across all interviews and consequently, it was the one 
which was most common. This theme was raised multiple times by all types of 
stakeholder, including participants from regulatory agencies, pharmaceutical 
companies and patient advocacy groups, indicating its importance to 
participants.  
 
The first semi-structured interview was undertaken with Participant SSI01, 
a senior pharmacovigilance expert who was a member of several committees 
at the EMA. When asked about the involvement of patients within EMA 
committees, this participant was vocal about their experience of patient 
advocates within their organisation. The participant replied that ‘at the level 
of our committee, you have only one representative of patient association, 
which do not represent all the patients [sic].’ This statement was one of the 
first statements collected during phase II of the research, and it was not 
realised at the point of data collection, how profound this statement would be. 
It was a statement which would continue to emerge time after time within the 
dataset. 
 
Participant SSI01 described their experience of patient advocates. ‘They have 
low (participation), because finally they really represent themselves, like I 
represent myself and you representative yourself.’ In addition, ‘they are a very 
old professional and probably too much old professional’ [sic]. 
 
This was an interesting statement as was a valid point. All people do represent 
themselves, but a patient advocate should place others ahead of their own 
career and aspirations. The general feeling obtained from the discussion with 
Participant SSI001 was that the patient advocate of which the participant was 
describing was only there in order to further their own agenda. Participant 
SSI01 continued: ‘So, you have one guy representing one type of illness, I don’t 
remember who he’s a representative for, but it’s not very efficient to be honest 
[…] It’s a big problem but my problem in your approach is that finally you will 
talk with patients which are more involved in a patient association.’ 
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Participant SSI01 also commented on how patients are selected: ‘now there 
is probably one main reason (for whom they select) is that most of the patient 
association (they use) have links with industry and so we probably choose only 
ones we know.’  
 
Participant SSI02 was a patient who represented other patients as part of a 
patient advocacy group and raised the importance of adequate representation. 
When discussing the involvement of patient advocates at the EMA level, 
Participant SSI02 was quick to point out that they were ‘missing the key 
factor,’ referring to the lack of actual patients involved. Participant SSI02 
questioned how other patients are able to represent others if they have not 
experienced the condition themselves. The participant used their own 
experience to back up this query: ‘I suppose really I am only thinking about 
pain meds because that is the only thing I can really talk about.’ It therefore 
appeared as though this participant did not feel they could describe other 
conditions or treatments which they had not experienced.  
 
Participant SSI03 was a patient who represented a large national patient 
advocacy group. This participant had previous experience of advising panels 
at the National Institute of Health and Care Excellence (NICE) on the cost 
effectiveness of drugs. NICE have a role of not only assessing B-R but also 
pharmacoeconomics, so this participant’s views were particularly unique and 
this signified an interesting contribution to the data. Participant SSI03 
detailed that ‘we’re fortunate because we’ve got a big large patient supporter 
base who are very active, proactive, so when we did our survey we got 
hundreds and hundreds of patients because it’s a highly motivated patient 
group. But if you’ve got a rare condition where you might only have 30 people 
affected, what do you do? Bring all of them in? Sometimes they’re hard to 
reach.’ The participant was describing how, although they act as patient 
representatives, they have large networks of patients who they aim to involve 
as much as possible in all their initiatives.  
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On the subject of patient involvement within NICE however, Participant 
SSI03 commented that ‘well, I think quite a lot of it is still tokenistic but it’s 
better than it used to be.’ Tokenism was a sub-theme which emerged often. 
Participant SSI03 continued: ‘so, by the time they get to patient engagement, 
you know, it’s, “Oh well, we’d really like to involve as many as possible but 
ideally they should be no more than a mile away on the Underground,” type of 
thing. And then, “We’ll find somebody, we’ll find a budget to pay for the tea and 
coffee”.’ This was an interesting perspective as it highlighted how patients 
which are involved are those most easily accessed, for example, those who are 
local. This was similar to the system used by the EMA described by Participant 
SSI01. In addition, the level of involvement was deemed by Participant 
SSI003 to be inadequate and tokenistic when they specified that ‘we were all 
excluded which I found very frustrating, because I had to sit silently as an 
observer and there were things where I felt if I had the opportunity to speak, 
with my long knowledge of dealing with thousands of patients over ten years, 
etc., that I could have had a voice there.’  The patient’s voice was an important 
sub-theme to Theme I. 
 
Participant SSI04 was a patient advocate from a national patient advocacy 
group. This participant was concerned that some patients may not be 
adequately included in initiatives such as this ‘either because they’re not well 
enough, because they don’t have the intellectual ability to be able to do it or 
because the actual fear of it is just too much.  So, the challenges will be 
essentially trying to find a group of patients who are truly connected enough 
and able to do it.’ This was important because the method of selection will 
impact the overall views and opinions obtained. Participant SSI004 said 
‘then, of course, you are self-selecting out others.’ After being questioned on 
how represent other patients, Participant SSI04 replied that ‘I will try very 
hard to give as many views as I can when I’m representing people.  Other 
people can’t stand back and do that and again you’ve just go to assess what is 
said, knowing that that could be the problem but that is no different to any 
other group of people.’ 
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Participant SSI05, a senior member of staff from a UK-wide cancer charity, 
raised concerns about how the size of a patient organisation affects their level 
of contribution. They stated that ‘not every patient group can carry at the same 
level of surveys or data collection as each other, which I think is a challenge.’ 
This is a good point, since better funded charities are more likely to have more 
resources, so they would have stronger patient engagement initiatives. 
Therefore, even patient advocacy groups at the organisational level are not 
comparable, due to their assortment of differences. When commenting about 
individual patient representatives, Participant SSI05 highlighted that ‘when 
you have one or two patient representatives, while that depth of knowledge 
and personal experience is really valuable, there is no guarantee that that’s 
going to be representative of everyone’s views. Participant SSI05 continued: 
 
‘Just thinking about <<type of cancer>>, and this is I suppose just from 
experience of talking to people, it’s not backed up by research, but I 
think people’s different treatment experiences, have they been on prior 
treatments and their experiences of that will certainly influence what 
they think about a new drug, so the side effects and benefits presented 
by something new might appeal to different people depending on what 
their previous experience of being of a similar or different type of 
treatment.  Age, I think will probably have a factor [...]. I think in terms 
of more demographic type backgrounds, I don’t know. I think that 
would be interesting to see if, for example, different ethnic backgrounds 
might have different views on benefit and risk of treatment but I think 
that is too difficult to say really.’ 
 
This was important, as Participant SSI05 raised the possibility where 
differences in demographics could affect the opinions raised, by using age as 
an example. In addition, they also noted that potential differences could exist 
between different ethnic groups. 
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Participant SSI06 was a patient from a much smaller charity compared to that 
of Participant SSI05. Like Participant SSI05 though, they also had concerns 
about how different sized organisations would inevitably implement different 
levels of engagement, depending on their resources. Participant SSI06 replied 
that ‘I think that is difficult, because the patients, generally, come from 
charities who have very little funding.’ Participant SSI06 described how 
funding for patient initiatives is always an issue. 
 
‘Although the charity pays for the people to be there; for their travel, 
accommodation, etc., it takes time out from the other work that they’re 
doing for the charity, which obviously isn’t covered.  So, that can be 
difficult, whether that person is actually a volunteer or a paid member 
of staff within that charity. There is a time element constraint for some 
charities in that, so I’m not sure how big the pool is that they can draw 
from for there to be more patients.’ 
 
Participant SSI06 also had an opinion on patient representatives’ 
understanding the patient’s perspective. They argued that training and 
education are required not only with patient advocates, but also with patients 
themselves, when they described that: 
 
‘I know how much pain I’m in. I know how tired I am.  You can’t measure 
it. So, if I tell you it’s a ten today…I can’t get out of bed, I hurt so much. 
You know? So, yeah, patients need advocacy training to be full partners 
and you have to accept that some are capable of that and others aren’t.’ 
 
Participant SSI07 also represented a small patient advocacy group. They also 
understood the challenges of ensuring adequate patient representation, when 
they replied ‘I think it’s the challenge of getting patients who are 
representative which I think can be tricky.’  
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Participant SSI07 also noted that it would be important to engage patients 
from a variety of backgrounds when they replied that patients should come 
from ‘a variety of ages, because younger people may have different ideas on 
which side effects are more or less helpful than older people because they 
prioritise different things in determining their quality of life.’  
 
Another patient advocate, Participant SSI08, also had concerns about 
individual patients acting on behalf of the larger patient community. They 
described patient representation as: 
 
‘Having a say in all of the parts of the processes that are relevant to your 
community.  I mean, I know you can have one patient trying to 
represent patients generally but I think that’s not really good enough. 
it has to be a patient with the disease at the meeting about that disease.  
It can’t be generic and I know sometimes it’s impossible to have a 
representative for every disease at every meeting, obviously, but for the 
important things like a risk-benefit for a medicine for a particular 
disease the person should be definitely someone with the disease.’  
 
Participant SSI09 had a different and unique perspective compared to 
previous participants, as the Director of Benefit-Risk Assessment at a large 
multinational pharmaceutical company. Participant SSI09 confirmed that 
‘my difficulty is to find representative groups, or a large organised patients’ 
organisation, you have a very different kind of people talking to you.’ 
Participant SSI09 was in the process of developing a patient engagement 
initiative within their organisation and had therefore identified several 
challenges unique to them. They were taking an international perspective, 
which was part of their responsibility. Participant SSI09 asked ‘how would it 
be for the patients you see in Guy’s Hospital compared to people I would treat 
in Nigeria?’ This is a valid point and demonstrates the complexity of this topic 
when considered at the international level.   
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Participant SSI09 continued ‘if we really will do this properly, that’s what we 
will have to consider. So, the benefit-risk that’s acceptable for EMA might be 
very different than what the South African’s health authorities will accept 
there.’ As a pharmaceutical company working across multiple countries with 
differing regulatory requirements, their approach to patient involvement will 
have additional considerations. On the topic of if patient advocacy groups 
represent patients, Participant SSI09 replied: 
 
‘I have patients’ organisations, patients’ advocates, I have field 
knowledge … and this is one thing drug companies do well.  So, usually 
we’ve established a network where we can get data, but this is I think the 
weak link in all of this: how we standardise or…yeah, standardise would 
be the best term, but not ideal, patient identification. So that it’s 
meaningful.  Because you’ll get the opinion that you choose to get, and 
the bias you choose to give, and that’s dangerous.  Well, it’s dangerous if 
you don’t recognise it. 
 
This was an important comment regarding bias, which emerged as a theme in 
several interviews. Participant SSI09 continued, ‘if you recognise the bias, 
you can measure it, and can (for lack of a better word) neutralise it. It’s a…I 
mean, bias, we have this everywhere. We filter, that’s the thing, but how do you 
filter this? I’m not sure that we have necessarily the right method so far or 
recognise it every time. So, that’s why, if you want my own preference, 
wherever I could I’d like to use broad multi-national selections of patients.’ 
 
Participant SSI10 also had a unique perspective, as s/he was a statistician 
involved in B-R methodology. This individual was an industry expert in 
developing quantitative methodology and was also a partner in the IMI-
PROTECT collaboration. Hence, as a quantitative expert, their views were 
indispensable. 
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On the topic of patient identification and selection, Participant SSI10 
described how previous initiatives had weaknesses: ‘generally, focus groups 
think diversity is good. Is that too diverse, you know, are you mixing apples 
and oranges, so to speak?  Or could they dominate a conversation? Yes, and 
also the sort of person who, you know that you're able to travel to a focus group 
and take part in it, it shows that you're not, you know, the sickest of patients.’ 
 
Participant SSI10 also compared how patient involvement initiatives are 
often not like the ‘real world’ by comparing them to clinical trials. This 
participant presented the idea that those patients are not eligible for clinical 
trials may in fact be the patients who would provide the most important 
insights with regards to their condition. Participant SSI10 stated that ‘in 
clinical trials, the patients are often generally healthy, except that they just 
have one problem, you know. If they had multiple co-morbidities they may not 
be eligible for study, but maybe that's the sort of person who you want to get 
values from. At some point, maybe this is done post marketing, you know, but 
at some point.’ 
 
Participant SSI11 was a medical writer within a pharmaceutical company 
responsible for producing medical reports and summaries, which would later 
be used within the context of B-R discussions. Participant SSI11 was keen to 
explore methods of enhancing their reports by including the patient’s 
perspective, however they also highlighted the challenges of ensuring 
adequate representation: ‘maybe for economic reasons, for disease reasons or 
age reasons. The youngest people are hard to get their opinions articulated.’  
 
The last participant to take part in study phase II was Participant SSI12, a 
relatively inexperienced patient advocate who had recently commenced work 
for a charity. Considering their limited experience, they had important insights 
about adequate representation.  
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Participant SSI12 predicted that ‘it won’t be easy to engage with a patient ‘s 
representatives because, a, it’s getting a mix of people that represent, I find 
that in relation to anything that I’m involved in, it’s usually the people that 
squeal the loudest that get included.’ The latter statement was particularly 
interesting as it highlights another emerging theme of ‘strong personalities.’ 
This theme was not just applicable to patients, but to all stakeholders and it is 
an important consideration. Participant SSI12 also commented on the 
appropriateness of some patient advocates: 
 
‘They’re not necessarily always the best people that you need most of 
all and you also probably need a mixture of understanding about the 
process too I would think because sometimes somebody who is totally 
in the dark can come up with something that is fairly simple and should 
have been thought of already. So, I think it’s getting a mix of people and 
it’s probably also, it’s a difficult one, a lot of people that are involved 
with medicines seem to be also sick themselves.’ 
 
Participant SSI12 described examples where they noticed certain individuals 
had a loud voice which affected the dynamics of the group. This is an important 
point as this is relevant to focus group methodology; where participants may 
not feel able to speak up due to the actions of another. They stated that ‘they 
were arrogant and you wanted to sort of say, excuse me, how do you 
represent? I just think that that’s totally wrong.’ Participant SSI12 continued: 
‘It just bothered me that certain people were representing, as you say, I 
presumed, the entire patient population’ and ‘I think whenever you start 
getting arrogant or you know blasé about the whole thing I think then it’s time 
to move on.’ This was particularly apt and supported the comments of 
Participant SSI01 regarding patient advocates at the EMA level. Some 
individuals were perhaps no longer adequately representing patients and this 
must be addressed. These data were further investigated by the emerging sub-
theme of ‘patient advocates are not the same as patients.’ 
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Sub-theme – Patient advocates are not the same as patients 
This was an emerging theme which on analysis fitted most appropriately as a 
sub-theme to the Theme I (Adequate representation of patients). Participant 
SSI01 was the first to make a comment on the role of the patient advocate 
within EMA committees which the participant resides over. Participant SSI01 
stated that ‘at the level of our committee, you have only one representative of 
a patient association, which also do not represent all the patients.’ This 
impacted on patient selection as ‘already bias was introduced by selection’ 
(Participant SSI01). 
 
Participant SSI02 commented on the staffing of patient advocacy groups, for 
example that other types of engagement occurred without direct patient 
involvement. They stated that ‘to be a patient advocate, you have to be the first 
part of those two words. You have to be a patient.’ Participant SSI02 
continued ‘you can’t possibly be a patient advocate unless, at the very least, 
you have lived with someone that is ill. It is a whole different ballgame.’ 
 
Participant SSI03 described the concept of the ‘expert patient’ which they, as 
a patient with the relevant condition their advocacy addresses, had strong 
feelings about who was appropriate to act on behalf of other patients. 
Participant SSI03 said ‘where you’ve got professional advocates, they may 
not have direct experience of the condition, but they’ve got experience of 
advocacy and policy and they can speak the language, and they’d be usually 
very good at summarising information and presenting it in a clear way, which 
is a benefit.’ This was a positive example of how expert patients also offer a 
unique and important contribution. 
 
Participant SSI04 had a different viewpoint. When comparing patient 
advocates and patients, Participant SSI04 stated that ‘they have a very useful 
point to be made, but it’s very interesting, I’ve worked with patient 
representatives on some boards and they simply don’t get it.’ 
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Participant SSI05 approached the comparison of patient advocates and 
patients from a philosophical perspective.  
 
‘This is very philosophical, but I think they’re not the same because in a 
sense we represent patients but we’re not a patient, so there is certainly 
that separation, and I think if we are going to gather patient views it’s 
got to be more than having one representative.  That representative has 
to be accountable to all those patients, as far as possible, which is why 
it is so important to get together as many robust views as possible and 
to reduce that uncertainty, because I think if you just nominate a patient 
representative without that patient representative having the feelers 
out and being able to gather that information, then you’re not really 
doing patients any service and there is a risk with patient 
representation that has to be done very carefully to make sure it’s 
democratic.’ 
 
This demonstrated that Participant SSI05 was aware of the limitations of 
their role as a patient advocate but addressed them with a transparent 
approach. Although examples of inadequate patient advocacy were prevalent 
in the dataset, this participant demonstrated that on the other hand, patient 
advocates also make a vital contribution. Correspondingly, it all depends on 
the individual, their motives and their awareness of their own limitations and 
impact. Participant SSI005 continued: 
 
 ‘Patient advocates can represent the views of others. The patients 
become very informed, not just about their own condition or about how 
it affects them, but they do become informed about the condition 
generally. So, I think they can certainly represent the wider experiences 
of others. […] They look at the data.  They look at evidence.  They speak 
to people and they do try very hard to represent the widest possible 
views and experiences.  I think if we can support them to do that better 
and more robustly, then that’s a positive thing.’ 
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Participant SSI06 highlighted how a certain type of individual would become 
a patient advocate and therefore, by default, does not represent all patients, by 
citing the EMA as an example. They presented the argument that ‘you know, 
you’re not going to get a shrinking violet saying, “Yeah, I’ll represent us on the 
European stage [laughing].’ 
 
Participant SSI07 also commented on the ability of some individuals to 
represent others, when they said ‘they can’t represent, not unless they’ve 
actually experienced the disorder. I think patient advocates vary. There's no 
one generic type. But, I think the core information comes from patients who 
experience the condition and who are taking medication for it.’ 
 
Participant SSI08 had a similar stance to the previous participant and 
described how patient advocates are so variable in their suitability and 
approach. Participant SSI08 confirmed in addition that, within their 
organisation, patient advocates ‘usually are patients, but sometimes they’re 
not.’ They continued: 
 
‘I think a patient advocate should really be a patient, it’s probably 
advantageous but I think they need to be one with a sensible head on 
and they need to leave the emotion at the door because I just think they 
could do a lot of damage to your patient group.  Because I know that 
there is an impression that some people think “Oh my God hysterical 
patient, like, is that what we're gonna get?" And you don't want to ruin 
your chances of being taken seriously and being credible if you turn up 
distressed and wailing and too emotional.  I’m not trying to say that 
these things aren’t important and serious but I think the best thing you 
can do is have a patient rep or advocate that has got the insight of being 
a patient but can stand back from the minutia of having the disease.’ 
 
The comments about emotion and the term ‘hysterical patient’ were 
interesting and highlighted this patient’s concern that their views were not 
seen as objective. 
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Participant SSI09 had the perspective from industry and they too understood 
that patient advocates were not the same as patients, though, their input was 
paramount. Accordingly, Participant SSI09 replied that ‘I have patients’ 
organisations, patients’ advocates … and this is one thing drug companies do 
well.  So, usually we’ve established a network where we can get data but this 
is I think the weak link in all of this: how we standardise or…yeah, standardise 
would be the best term but not ideal, patient identification so that it’s 
meaningful.  Because, you’ll get the opinion that you choose to get and the bias 
you choose to give, and that’s dangerous.  Well, it’s dangerous if you don’t 
recognise it.’ Again, like Participant SSI05, this participant recognised the 
limitations of their approach, while continuing to develop their initiative with 
as much transparency as possible. Participant SSI009 recognised that patient 
advocates were ‘a necessary surrogate in many situations. We need to 
recognise, like any surrogate, they’re not ideal […] As long as we don’t make it 
what it isn’t. But we use them (patient advocates) because there’s nothing else 
you can do.’ 
 
Participant SSI10 offered a different perspective. Although this participant 
recognised patient advocates were different, they argued that ‘they’re pretty 
close. Because, often, they are patients. They may not be the typical patients, 
because of the nature of wanting to be an advocate. They probably have a good 
idea of the kind of scope of what patients think in general.  And they'd be very 
informed in terms of, you know, the disease and the literature and anything 
like that.’ 
 
Participant SSI11 also mentioned the patient advocate as being a certain 
‘type’ of individual. They mused that ‘the advocacy groups are composed of 
patients who are eager to have their opinions asserted, whereas we’re missing 
the ones who don’t want their opinions asserted and so we don’t have access 
to what those opinions are as much.’ Participant SSI11 also noted that ‘we 
need to recognise that there are certain self-selecting patient advocates who 
will get involved early, because a lot of patients don’t want to bother with the 
details of these definitions.’ 
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Theme II: Adequate methods for involving patients in B-R assessment 
Topic 1 of the semi-structured interviews were centred around the methods 
of involving patients in B-R analysis. Participants were directly questioned on 
this topic, which meant it was inevitable to emerge during the interview. Be 
that as it may, it was surprising how often methodology was mentioned 
throughout the interviews, even when it was not the direct topic of 
conversation. Participants recognised the difficulty not only in identifying and 
selecting the right patients to be involved, but they also had concerns about 
the methods utilised to include them. 
 
Participant SSI01 was interested in using both quantitative and qualitative 
approaches. During interview, there was a robust discussion about a semi-
quantitative concept, where patient preference elicitation could be used in 
combination with qualitative focus groups. Participant SSI01 confirmed that 
this approach ‘explores two different ways, but it’s not possibly for the same 
goal. It’s for two different goals, so, the two approaches are very interesting for 
me.’ 
 
Participant SSI02 found the idea of qualitative focus groups appealing. They 
confirmed ‘that would be very interesting, because it would be good to have a 
discussion with someone that was thinking about going on a drug I’ve taken 
and they hadn’t been on yet.’ Participant SSI02 understood the need to review 
information in advance of any such focus group. They noted that ‘graphs, pie 
charts and anything else visual are always easier (to absorb).’ Participant 
SSI07 also described how they would like to review B-R information if they 
were invited to do so. They would like to see ‘a mixture of data: bullet points 
and bar charts, pie charts. Make it brighter, make it bold, and make it attractive, 
yes. And also include links to where they can find out more information.’ 
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Participant SSI03 commented on how as a patient representative for NICE 
committee meetings, they were provided with lengthy dossiers in advance of 
their committee meetings. They pointed out however that, due to its length, 
they ‘didn’t think the NICE Committee had had enough time to read the 
dossier.’ Participant SSI03 described the dossiers and how published articles 
were provided with commentaries: ‘The commentaries are not always positive 
of course […]. Some intermediary will take the information and usually, with 
the help of one of our medical experts, we will write up, what I like to think, is 
a lay-friendly version.’ Participant SSI03 also described how they were aware 
of quantitative methodologies, also employed within their NICE committee 
meetings. They stated that they use ranking to rate benefits and risks: ‘they’d 
gone through a process of pre-ranking through quantitative work to try and 
avoid that small (sample) size issue.’  Participant SSI03 commented how, in 
addition to patients, they thought other stakeholders were essential to be 
included. Participant SSI003 emphasised the importance of other 
stakeholders: ‘pharmacists, because we know adherence is a huge issue, and 
nurses, you know, are increasingly involved in prescribing and specialist care’ 
(Participant SSI03).  
 
Participant SSI05 described the challenges of implementing a valid method 
of involving patients in B-R. 
 
‘The challenge is also around getting real world data from patients who 
haven’t actually had any experience, so that’s the conundrum of benefit-
risk.  So, we do regular surveys, interviews with people, but again it’s a 
small number of people or we try and bring in supplemented data from 
other studies, if there is a particular side effect associated with a drug 
we’ve got evidence, people’s tolerance for that side effect, we can bring 
that in but it’s not… we’re aware that it’s limited.’ 
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Participant SSI08 understood the logistical challenges of patient selection 
and identification, and how this influenced the development of an adequate 
methodology: ‘I can see the administrative nightmare of pulling a patient from 
the correct disease group into the meeting about that disease because they 
might not have a patient directory for each or they might not have somewhere 
they can access that patient. But, I think they should at least try’ (Participant 
SSI08). 
 
As Participant SSI09 was developing methodology to include patients in B-R 
discussions, they had an important insight and they also appraised the 
proposed framework which would be developed from this research study. 
Participant SSI09 argued that this was a considerable task for the organisation. 
They commented that they were collaborating with the IMI-PROTECT 
consortium in order to standardise their approach: ‘We’re trying to see which 
methods we would use. We’re doing this with now I think it’s about eight or 
ten companies who have joined.  Academia are very interested so they’re part 
of the process. On further discussion, Participant SSI09 confirmed that ‘by 
preference I’m a quantitative person, so we said let’s move to quantitative 
methods. Semi-quantitative structured benefit-risk is not exactly quantum 
physics yet, but we’re working toward developing these methods.’ 
 
When proposing a semi-quantitative framework involving patient preference 
elicitation and focus groups, Participant SSI009 stated ‘the challenge of this 
is it takes a lot of effort to validate, like to really know you got the right choices 
(B-R criteria) and that people have actually understood what these choices 
were and expressed it in a proper way.’  
 
This is an important challenge, and one that can only be addressed in 
collaboration with all stakeholders. It was not possible to develop elicitation 
methods during research phase II, as the complexity of an individual drug’s 
benefit and risk criteria are lengthy and require various technical input.  
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Participant SSI09 confirmed that ‘I would like to end up in a truly quantitative 
approach, but when you get into this you realise there’s nothing: nothing 
validated and no clear way to get there, so you fall back to the semi-
quantitative approach.’ When discussing qualitative focus groups, Participant 
SSI09 confirmed that ‘focus groups are not something that just got invented. 
There’s a science to this.  It’s not the most rigorous, I mean we’re not talking 
gene splicing here, but that being said we need to use what’s there, try to keep 
improving this, because I do find that it’s your input that will determine your 
output, and if your input is incorrect or incomplete then you suffer a risk.’  
 
This is an important point. Participant SSI009 was referring to the quality of 
the focus group itself. By asking particular questions, the focus group is led, 
much like the discussion was for the semi-structured interviews. Therefore, 
there is a risk that the moderator of the focus group can in fact introduce their 
own bias into the data that is collected. The thesis author had to take this 
consideration into account when developing their own B-R framework. 
Participant SSI009 concluded that although challenges remained, new 
methods of patient inclusion would be a valid contribution, when they stated 
that ‘I think people have to get beyond this and that, in a sense, this will come, 
this will get better, more structured, and will be applied by different players in 
the healthcare system.’  
 
As a statistician, Participant SSI10 had an important perspective about the 
methodology of including patients in B-R discussions. Firstly, the participant 
described their background in greater detail: 
 
‘A bit of history, actually my background is in statistics, or my formal 
training's in statistics and then I moved into health economics and the 
health economists are very advanced in eliciting not just patient 
preferences, but, eliciting preferences in general. And then I moved into 
decision analysis, which is a way of kind of structuring and analysing 
decisions. And part of that discipline is you make decisions in a way to 
kind of optimise utility, so there are ways of placing values on outcomes 
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for the decision-making. So, there's a rich history in eliciting 
preferences.’ 
 
When presenting a semi-quantitative approach, which would involve patient 
elicitation and qualitative focus groups, Participant SSI10 confirmed that ‘a 
combination of these methods is mathematically robust, they all satisfy utility 
axioms and things like this. I think the real problem is the behavioural science 
aspect and how to codify and capture patient's beliefs accurately.’ 
 
Participant SSI10 also commented on how data is presented during B-R 
discussions when he stated that ‘historically, the benefit-risk assessment was 
a narrative. It’s just a text description of the benefits and risks and it always 
says so therefore the benefits outweigh the risks.’ Participant SSI10 was 
pleased with recent developments to involve patients when they stated ‘so, 
this is trying to make that process a bit more transparent.’ When discussing 
the idea of a list of benefits and risks which could be presented to patients, 
Participant SSI10 had the following comments:  
 
‘Well, you can be completely surprised by what comes up from what 
actually patients are most concerned about in diseases, it might not be 
what you first thought, not experiencing that disease. But at the same 
time, if you look at the list of risks that you see in a clinical study, it's 
hundreds of risks, say 4, 500, risks and it would be overwhelming. So, 
it's a very difficult question to answer. I mean I sympathise that there 
should be an open part of this, it shouldn't be constrained by a list, but 
maybe it needs some structure, I don't think you can be completely free 
and I think having lists can help prompt someone to... so I think some 
hybrid, I don't know if that's the sort of.’ 
 
 
 
 
 
 
 
- 136 - 
When discussing focus group methodology, Participant SSI10 confirmed ‘I 
don't have a clear opinion on that. In fact, it would be interesting to see if it 
makes a difference, you know, between a smaller group and doing things in a 
focus group, an interactive focus group and kind of a large independent 
sample.’  
 
Participant SSI10 also commented on patient representation: ‘To me, it's 
fundamental that the patients should be representative of the target question, 
the research question. You find a research question and in that is a target 
population. And, ideally, there should be real world evidence, not the kind of 
selective patients you know in a study.’ When discussing the idea about 
presenting patients with hypothetical scenarios, Participant SSI10 noted 
some key issues with this approach: 
 
There are, perhaps, extra complications in that asking a patient about 
adverse events before they've taken the drug and haven't experienced 
them, and asking their opinions about them at the end of the a study 
where they may have experienced an adverse event could change their 
opinion on it It's very different, to you know, imagine what constant 
nausea feels like and then actually experiencing constant nausea, it's 
better or maybe it's worse than a figure of experience. Or patients 
who've had the disease for a long time and have somehow adapted or 
coped, developed coping mechanisms compared to someone who's 
brand new.’ 
 
Participant SSI11 also noted issues with presenting data to participants in 
advance of a focus group or when they stated that ‘maybe it will be the order 
that you put the benefits and the risks when you’re asking them about them, 
they influence them when they’re doing their ranking.’ 
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Theme III: Objectivity of patients 
The objectively of patients involved in B-R discussions was a theme which 
arose numerous times during phase I in particular. Yet, although participants 
were quick to highlight a patient’s objectively, a number of participants in 
phase II gave examples, either, where their objectivity was questioned or 
where they had seen examples of a lack of objectivity of others.  
 
Participant SSI01 responded that they use ‘gut feeling’ during their B-R 
assessment meetings. When making their decision, they argued that, ‘for 
example, if I take the example of, say, liver injury or skin injury, I am the only 
expert able to give my opinion but its only my opinion and what I try to say to 
the regulator is that they should use very useful method like algorism to assess 
the causality between an event and a drug. They don’t use it, so I said ‘believe 
me.’  
 
As a patient representative, Participant SSI02 was well aware of the need to 
remove emotion from any discussions, ‘yet, I suppose, if you are desperate. I 
suppose there is always going to be bias in things.’ 
 
Participant SSI03 had seen evidence of bias in NICE committee meetings, and 
not from patients, but ‘bias from people dominating meetings who’ve got a 
particular viewpoint. When discussing the potential bias of patients, 
Participant SSI03 compared it with the inherent bias that all people present:  
 
‘Well, there’s a huge bias, isn’t there? It’s either tokenistic or it’s usually 
biased, especially for a patient organisation because the majority of us 
are assisted in some way by pharmaceutical sponsorship, even if it’s not 
the sponsoring company. And you try your best to be completely 
agnostic but clearly if there’s a drug which appears to have worked in a 
trial you’d be mad not to support it. But you have to be extremely 
careful about being seen to be or being biased in favour of the drug. And 
the data is hard to interpret. You don’t see all the data of course; you 
only see what’s published. You instinctively look for the positives in 
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data, particularly if it’s been a well-regarded trial. And again, when you 
start to look at the dynamics of the people around and the voices, again, 
you could feel in that committee meeting I had somebody with perhaps 
a bit more knowledge or a particular bias could change the outcome of 
those decisions.’ 
 
Participant SSI04 also commented on other stakeholders, ‘I mean if you have 
a room full of doctors who are discussing a topic, they’ll be biased.’  
 
Participant SSI05 understood why a framework was therefore necessary to 
reduce the likelihood of bias, ‘I suppose that’s why it’s important to have some 
kind of framework rather than a survey which could be challenged potentially 
or a focus group run by a drug company and they happened to get results to 
say they preferred this type of drug.’ Participant SSI06 also noted that ‘I 
mean, the pharmaceutical companies have got a wealth of bias. ‘ 
 
Participant SSI07 was quick to point out that ‘whenever you've got human 
beings you’ve got bias.  Yes, in an ideal world everyone would go into a room 
and they would be very objective about their experience and their clinical 
findings, that doesn’t happen […]. It's very hard to get rid of bias, but you can 
reduce it by making sure it’s a calm, you know, measured meeting.  And 
everyone is given enough time to speak. And what you say is not going to be 
discounted in any way because you are not a qualified clinician.’ 
 
Participant SSI08 had seen previous evidence of lack of the patient’s 
objectivity, and examples of too much emotion. They thought that: 
 
‘In my experience of patients, bless them, and I am one of them, I mean 
it’s an emotional subject, there is I think sometimes a problem with 
people being able to be objective about processes and outcomes.  
Separating it from their personal experience and their daily quality of 
life because when people are very sick, (A), they’re probably not going 
to be involved in these processes because they can’t be dealing with it 
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but (B), I just think that is one of the difficulties you get somebody who 
is very passionate but, like, overly emotional.  In a way, you need to find 
someone who’s a patient but who is objective.’ 
 
From an industry perspective, Participant SSI09 was well aware of this 
challenge. Though, they had some recommendations on how to deal with this 
issue. Participant SSI09 stated that ‘I would like to think we can do this 
scientifically; we can come with arguments that everybody will agree to, say 
that that’s the right methodology, these were the right samples, these are the 
right knowledge, and therefore your benefit-risk here differs from here, and 
while it might not be acceptable in that setting, or it might be acceptable in this 
setting, it may or may not be in another setting. But, remove emotion out of 
this.’ 
 
Participant SSI009 described how one option would be to move away from 
the current system of using patient advocacy groups linked to the organisation 
when they stated that ‘I think a big part of what we’re going to have to do is 
step away from these very selected or bias groups.  I don’t want to say bias in 
a bad way, but to learn to work with probably the organised regional care unit, 
whether they’re regional hospitals or primary care practices, to better 
understand most of these patients […] And as much as we can, and that’s not 
easy, and I don’t say this in a pejorative manner, but avoid professional 
patients’ groups, because it becomes a different thing. They don’t think of 
themselves anymore, they speak for others, and what I want is the input of 
people as it affects them as a person; not how they think it affects the millions 
of other patients with the same disease.’ 
 
Even though the focus was on involving new patients, discussions were very 
much focussed around the objectively of those stakeholders already involved. 
This was interesting and supported the general hypothesis that involving 
patient advocacy groups alone was insufficient, and processes must be 
developed which link directly with patients themselves.  
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Patient advocates are an important stakeholder, yet, they should contribute in 
collaboration with patients and not be used as an alternative. 
 
Theme IV: Understanding and education 
Another theme which emerged during research phase I and was verified 
during phase II was that of a patient’s understanding and education.  
 
Participant SSI02 gave an opinion on who was best placed to make decisions. 
This was perhaps an example of the risk that patients could potentially ‘over 
step the mark.’ The thesis author does not support this position. It is vital 
patients are involved, yet clinicians and regulatory assessors are undoubtedly 
the most qualified to make licensing decisions. Participant SSI02 stated that 
‘I think only we can assess the risk and the pros and cons. And I think as well 
you have to be… I am not talking just about aspirin or whatever, if you are 
talking about specific drugs for long-term illnesses.’  
 
Participant SSI03 highlighted that even as a member of a NICE committee, 
they sometimes struggled to understand. They said ‘Because the language is 
completely alien, the utility of death or the disutility of death. I’ve no idea what 
they’re talking about here half the time.’ This participant was well educated, 
experienced in B-R discussions and they had made contributions at NICE 
committee meetings previously. Therefore, this acts as evidence that even 
experienced patient advocates need additional support and training. There is 
also a clear need for educating all patients, if they are to successfully contribute 
to B-R discussions. Participant SSI06 also noted that the process is worthless 
‘if you don’t educate the patient to take part properly in the background and 
within the whole process.’ 
 
Participant SSI07 had a different point of view when they stated that: ‘It’s 
never a good idea to assume that patients won't understand simply because 
they do not have the clinical expertise. Patients are very, very good at finding 
things out themselves and asking questions as well.  So, I think the best way to 
involve patients is include them, wherever possible, and then you learn where 
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best they can help.’ This was a valid point and one which is supported by the 
thesis author. 
 
Participant SSI09 also pointed out that ‘regulators ultimately serve patients, 
[…] their mandate is to help patients.  I’m not sure they understand what it 
means fully; I don’t think they understand how profoundly it (involving 
patients) will change the way they will oversee and approve treatments and 
drugs. And, similarly for patients: I think patients think, ‘all of a sudden I’m 
going to better cared for because I have input.’ Participant SSI09 ended with 
‘we need to not present this in a fallible way.’ Indicating the way in which 
training is undertaken will impact on the outcome. 
 
Participant SSI11 expressed concerns about the patient’s understanding of 
clinical documentation when they stated that ‘patients will have a harder time 
breaking down the entire portfolio, compared to if they’re led through it first. 
Ranking (of benefits and risks) would be good. It would also be of high interest 
to the industry people, in my opinion, because I can see that this patient group 
ranks this risk high or low.’ Therefore, a collaborative approach between 
regulatory assessor and the patients would be appealing to industry. 
 
Theme V: Insight into the patient’s experience  
When participants were questioned about the benefits of involving patients in 
B-R discussions, a theme which arose time and time again was regarding the 
‘insight into the patient’s experience.’ 
 
Participant SSI02 had a strong opinion on the matter when they stated that 
‘nothing annoys me more when somebody says, “Oh I know how you feel.” I 
feel like saying, “Just don’t say that. Don’t say that to me because you don’t, you 
can’t.”’ 
 
Participant SSI03 described how in preparation for NICE committee 
meetings, they would review relevant articles. They went on to say ‘so, there’s 
this one pivotal trial, in our case. I was just reading the Cochrane review of it 
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all. They don’t seem to impress anybody. And also, they’re only looking at a 
certain set of outcomes anyway; they don’t seem to be looking at all the 
outcomes that are important to the patients.’ Participant SSI03 understood 
the importance of viewing data at the population level, yet also the relevance 
of the individual perspective, ‘yes, there’s the population level, but 
nonetheless, the patient’s experiences can still bring a richness to the data 
which you don’t see. But I would say on the main, they bring the richness to 
the data. It’s not captured usually in the primary outcomes or the endpoints of 
clinical trials.’  
 
When describing insight into the patient’s experience, Participant SSI04 
highlighted that: 
 
‘I think we actually do look at things from a different angle.  Now, when 
you’re talking about patients you are of course talking about everybody, 
because basically, everybody is a patient.  So, I would be talking about 
people who are long-term patients because it’s mostly long-term 
patients who are well involved with their care, a lot of them have to 
actually juggle a lot of medications anyway.  So, when we’re talking 
about long term patients being in a cost risk-benefit analysis, I think 
that’s absolutely essential, because they’ll be looking at it from a 
completely different point of view from professionals.’ 
 
Participant SSI05, whom was not a patient but who acted on behalf of 
patients, also understood the unique insights which patients offer, when they 
stated that: 
 
‘I think we want to see better patient input at both stages.  Also, to make 
sure that actually what goes into the system, so the right drugs are 
developed, and that we understand their value much earlier on.  So, it 
doesn’t come to the licensing or HTA stage and you find that it’s actually 
only going to benefit a very small number of patients and we don’t have 
the data to express that.  It’s trying to understand that much earlier on 
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in the clinical development process, that the right things come through 
the system.’ 
 
Participant SSI06 disclosed that ‘however empathetic you are, you can’t 
really know what it’s like. The patient is the only person that really knows what 
it feels like to have the condition and the only one that knows what the 
medication effects feel like.’ 
 
Participant SSI07 described ‘lived experience’ when discussing the insights 
which patients offer. They argued that ‘patients have the lived experience, they 
know what is meaningful in terms of benefits and risks because they live it. 
Also, patients often have done a lot of research online because so much is 
accessible and so they very often have a technically informed view as well as 
an experiential informed view.  So, they are very good at telling you how it is 
and making points which perhaps someone who hasn’t experienced the 
disease wouldn’t think of.  So, yes, they can provide invaluable input. ‘ 
 
Participant SSI09 approached this from a population perspective, again due 
to their position as Director of B-R across a range of countries. 
 
‘You know, if you wanted to look at benefit-risk for malaria, which we’re 
very deeply involved, I can fly samples of people from ten countries in 
Africa and bring them here, but I will learn much more to go there and 
sit where they are, because to them it might be self-evident some of 
these things, and they don’t mention them but [laughter] you start 
looking and it’s ‘Hmm!’ yeah.  So again, this is something we need to 
learn to do, like, when it’s appropriate or not.  I think for conditions, for 
instance for psoriasis, it’s essentially something we’re focusing on in 
the Western world.  I think we can bring patients to larger centres and 
do it; in other things it won’t work, it really is not the right way to do 
this.’ 
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Theme VI: Motivation and ulterior motives of stakeholders 
Another theme of particular importance which emerged during phase I and 
which was clarified in phase II, was that of the motivation of stakeholders. 
Initially, the focus was on the motivation of patient advocates, however, as the 
study progressed this theme arose in a variety of difference contexts. 
 
Participant SSI01 described how patient advocates, at the EMA level, were 
often pre-selected based on their links with industry. They stated that ‘now 
there is probably one main reason (for their selection) is that, most of the 
patient association have links with industry, and so we probably chose only 
ones we know.’ This is an example of how pharmaceutical companies may 
influence who is involved in their B-R discussions. 
 
Participant SSI02 described those patient advocates who may not have the 
correct motives behind their involvement: ‘one thing you have got to guard 
against is the people that have got nothing else to do and just want to 
perpetually do this.’ 
 
Participant SSI05 was clear in that all stakeholders have different motives, 
and this is not only applicable to patient advocates. They confirmed that: 
 
‘I think sometimes it gets forgotten because, quite rightly, everyone has 
got different agendas, whether it’s to get a paper published or whether 
it’s to make profit on this drug or to be responsible for their 
stakeholders or to be careful about the NHS budget but, ultimately, it’s 
got to be about patient benefit, so it’s not just about patients just coming 
in at the table at a certain point towards the end, it’s about patients 
driving the agenda all the way through.’ 
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Participant SSI06 described how patient advocates may have their own 
agendas: ‘Well, they’ve usually only got a personal hidden agenda. You know, 
not a professional, not a commercial’ whereas Participant SSI08 stated that 
‘it’s quite clear that pharma. has almost an obligation to engage and so it’s 
obviously going to be part of their compliance and their governance to do so.’  
 
Participant SSI09 presented their industry perspective: ‘my view is it’s as 
clear as day. This is coming, so you might as well embrace it, try to make the 
best of it, and […] I don’t have to be emotional about it, I just have to make sure 
I do it well.  And if I do it well I do believe everybody will benefit, and those 
companies who do it better will have a competitive advantage over others.’ 
The latter part of the statement was interesting. Not only did the participant 
confirm that this was the right direction to take, but they also presented the 
idea that this would give a competitive advantage over other companies who 
did not follow the same path. Participant SSI09 continued: ‘I have twenty 
people doing this now in this group, because I see this as the next big thing, 
and it’s putting medicine back where it should be, which is centred on the 
patient. You don’t do medicine for the money, you don’t do the medicine for 
the prestige or the fun; you do it because you want to help patients. But the 
patient, (it’s important to) ask them what they want, you know?’  
 
Still, Participant SSI09 also raised the possibility that ‘my fear is that 
regulators will use this to confirm your bias. For example, this drug doesn’t 
provide anything more.  We’re going to go to…’, and that’s why I’m so adamant 
that we need to do this pre-competitively: all agree on the rules so we don’t 
come in twisting the truth.’ 
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Discussion 
 
Research Phase II presented in Chapter V identified that patient involvement 
in B-R assessment was a current initiative which still posed challenges to even 
the most experienced experts involved in B-R analysis. Chapter V further 
contributed to the overall aim of this research of developing a framework to 
include patients. It was imperative to gain a deeper understanding of the 
perspectives of regulatory agencies, pharmaceutical companies and patient 
advocacy groups, as a framework which would ultimately be developed had to 
be acceptable to all relevant stakeholders. Thus, data was analysed so that the 
challenges faced by regulatory agencies and pharmaceutical companies could 
be further understood. To further develop the concepts and themes which 
were identified from phase I of the research, semi-structured interviews were 
completed with a number of key stakeholders. The objective of phase II was to 
(3) using qualitative semi-structured interviews, establish the opinions of 
representatives from pharmaceutical companies, regulatory agencies and 
patient advocacy groups, by undertaking thematic analysis of their views and 
opinions. In order to achieve this overall objective, several sub-objectives were 
established for research phase II.  
 
The first sub-objective was to discuss the challenges of involving patients in B-
R assessment with stakeholders. All stakeholders agreed that adequate 
representation of patients was an important topic requiring further 
investigation. Not only were patient advocates deemed to be an important 
stakeholder, they were also criticised by some; as the motivations of patient 
advocates were sometimes not always transparent. The involvement of 
patients was seen as tokenistic, yet it was also recognised that processes were 
in early stages of development and, overall, patient involvement initiatives 
were developing. The logistical challenges of involving patients were raised by 
several participants, and the logistics of running focus groups was also 
pinpointed as an obstacle which would need to be overcome.  
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The difficulty in identifying representative groups, or larger organised 
patients’ organisations which were representative of the target patient was 
also a challenge. The objectively of patients involved in B-R discussions was a 
theme which arose multiple times during phase I of the research in particular. 
Yet, although participants were quick to highlight a patient’s objectively, a 
number of participants in phase II gave examples, either, where their 
objectivity was questioned or where they had seen examples of a lack of 
objectivity of others; namely clinicians, regulatory assessors or patient 
representatives. Bias was described by all participants, yet all participants 
gave examples of bias by other stakeholders. Once this is recognised, the 
challenge of a patients’ bias becomes less important. The key aspect is to 
recognise all potential sources of bias, whereever it arises, and then accept it, 
document it, and ensure transparency.  
 
The second sub-objective was to develop solutions to the challenges of 
involving patients in B-R assessment. The method of involving patients was 
critiqued by participants and the general feedback by participants was that a 
qualitative focus group, undertaken alongside quantitative preference 
elicitation studies, could be a suitable way of gaining the patients’ perspective, 
which could ultimately be used in B-R discussions. It was suggested the current 
model to involve patient advocates was no longer fit for purpose. Rich data was 
obtained to support the themes which were identified and verified during 
phase II. Themes describing adequate representation of patients, adequate 
methods for involving patients, the objectivity of patients, understanding and 
education, and insight into the patients’ experience were all confirmed, 
analysed and verified. Subsequent to the completion of phases I and II, and the 
achieve the overall aim of this research a framework was proposed. This will 
be further investigated in Chapter VI. 
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Summary 
 
• All stakeholders agreed that the adequate representation of patients 
was an important topic requiring further investigation. Not only were 
patient advocates deemed to be an important stakeholder, they were 
also criticised by some; as the motivations of patient advocates were 
sometimes not always transparent.  
 
• The involvement of patients was seen as tokenistic, yet it was also 
recognised that processes were in early stages of development and, 
overall, patient involvement initiatives were developing.  
 
• The logistical challenges of involving patients were raised by several 
participants, and the logistics of running focus groups was also 
pinpointed as an impediment which would need to be overcome.  
 
• The objectively of patients involved in B-R discussions was a theme 
which arose multiple times during phase I of the research in particular. 
Yet, the objectivity of other stakeholders was also seen as inadequate.  
 
• Examples of bias were identified. Moving forward this must be 
considered by all stakeholders. It is essential to recognise all potential 
sources of bias, wherever it arises. 
 
• Solutions to the challenge of involving patients in B-R assessment 
included implementing an adequate method.  
 
• Rich data was obtained to support the themes which were identified 
and verified during phase II. The adequate representation of patients, 
adequate methods for involving patients, the objectivity of patients, 
understanding and education, and insight into the patients’ experience 
were all confirmed, analysed and verified. 
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Chapter VI: Evaluation of the 
patients’ perspective on their 
involvement in the benefit-risk 
assessment of medicines and a 
thematic analysis of the patients’ 
experience 
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Introduction 
 
Phase II of the research, presented in Chapter V, described the themes which 
emerged when participants from regulatory agencies, pharmaceutical 
companies and patient advocate groups were questioned about patient 
involvement in B-R assessment. Six overarching themes were emerged from 
the analysis. The most prevalent theme was the ‘adequate representation of 
patients’ followed by ‘adequate methods for involving patients in B-R 
assessment,’ ‘objectivity of patients,’ ‘understanding and education,’ ‘insight 
into the patient’s experience’ and ‘motivation and ulterior motives of 
stakeholders.’ Data suggested that some patient advocates, especially those 
involved at the EU regulatory level, were perhaps not as representative of the 
relevant patient group as would be expected by stakeholders. The data 
collected in phase II suggested that stakeholders understand that patients 
should have an understanding and experience of the condition, to be able to 
represent others. Whether that experience is a result of them having the 
condition themselves, or perhaps because they care for someone with the 
condition, as a carer or relative. 
 
Phase III was undertaken to confirm the themes which were identified and to 
identify any new themes which emerged directly by conversing with patients. 
Subsequently, this data would be used to generate a framework to involve 
patients in B-R assessment. Firstly, though, it was essential to gain an 
understanding of the different disease areas which would be investigated 
during phase III of the research. The FDA’s Patient Focused Drug Development 
program contained information on several disease areas, however, due to 
resource implications, only a limited number of patient indications were 
selected for inclusion in the study. 
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Kidney disease and organ transplants 
Kidney donation and transplantation ‘can be lifesaving, transformative, and 
restorative’ for patients with nephrotic disease (FDA, 2016b).  Many organs 
are recovered from deceased donors, ‘but a substantial contribution of kidneys 
come from living donors’ (FDA, 2016b). A successful organ transplant requires 
a strict pharmacologic regime in combination ‘with non-pharmacologic 
management, before and after receipt’. (FDA, 2016b). Once the patient has 
received their transplant, clinicians focus on four main objectives: ‘prevention 
of organ rejection by the recipient’s immune system, treatment of the 
underlying medical condition, treatment of emergent complications of the 
immunosuppression (IS) regimen, including prevention and treatment of 
infections, and managing the adverse effects of the IS regimen.’ (FDA, 2016b). 
Post-operative management is complex and serious illness can result due to a 
number of different causes, for example, ‘viral, bacterial, fungal and other 
opportunistic infections.’ Long-term pharmacologic treatments are required. 
They include ‘induction immunosuppression with intensive combination 
regimens, maintenance immunosuppression with less intensive combination 
regimens, and additional medications for treatment of acute organ rejection’. 
(FDA, 2016b). 
 
Cancer and curative therapies  
Cancer is a disease caused by uncontrolled growth of abnormal cells within 
human tissues, which, if left untreated, ultimately spread (metastasize) to 
other parts of the body (FDA, 2013c). Patients in the early stages of cancer may 
not experience many symptoms, and the cancer can grow for years before 
symptoms are felt. When symptoms do appear, they typically include 
shortness of breath, coughing, pain, weight loss, and fatigue (FDA, 2013c). 
Cancer treatments fall into two main categories.: (1) ‘Therapies to cure, reduce 
the size of tumour, or control the spread of disease include surgery, radiation 
therapy, chemotherapy, and molecularly-targeted therapies’ (FDA, 2013c).  
‘Chemotherapy drugs are designed to kill cancerous cells or stop them from 
dividing, while targeted therapies are drugs optimally used for specific 
individuals whose tumours have a particular molecular defect’ (FDA, 2013c).  
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(2) Palliative or supportive care therapies are used to improve or manage 
symptoms of the disease or side effects of treatments; such as ‘supplemental 
oxygen, pain medications, steroids, and non-drug therapies such as breathing 
exercises’ (FDA, 2013c). 
 
Human Immunodeficiency Virus (HIV) and antiretroviral therapy (ART) 
Over time, the HIV virus attacks and gradually degrades the body’s immune 
system by depleting infection-fighting T-cells; ultimately resulting in acquired 
immunodeficiency syndrome (AIDS) (FDA, 2014b). The use of antiretroviral 
therapy (ART) to prevent viral multiplication is now recommended, reducing 
the likelihood of T-cell depletion (FDA, 2014b). ART involves a strict treatment 
regime, which can often require a ‘daily combination at least three 
medications’ (FDA, 2014b). ART is not curative, however, with careful 
management of the patient’s viral load there, is not only a reduced risk of 
ongoing transmission, but also a reduced risk of progression to AIDs (FDA, 
2014b). Still, an important consideration of ART therapy are the short and 
long-term side effects of treatment, which can greatly impact the patient. 
‘Short-term effects include diarrhoea, nausea, headache, and sleep 
disturbances, among others’ whereas ‘potential long-term effects can include 
body changes (e.g., fat build up or depletions in particular areas of the body), 
kidney, liver, heart or bone side effects, and others’ (FDA, 2014b). Without 
strict adherence to the ART regimen, drug resistance can occur which may 
ultimately result in a progression to AIDs. 
 
Psoriasis and psoriatic arthritis  
The clinical presentation of psoriasis, a chronic inflammatory disease, often 
includes areas of red, thickened, scaling skin that are itchy or sore. The most 
common type, plaque psoriasis, is ‘characterised by inflamed, red skin covered 
with silvery white scales. The patches may itch and burn and can appear 
anywhere on the body, but often on the elbows, knees, scalp, and lower back’ 
(FDA, 2016a). Psoriasis has been shown to be closely linked with psoriatic 
arthritis and therefore patients’ often present both skin and joint 
manifestations (FDA, 2016a).  
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Psoriatic arthritis ‘typically manifests as joint pain, stiffness and swelling’ 
(FDA, 2016a). ‘There is no cure for psoriasis; however, there are several 
treatment options that aim to reduce and manage symptoms and improve the 
quality of life’ (FDA, 2016a). Topical treatments, phototherapy and oral and 
injected medications are all used to treat psoriasis and psoriatic arthritis. 
Medications include ‘methotrexate, acitretin, cyclosporine, apremilast, and 
biologics, such as etanercept, infliximab, adalimumab, ustekinumab, and 
secukinumab’ (FDA, 2016a).  In addition to medications, changes in lifestyle, 
‘such as diet and alternative therapies, are also common components of 
psoriasis treatment regimens’ (FDA, 2016a). 
 
It was important to gain an understanding of disease areas which were to be 
investigated in phase III. To further develop the concepts and themes which 
were identified from the survey data, semi-structured interviews were 
completed with those participants who wished to participate in phase II of the 
research. The objective of phase III of the research study was to (4) using focus 
groups to disclose the views of patients, identify the patient’s perspective; to 
include an insight into their condition and their opinions on patient 
involvement in benefit-risk assessment discussions. In order to achieve this 
overall aim, several sub-objectives were established for phase III of the 
research.  
 
Sub-objectives 
 
• Evaluate the patient’s perspective on their involvement in the B-R 
assessment of medicines. 
 
• Obtain rich data on the themes which were generated in previous phases 
of the research. 
 
• Compare and contrast the perspective of patients with different diseases. 
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Methods 
 
Review of FDA’s Patient Focused Drug Development Disease-specific meetings 
In addition to the ongoing literature review, which focussed on the benefit-risk 
assessment of medicines, an ongoing review was undertaken on the FDA’s 
Patient Focused Drug Development ‘Disease-Specific Meetings’. This was 
completed to prepare for data collection, and later to compare and contrast the 
data collected in phase III of the research (FDA, 2013c, 2014b, 2016a, 2016b) 
 
Patient and public involvement (PPI) review 
As a study investigating how patients could be incorporated into a benefit-risk 
assessment framework, it was essential to start the research as it meant to go 
on: to include patients in the study design and theory generation. The Patient 
and Public Involvement Group as Guy’s hospital were invited to review the 
study documentation. Three patients responded to the request and their 
comments were included in the study application.  
 
Development of the focus group interview schedule  
A schedule of questions was prepared (Appendix VII). Questions were based 
around existing methods of including patients in B-R assessment as well as the 
challenges of involving patients and potential solutions. The questions were 
divided into three topics: 
 
• Topic 1: Disease overview 
• Topic 2: Patient perspectives on current approaches to treatment 
• Topic 3: B-R assessment methodology 
 
Local applications for approval 
Firstly, agreement was sought from those departments that would ultimately 
be involved in the study at Guy’s and St Thomas’ hospitals: the clinical research 
facilities and the following clinics: renal dialysis, oncology, rheumatology, and 
HIV.  The set-up of phase III of the research commenced only after agreement 
had been sought from the lead consultants within each clinic. 
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Integrated Research Application System (IRAS) application 
An application was prepared using the integrated research application system 
(IRAS).  The IRAS form was finalised, signed electronically by the chief 
investigator and sponsor; and submitted to the ‘NRES Committee South East 
Coast – Surrey’ research ethics committee for ethical review.  
 
Study set-up 
The study was presented to the CRF review board of the clinical research 
facilities, and approval was obtained to complete the data collection and 
analysis within the clinical research facilities. A central study master file was 
maintained, which contained all study-related documentation. 
 
NHS Research Ethics Committee and Health Research Authority applications 
An NHS Research Ethics Application was prepared in line with the 
requirements of the Health Research Authority (HRA) and the national 
research ethics committee. 
 
Ethical implications 
The main ethical issue to highlight to the REC was interviewing patients during 
patient focus group meetings about how their medical condition affected them. 
There was potential that this could be distressing for some people, for example 
the pain they experienced or the way in which their treatments affected them, 
such as drug side effects. This may involve divulging issues of a sensitive 
nature, so these issues had to be approached carefully by the thesis author. It 
was made clear to all participants that they were free to discontinue at any 
time and that they did not need to divulge anything that they were not 
comfortable sharing. In addition, the patient focus groups were to be recorded, 
therefore some people may not have wished to discuss personal issues while 
being recorded.  
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Research ethics committee meeting 
The researcher presented the protocol, study documentation and the focus 
group schedules to the research ethics committee, who requested minor 
amendments and clarification. Once REC approval was received, the Health 
Research Authority (HRA) was also approached. Approvals were received and 
copies are stored in Appendix VIII.  
 
Research and Development (R&D) approval 
Once the REC and HRA had approved the study, the study was approved by the 
R&D department at Guy’s and St Thomas’ NHS Foundation Trust (Appendix 
VIII). Thus, recruitment could commence. 
 
Recruitment 
Patients were identified from clinics by doctors or research nurses based 
within each department. Patient medical records were reviewed before 
patients were approached by the clinical team who then advised the 
researcher who was eligible. The study was introduced to eligible patients 
during their routine clinical appointments by doctors or nurses responsible 
for their care. The doctor or nurse gained consent from the patient to be 
contacted by the researcher. The researcher sent an invitation letter and 
Patient Information Sheet with a tear off slip (and prepaid stamped addressed 
envelope) which patients sent back if they were interested in being contacted. 
Once the patient replied, the researcher booked the participant in to attend an 
appropriate patient focus group (depending on the condition that they had).  
 
Focus group logistics  
The meeting room was booked, the room prepared and the patients were 
informed of the date and time of the focus group. The researcher arranged for 
a taxi if the patient requested one, otherwise patients made their way to the 
meeting as agreed. 
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Consent  
Patients were consented on arrival, after confirming they were happy to move 
forward with the study. They signed the consent form while the researcher 
countersigned. A copy of the consent form was filed in the study file, one was 
added to the patient’s medical records and a copy was given to the patient. 
 
Focus groups 
Braun and Clarke (2013) describe how ‘using a group discussion format has 
become increasingly popular way to collect data from participants.’ The 
researcher leading the discussion is called a ‘moderator’, rather than an 
‘interviewer’ (Braun and Clarke, 2013). This is because the moderator is not 
asking direct questions as with an interview, although some questions of 
course in involved, but rather they lead a discussion; which is hopefully 
generated between participants (Braun and Clarke, 2013).  ‘Social interaction 
among group members is central to the method; it’s what distinguishes focus 
groups from methods like interviews or surveys’ (Braun and Clarke, 2013). 
They are potentially complex social situations, as participants interact with 
each other to make comments, ask questions and generate discussion (Braun 
and Clarke, 2013).  It was planned that each focus group would include up to 
five people at a time, based on both feedback received from the Patient and 
Public Involvement group at Guy’s hospital, and also that ‘smaller groups 
(three – eight participants) work best in gathering a rich discussion’ (Braun 
and Clarke, 2013). Refreshments were served at the onset of the focus group, 
to relax participants and for the moderator and participants to get to know 
each other, prior to the data collection stage. 
 
Recordings, transcription and coding of themes using QRS*NVIVO 
After data was collected via audio recordings and all interviews were 
complete, data was prepared for analysis, using orthographic transcription. 
The transcripts were uploaded to QRS*NIVO and the qualitative data were 
coded and the data allocated to nodes (theme categories).  
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Participants were given the opportunity to review transcripts and the 
emerging themes, to ensure the data was an adequate representation of their 
opinions. This process, known as ‘member checking’ is a form of quality 
control. 
 
Figure 6.1 - Screenshot of coding using QRS*NIVO 
 
 
Thematic analysis and generation of themes 
Thematic analysis, coding and the further validation of themes already 
identified was completed. After the transcription, it was important to read and 
to become familiar with the data, making note of items of potential interest. 
The next stage was to undertake coding, or organising the data into themes, 
before deciding upon which themes and sub-themes were prevalent across the 
dataset and which were of most importance. The themes identified were used 
to develop theory in phase III. 
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Results and thematic analysis 
 
Once the coding and analysis was complete, the data held on QRS*NIVO was 
reviewed and compared against those data collected in phase II. After analysis, 
the following themes continued to emerge, but this time from conversations 
with patients themselves. The themes were: 
 
• Objectivity of patients 
• Understanding and education 
• Insight into the patient’s experience  
• Motivation and ulterior motives of stakeholders 
 
Participants 
After being approached by their consultants, fifteen participants agreed to 
participate in the focus groups. Yet, on the days of the focus groups several 
participants decided they no longer wished to participate and did not turn up, 
therefore, only 8 participants moved forward into phase III (53%).   
 
Of the 8 participants whom participated in the focus groups and completed 
phase III of the research, 2 participants (25%) were recruited from the renal 
clinic, 2 participants (25%) were recruited from oncology, 2 participants 
(25%) were from the HIV department and 2 participants (25%) were 
recruited from rheumatology. All participants were allocated a pseudonym to 
protect their identify. The participants who participated in the focus groups 
are displayed in Table 6.1. 
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Table 6.1 – Focus group participants 
Participant’s 
Pseudonym 
Patient indication Primary therapy 
George Previous renal failure 
(post-transplant) 
Immunosuppressants  
Robert Previous renal failure 
(post-transplant) 
Immunosuppressants 
Peter Solid tumour Phase I chemotherapy 
 
Mary Solid tumour Phase I chemotherapy 
 
Henrietta HIV ART 
 
Charlie HIV ART 
 
Phil Psoriatic arthritis Phase III monoclonal antibody 
 
Susan Psoriatic arthritis Phase III monoclonal antibody 
 
 
Thematic analysis and the clarification of emerging themes 
After analysis, four themes previously identified continued to emerge. 
Throughout the focus groups, similar themes arose and also new information 
was identified. In addition to those candidate themes which were identified in 
phase II of the research, any new themes or concepts which emerged during 
phase III were also documented and investigated. The themes which were 
identified and verified will now be presented. A description of theme will be 
presented as will examples of how the theme emerged from the data, by 
quoting participants and presenting what they said and how they said it. 
Themes which were most prevalent are described first and any sub-themes 
which were identified are also described. 
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Theme III: Objectivity of patients 
The objectivity of patients was a concern for a number of stakeholders during 
phase II of the research. Yet, participants in the focus groups appreciated this 
risk. Peter, a participant from Focus Group 2 (Cancer) used the term 
‘objective’ without any prompt from the researcher, indicating he was well 
aware of this potential issue: 
 
Peter  To be honest with you, trying to be objective, I don't find it 
impacts me at all really, because the impact it would have...I have 
a part-time job, I work three days a week, I work Wednesday, 
Friday and Sunday. So, it's not impacting my work, because I 
come on a Tuesday, it's not that onerous, I'm not sitting in 
draughty corridors, you know, I'm talking about the, sort of, nuts 
and bolts of the treatment.  Obviously if I were working, I would 
say, well I've got to come...you know, one day a week I've got to 
come up here. 
 
    Focus Group 2 (Cancer) 
 
Peter also commented on emotion, which also supported that it appeared  
he understood the importance of objectivity, when he said: 
 
Peter  To be honest, through this data, because I think at that stage, 
when scientists and clinicians are doing that, evaluating, 
whatever, the last people you want in there are politicians and 
people with, like, an emotional interest in it.  Because you need 
the judgment of Solomon, don't you, really? 
 
Focus Group 2 (Cancer) 
 
Phil, a participant from Focus Group 4 (Psoriatic arthritis) also raised the 
issue of bias, especially when something may be to a person’s benefit, 
highlighting the theme of ‘motivation’ at the same time. 
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Phil  It’s hard to say when the medicines have had such a positive 
result, the bias, you can’t really see the bias because it’s 
obviously, it’s gonna benefit you.  But if there was something 
which was a bit, “Oh I’m not sure whether it works on 50% of 
the people,” so the bias would be more. 
 
Focus Group 4 (Psoriatic arthritis) 
 
Later, Phil also highlighted how all people have some element of bias: 
 
Phil That’s what I said early on, because we’re all gonna be bias to it 
because it’s got such a good result, to the point where if you are 
getting side effects you’re not gonna make much of a big deal out 
of them because you’ve got such a good benefit of the drugs. 
 
Focus Group 4 (Psoriatic arthritis) 
 
 
Theme IV: Understanding and education 
The theme of understand and education was another concern for stakeholders 
during phase II of the research. Examples did exist where patients may have 
misunderstood certain elements, however many patients came across as 
proactive and eager to learn about their condition, their treatment and how 
they could modify their lifestyle in order to improve their lives. 
 
During Focus Group 3 (HIV), Charlie described the challenges he faced of 
dealing with not only HIV but also diabetes too. On this subject, he questioned 
the understanding and education of all stakeholders, namely clinicians.  
 
Charlie  The HIV doctors will not tell you it’s the medication but when I 
went to Pain Management, the consultant told me it’s because of 
the HIV medication. 
Focus Group 3 (HIV) 
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Charlie was frustrated by the mixed messages he had received from different 
consultants about adverse events he had experienced.  Charlie described how, 
after not receiving a ‘straight answer’ from his consultant about whether ART 
and diabetes had some relationship, he used Google to investigate ART side 
effects himself: 
 
Charlie  Basically I got told off for doing it because I’m not supposed to 
do that because one could get called a hypochondriac and take 
everything on board and I said, “Well I’m not stupid.”  Anyway, I 
got GlaxoSmithKline actually published a booklet about HIV and 
diabetes in line with positive, the American version of positive 
UK and a positive life in America. 
 
Moderator Right. 
 
Charlie So I wrote to the man over here and I said, “Why isn’t this kind 
of booklet being published over here?”  “Well it’s not down to us, 
it’s down the Government.”  So, I wrote to the Government and 
they said, “Well it’s not down to us.”  I’m thinking, “Then who is 
it down to?”  As I said, when I gave that talk a couple of minutes 
ago where the doctor said, “Well we’ve known about the side-
effects since 1990.” I said. “That’s terrible, because there are 
some of us out there now that our lives are totally ruined.”   
 
Focus Group 3 (HIV) 
 
The patients’ understanding around risk perception and risk understanding 
was also discussed. Charlie described how he felt he wasn’t being listened to 
when he reported adverse events. 
 
Charlie  At the end of the day you’ve obviously been given that 
information and that must probably be…  Do you know what I 
wouldn’t have gone through what I had gone through but then 
again in one sense what I have gone is literally what I’m doing 
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now.  So, some good has come out of it.  Like I said, the side-
effects…you try and tell your HIV consultant. “Well it can’t be the 
antivirals.”  I’m thinking yeah, but we’re not stupid.  Of course, 
the medication is causing problems. 
 
Focus Group 3 (HIV) 
 
During Focus Group 3 (HIV), Henrietta argued she wouldn’t participate in 
research because of the perceived risks. 
 
Henrietta How would they know (what the risks are)? 
 
Moderator How would they know?  They don’t know. 
 
Henrietta Because if you remember this, what was it again, that tablet they 
used to give to women when they were pregnant…? 
 
Moderator  Oh, yeah, thalidomide.  
 
Henrietta Did they know?  No. 
 
It was interesting how an event so long ago still has such damaging effect on 
the perception of research as a whole. It underlines the importance of 
education, to assure patients that such events are, in fact, incredibly rare. The 
conversation continued: 
Moderator  Do you think we all focus on risks too much or do you think it’s 
important that we do? 
 
Charlie  No, I think it’s important that you do. 
 
Henrietta Hmm, it’s important. 
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Charlie I don’t think everybody weighs the risk up and then says, ‘no, I’m 
not going to take it.’ But, I think it’s just having that knowledge.  
Like I said, if I had been told I would get diabetes, at least I would 
have known what I was dealing with.’ 
 
Focus Group 3 (HIV) 
 
Charlie’s point was valid. When people are well informed and if something 
negative does happen, they are more likely to accept it. 
 
Theme V: Insight into the patient’s experience  
This theme was widely expanded during the focus groups, which would be 
expected. Thus, the theme was coded into two sub-themes: (1) disease 
progression and making lifestyle changes and (2) treatment and medication. 
George, from Focus Group 1 (Renal), was diagnosed with kidney disease in 
his twenties. He remembered the day when he first accepted that his condition 
was deteriorating. 
 
George I remember one day I was going to a meeting and I was crossing 
through Covent Garden and there was a guy walking towards 
me.  He was obviously a bit the worse for wear.  He was really 
quiet, and, well, he looked like he had been up all night.  As he 
came across my path he looked up at me and said, “Gaud, you 
look bloody awful, mate.”  I thought, oh great, thank you very 
much. And I did, I just felt exhausted all the time.’ 
 
Focus Group 1 (Renal) 
 
This real-life example was incredibly impactful. It is an example of why the 
patient’s perspective is so important, yet, this in itself presents a risk where 
other stakeholders may lose their objectivity, due to the emotive stories 
presented to them. Robert, the second patient who attended Focus Group 1 
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(Renal), had a similar real-life story to present when he noticed that he was 
unable to do as much at the gym as he could previously: 
 
Robert I thought to myself, “I’m struggling now.”  Things I used to use, 
twelve or fourteen kilos with, I was back down to about nines 
and eights, and I thought that this is getting probably because of 
my symptoms.  Anyway, a month before my operation I stopped 
going to the gym totally, because it was just silly.  I struggled to 
walk round there, which is about a mile.  That’s my warm-up is 
walking to the gym. 
Focus Group 1 (Renal) 
 
Robert also described the months leading up to his renal transplant. 
 
Robert  I was ballooning with the water but nothing else really so I was 
getting really sort of gaunt at the top and sort of really 
ballooning down there at the bottom end.  But, when all that 
corrected itself I found that I was still…I was about a stone 
lighter than so yeah, I was yeah about six, seven kilos lighter 
than I was when I…. Before I had the op.  And I thought “Well 
that’s good” because I really always wanted to lose that and I’ve 
managed to keep that off and although sometimes I’ll go up a kilo 
a kilo and a half I know that if I just watch what I eat for a week 
it will come back down again. 
 
Robert displayed real emotion on discussing the moment he discovered his 
wife’s kidney was a match: 
Focus Group 1 (Renal) 
  
Robert  When they said it, I was almost…  When my wife told me that I 
could have one (a kidney) and it was really good match, I went 
outside and cried and I’m feeling well enough now. 
Focus Group 1 (Renal) 
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After asking about how he considered his post-transplant medication, Robert 
confirmed he didn’t even think about it.  
 
Robert As far as I was concerned, I don’t think it made any difference to 
me. The tablets I took were for the conditions that I was taking 
them for. 
 
Focus Group 1 (Renal) 
 
George described how his perspective changed when compared the time 
before and after his transplant. 
 
George  Pre-transplant, […] you’re ready to give almost anything 
a go.  Post-transplant, when things are going very well, I 
think it would be much more difficult a decision.  I know 
there is this talk that they’ve been looking at doing a trial 
of taking people off immune suppressants altogether 
because some people have had to come off for other 
reasons’ 
 
This is a good example of ‘insight’ but it also demonstrates the ‘objectivity of 
the patient.’ There is a risk that patients ‘will give almost anything a go,’ 
therefore this is a risk in B-R discussions, as objectivity is essential. Peter, from 
Focus Group 2 (Cancer) described how he’d already experienced sensitivity 
since commenced his chemotherapy for a solid tumour. 
 
 
Peter  (I had his drug) I still haven't got the feeling back in my 
fingertips 100% now, and my toes.  That cup, you know, 
(pointing to a plastic cup) if you put a temperature on it, it would 
be whatever, but if I pick that cup up, when I was (on the drug), 
that would slightly burn through coldness.  
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Moderator Really? Sensitivity? 
 
Peter  Yeah. Anything out of the fridge, it would be like holding a kettle, 
because your fingertips go numb.  When you drink, your throat, 
it doesn't swell, but it feels like it's swelling, and it feels like you 
can't swallow - and like I say, that is a new beneficial drug.  Now 
if this, in any way, can replace that sort of thing, that would be 
stunning.  If me taking this forms part of information that stops 
one person feeling like that, it would be...yeah, so worth it - yeah.  
So, yeah, part of it is: I hope to god it helps me.  But if it doesn't, 
I would take some comfort, not insubstantial comfort, from it 
helping the general picture, even if it was negative to positive, to 
be honest. 
 
Peter went on to describe the environment where he received his 
chemotherapy, and now they impacted on the way he felt. 
 
Peter For a clinician, or whatever, a Carer, the bigger picture must be 
helpful.  You know, I've been fortunate so far, touch wood, I've 
been in rooms and I've been eight times out of ten the youngest 
person in there.  So, consequently, I haven't had the 
complications that other people have, and I've seen some people 
privately struggle with sickness during their treatment.  I think 
the treatment is geared up to plug you in, you know, in the nicest 
possible way, I don't mean...  
 
Moderator  Yeah, I know. 
Peter I would not sit here and go: right, it's horrible this, it's horrible 
that. But there's a certain impersonality to it, because a nurse 
has gotta get through the day, you've just gotta treat people.  But 
maybe this sort of thing would... 
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Moderator Consider people's thoughts and feelings a bit more, makes it a 
bit more personal? 
 
Peter Yeah.  I mean, maybe some guys...guys, people refuse treatment 
and the reason, I think it's irrational, and that could be avoided 
simply.’ 
 
Focus Group 2 (Cancer) 
 
Mary described how she hadn’t really had any symptoms from her cancer, 
however, the treatment was far worse.  
 
 
Mary   I never really had symptoms, it was just a fluke that they found 
it really, so I suppose chemo’s been the worst.  
 
Focus Group 2 (Cancer) 
 
Yet, as Mary’s disease progressed, she did notice symptoms develop. 
 
Mary  It’s breathlessness as well with me, but that is easing slightly.  
I’m not saying I’m back to normal, but I can do a little bit more 
and then sit down.  I can do something for a little bit longer 
period now then, so it must be easing off slightly.  I’ve had three 
lots of chemo.  The first two were bearable, but the third one, I’d 
only had a couple and then before Christmas, I was admitted to 
hospital and I had sepsis and pneumonia and I was isolated for 
a couple of weeks.  When I started it again, instead of having 
100% of it, they dropped it to 80%... 
 
Moderator Reduced dose? 
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Mary  Yes, and well, I was still sick and that, but it was bearable.   
 
Focus Group 2 (Cancer) 
 
Mary described the sickness she’d experienced as part of treatment. She 
mentioned her family were always there to watch over her. 
 
Mary  But, it made me laugh really, because they’ve always said I’m 
very loud when I’m being sick, you see.  So, my husband rang my 
son on the train and he said, oh how’s mum, so he said, well, she’s 
been sick but she’s not very loud this time. So, we always laugh 
about that.  
 
Focus Group 2 (Cancer) 
It was positive to hear that Mary was able to use humour to deal with her 
situation. Charlie, in Focus Group 3 (HIV), had strong opinions about the 
‘generation below’ referring to the younger generation. 
 
Charlie  But, it is scary that this recent thing about the generation below 
is that could be HIV on medication.  That they see it as, “Oh our 
lives are going to be wonderful.”  Yeah, they might be for a 
shorter time but you’re looking at the long-term and that what’s 
scares me. 
 
Moderator Oh really? 
 
Charlie  I feel like it, yeah, I feel like just handing our sweets and I’ve said 
that before. I’ve said it’s like the doctors couldn’t 
decide…doctors are handing out packets of Smarties and they’re 
not taking into consideration the side-effects. I’m thinking well 
fine and like I said at the end of the day, the HIV consultants do 
need to be responsible because they’re the ones that are handing 
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out the medication. If a patient goes to them and says it’s causing 
A, B, and C, they should take it more seriously. 
 
Focus Group 3 (HIV) 
 
Henrietta, Focus Group 3 (HIV), described her experience of having an eye 
infection. After complaining several times, she described her experience: 
 
Henrietta Nothing happened, until I got so upset I started crying. They 
called in the eye specialist and I was […] treated…well, they said 
I had shingles in it, so I was treated.  I’ve had a glaucoma 
removed two times. It didn’t work, until, in the end, I just 
decided I cannot take it anymore, so I had it removed (her left 
eye).    
Focus Group 3 (HIV) 
Susan, in Focus Group 4 (Psoriatic arthritis), described her diagnosis and 
the experience she had over the years. 
 
Susan I’ve had psoriasis for, I think about, ‘cause I’m quite old, so I’ve 
had it about 40, 40 odd years.  And initially it wasn’t, probably 
even more than that, it wasn’t really diagnosed then you know, 
it was sort of like a creeping eczema I think they thought it was, 
and then it was eventually diagnosed, and I had various 
treatments.  And in the last, I think two years, going to 
rheumatology I was referred to rheumatology because I’d been 
complaining for a long time that every time I got out of bed my 
feet were like a pair of flippers, you know, I couldn’t get up and 
down the stairs comfortably, I could walk but it was 
uncomfortable.  My hands for a long time had felt like cotton 
wool and they’d ache as well, and I couldn’t open things 
properly, they were very, very, woolly, and I was then diagnosed 
with psoriatic arthritis.  Is that enough at the moment? 
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Moderator  Please continue… 
 
Susan It was and, you know, at the moment when you think back all 
those years I’ve looked like a lizard really, you know, I could cry 
sometimes when I think now, “You’re clear,” and people don’t 
realise, they treat you like lepers, you know, I’ve had many 
people in the past saying, “Is it catching?”  You get, that’s quite 
common, it’s quite common, you get, “Eurgh what’s that?”  And 
it’s awful really. […] and it does affect you mentally. 
 
Focus Group 4 (Psoriatic arthritis) 
 
Phil and Susan compared their experiences in Focus Group 4 (Psoriatic  
arthritis). 
 
Phil I was kind of fortunate that most of my psoriasis wasn’t really 
visible. 
 
Susan But, it doesn’t matter whether it’s visible or not because you’ve 
still got pain, whether it’s externally or internally, it’s there and 
you feel just as rotten, whether you can see it or not. 
 
Phil  Yes that’s right. 
 
Susan  And, it does affect you mentally. 
 
Phil  You, kind of, forget, well for me anyway, the way the medicines  
   for me I kind of forget how bad it was and I’ve… 
 
Susan Yeah, I can imagine and I mean, since we started this 
programme, I can’t believe how quickly it actually changed. It 
wouldn’t completely go, and some on the rear end, so it wasn’t 
completely gone but it was much, much better than what I’d had.  
‘Cause psoriasis is a funny thing anyway, you know, you might 
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be completely covered, or relatively, more than 50% of your 
body, but it can go away and just come back somewhere else that 
it hasn’t been before, so you’re constantly not sure what’s gonna 
happen next, and having the methotrexate I think with this 
secukinumab has worked quite well really. 
 
Focus Group 4 (Psoriatic arthritis) 
 
Phil and Susan compared their experiences of treatment and they also 
commented on how positive they found the focus group experience. 
 
Susan  Even if they had two patients, it’s better than one patient. 
 
Phil   Yeah, ‘cause even just between us two it sounds like there’s quite 
a different, you have very different symptoms to me, and the 
medicines working slightly different by the sounds of it, but 
we’re getting the same results. 
 
Focus Group 4 (Psoriatic arthritis) 
 
Theme VI: Motivation and ulterior motives of stakeholders 
The motivation of patient involvement was a particularly interesting theme 
when viewed from the patient’s perspective. 
 
Peter The thing is, once you start the trial, you're on it for your own 
benefit, initially, but then obviously it works or it doesn't work, 
so the general use of the trial, kind of, becomes more important. 
Focus Group 2 (Cancer) 
Mary, the second patient who participated in Focus Group 2 (Cancer), had a 
similar perspective. 
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Mary  Well, (a) hoping it would help me and (b) for people in the 
future. […] I like to help other people but as I say, I suppose you 
put yourself first don’t you, you know, hoping it will help you.  
 
Focus Group 2 (Cancer) 
 
Charlie had a lot to say about how being an early user of ART, in Focus Group 
3 (HIV).  
 
Charlie I think what comes to mind will be…because we’ve already done 
that, we already participated.  So, really, we’ve helped society as 
such. People that are utterly the new patients, they are 
benefitting from what research they’ve done on us […] It 
(helping others) might make us feel better, but the psychological 
side of it, we might be taking the medication, and we’re not 
dropping dead, but the psychological side of it is that you’ve got 
to take your tablets every day, you’ve got to inject yourself.  Then 
socially you’ve got to help other people to understand it.’ 
 
Focus Group 3 (HIV) 
 
Phil and Susan discussed their perspectives on their motivations during 
Focus Group 4 (Rheumatology).  
 
Phil I think personal first, because I was…I’m self-employed, I make 
furniture and some of the job’s very physical so I’m lifting all the 
time, and I was starting to worry how long I was gonna be able 
to do my job for because of the way my psoriasis, the arthritis 
was going, that was gonna stop because I started to lose strength 
in my grip and lifting things, I could still lift but it was more 
difficult or painful, so yeah…and on your feet all day as well. 
 
Moderator Yeah, and yourself? 
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Susan I think I reiterate, personal really.  Purely from the point of view, 
if I was still working, ‘cause I’m retired now, but you want to 
feel…I mean I had an office type role, manager role, and you 
want to feel comfortable when you’re with other people, so it’s 
a bit of a selfish reason. 
 
Moderator It’s not selfish at all, not at all.  So, do you think that’s more how 
it affects you physically, or do you think that’s more how it 
affects you mentally, socially as well? 
 
Phil  Yeah, it would have been… 
 
Moderator Or is it a bit of both? 
 
Susan I mean there’s an element of both with mental, because if you’ve 
got a, as you both know, if you’ve got a problem, an illness, or 
whatever you like to call it.  If you’ve got an illness and it’s 
causing you problems it can sometimes make you grumpy, you 
don’t wanna communicate, you start worrying about what it’s 
doing to you and then eventually it’s what you’re doing to other 
people, so you know it encompasses a number of things really, 
but really it’s the personal thing, if you feel good everything’s 
rosy. 
 
Phil There is the social side of things that people, if it’s not a visible 
disease, people don’t really have any sympathy for you. 
 
Susan  No, course they don’t. 
Focus Group 4 (Psoriatic arthritis) 
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Demographics characteristics of the participants 
 
Figure 6.2 – Age range of focus group participants 
 
 
Ethnicity of focus group participants 
Six participants described themselves as ‘White British,’ one participant 
‘African-Caribbean’ and one participant ‘dual heritage’ (of White British and 
African -Caribbean descent).  
 
Figure 6.3 – Gender of focus group participants 
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Figure 6.4 – Highest level of education (Focus group participants)
 
 
When comparing the demographics of the participants from phase I and 
compare them against those participants who took part in phase III, there is a 
clear difference. Regulatory agencies, pharmaceutical companies and patient 
advocacy groups are notably staffed by white, educated, middle class 
individuals. The patients recruited for phase III were from a range of 
educational backgrounds and the group was more diverse (notably that no 
ethnic minorities were represented in phase I and II). 
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Discussion 
 
Through the focus groups, rich data was obtained on the patients’ perspective 
on their involvement in B-R discussions. The objective of phase III of the 
research study was to (4) using focus groups to disclose the views of patients, 
identify the patient’s perspective; to include an insight into their condition and 
their opinions on patient involvement in benefit-risk assessment discussions. 
In order to achieve this overall aim, several sub-objectives were established. 
The first sub-objective was to evaluate the patient’s perspective on their 
involvement in the B-R assessment of medicines. This was an interesting 
element of phase III, as patients with different diseases definitely had unique 
perspectives. It was surmised that even patients with the same disease would 
be willing to accept different levels of risk depending on their prognosis, 
adding even more complexity to ensuring an adequate method of patient 
selection.  
 
The second sub-objective was to obtain rich data on the themes which were 
generated in previous phases of the research. Rich data were obtained; 
especially regarding Theme V: Insight into the patient’s experience. Patients 
provided evidence for both sides of the argument. On one side, Peter 
demonstrated his ability to remain objective, even while undergoing the 
challenges associated with chemotherapy. Charlie, on the other hand, had a 
strong personality and, although he made some good points, his inherent bias 
was also apparent. Patients demonstrated their ability to understand B-R, 
whatever their education level, yet, Henrietta highlighted the point that 
patients can be influenced by previous negative press, such as the coverage of 
the thalidomide disaster. Mary was able to remain positive, even when she was 
experiencing terrible side effects. Phil and Susan offered a unique experience 
for the researcher, when they were able to compare and contrast their 
individual experiences regarding their secukinumab treatment. This had 
particular meaning for the researcher, which will be further described in 
Chapter VII. 
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The third subobjective was to compare and contrast the perspective of 
patients with different diseases. It was clear that different patients had lots in 
common.  did appear that what they were prepared to accept with regards to 
treatment depended on the severity of their disease and the patient’s 
prognosis. Patients with severe disease would be more likely to accept higher 
risks than those with less severe conditions, which is not surprising. The 
patients’ accounts described during phase III were all interesting and unique 
experiences which demonstrate the importance of the patient’s perspective, 
and how insight in the patient’s experience would contribute greatly to B-R 
discussions. The proposed framework, developed as a result of this PhD 
research, will be presented and critiqued in Chapter VII. 
 
Summary 
 
• Patients are able to offer a unique perspective into their condition, their 
treatment regimen and their overall outlook with regards to their 
treatment decisions. 
 
• With regards to the objectivity of patients, evidence was provided for both 
sides of the argument.  
 
• Patients can be influenced by other sources such as negative press, 
therefore adequate training and education is essential.  
 
• Different patient groups offer completely unique perspectives, depending 
on their condition, its severity and the treatment which they’re undergoing. 
 
• Patients remain robust in their mission to face their challenges and would 
be important partners in future B-R initiatives. Still, Patients with severe 
disease could perhaps be more likely to accept higher risks than those with 
less severe conditions. 
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Chapter VII: General discussion 
and conclusions 
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Introduction  
 
It is recognised that when considering those personnel involved in the B-R 
assessment of medicines, there are several important stakeholders; including 
pharmaceutical companies and regulatory agencies. It is also accepted that the 
inclusion of patients is essential for understanding what is most important to 
them with regards to the disease and treatment. The crucial question raised 
from this PhD research, however, was should patients be involved in B-R 
assessment? Indeed they should, yet stakeholders must recognise the risks 
and challenges which emerge from their inclusion. 
 
When this programme of PhD research commenced in 2013, multiple 
stakeholders were in the process of publishing their plans to develop methods 
for involving patients in B-R assessment. By the end of 2017, several projects 
had been completed, including the FDA’s Patient Focused Drug Development 
Initiative. Still, a framework, developed solely for the purpose of involving 
patients in B-R assessment was at the time of writing this thesis still not 
forthcoming. This was due to the complexity of the topic itself and the different 
approaches available. The fact that different organisations were implementing 
varying strategies indicated there was an opportunity to make a novel 
contribution to this topic. Both regulatory agencies and pharmaceutical 
companies are under increasing pressure to improve transparency and 
accountability with regards to their internal processes regarding B-R. By 
involving patients in these initiatives, they have an opportunity to develop B-
R systems and processes for the better. A survey conducted with regulatory 
agencies, pharmaceutical companies and patient advocacy groups confirmed 
that one major challenge for stakeholders was the lack of an internationally 
accepted, validated framework. The ultimate aim of this research was to  
describe, analyse and synthesise study data to ultimately propose a semi-
quantitative framework for involving patients in the benefit-risk assessment 
of medicines, using a Grounded Theory (GT) approach. The framework which 
was therefore developed is displayed subsequently. 
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A proposed semi-quantitative framework for involving patients in the B-
R assessment of medicines, incorporating patient views as key criteria in 
decision-making 
 
Stage 1 – Identification of B-R assessment requiring the patients’ 
perspective 
 
• A pharmaceutical company selects the drug which requires a B-R 
assessment. This is likely to be a drug which is undertaking or about to 
undertake phase III clinical trials, including pivotal trials.  
 
As soon as company procedures are implemented with regards to B-R 
assessment, a representative would indicate that a ‘patients’ perspective 
report’ is required.  
 
Stage 2 - Identification of stakeholders  
 
• The pharmaceutical company must identify all relevant stakeholders.  
 
• At this point, an independent moderator should be appointed to oversee 
the process. The independent moderator undertakes a stakeholder 
assessment, which involves the identification and assessment of patient 
advocacy group(s) and patient representative(s).  
 
• In addition, the independent moderator identifies hospitals which acted as 
clinical trial sites for clinical trials of the drug. As part of the Independent 
identification of stakeholders, investigators involved in undertaking the 
trials are contacted. 
 
• Patient advocacy group(s) and patient representative(s) confirm their 
participation in the initiative. 
 
• Hospital investigators confirm their participation in the initiative. 
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Stage 3 - Benefit-risk stakeholder collaboration meeting 
 
• The pharmaceutical company invites all relevant stakeholders to a 
stakeholder collaboration meeting. This is where the pharmaceutical 
company can present the drug to patient advocate(s) and patient 
representative(s), provide education and training on the topic of B-R 
assessment and on the drug’s benefit and risk profile. There would also be 
the opportunity for patient advocacy groups(s) and patient 
representative(s) to undertake qualitative preference elicitation work, 
which aids the training but also provides additional information for 
inclusion within the final analysis and reporting. 
 
• The following topics could be included on the agenda: 
 
o Introductions and overview of initiative and drug to be assessed. 
o Education and training session for patient advocacy group(s) and 
patient representative(s). 
o Presentation of a comparison of benefit-risk profiles and an analysis 
of benefit-risk rankings (quantitative). 
o Patient advocacy group(s) and patient representative(s) undertake 
quantitative B-R rankings with support from statisticians and 
regulatory personnel. 
o Question and answer session with active patient advocacy group 
and patient representative participation. 
 
Stage 4 – Patient stakeholder focus groups  
 
• Investigator involvement is essential. It is proposed that those sites which 
participated in clinical trials of the drug requiring B-R assessment are 
invited to participate.  
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• A simple process of selection would be required which would be monitored 
by the independent moderator. 
 
• Regulatory (HRA), REC and local R&D approval (in the UK) would be 
required before a patient stakeholder focus group could be undertaken at 
site. It is proposed that the investigator and their team are tasked with 
recruitment and logistics. The independent moderator would then agree a 
date and time with all stakeholders. 
 
• The day event at each hospital would include a short education and 
training session, assisted by the patient advocacy group(s) and patient 
representative(s). 
 
• A qualitative focus group would be undertaken (moderated by the 
independent moderator). 
 
Stage 5 – Analysis and reporting  
 
• The focus group data would be transcribed and thematic analysis would be 
undertaken. Themes would be identified which would subsequently be 
presented back to participants for member checking (quality control). 
 
• Once complete, the themes would then be confirmed and documented and 
a patients’ perspective report is generated. 
 
• The reports would be combined with any other patient elicitation data 
already collected, such as preference elicitation study data. However, the 
core elements of the report would be: 
o Summary report of the quantitative benefit-risk rankings from the 
B-R stakeholder collaboration meeting. 
o Qualitative thematic analysis, highlighting themes most important 
to patients. 
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Stage 6 – Presentation to regulatory agencies 
 
• A report would be published and submitted to regulatory agency for 
consideration during B-R discussions. Patient advocate(s) and patient(s) 
should be given the opportunity to attend B-R discussion meetings. 
 
• The B-R discussions will be undertaken as per standard process, yet the 
addition of the patients’ perspective report, has the potential to add new 
information to the assessment, which will benefit regulatory professionals 
with their decision-making. 
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General discussion 
 
Each stage of the proposed semi-quantitative framework was developed based 
on key findings from this research study. In addition to the research findings, 
several stages of the framework were also informed by discussions with key 
stakeholders during the conduct of this PhD research programme.  
 
Participants highlighted the need to use both quantitative and qualitative 
approaches with their patient participation initiatives. However, the methods 
of data collection for these two different approaches require additional 
resources. It would be recommended that preference elicitation studies are 
completed in the first instance, to generate quantitative data which could then 
be presented to stakeholders. Groups such as the IMI-PROTECT (2018) 
consortium and PREFER (2018) have already undertaken research into this 
area.  
 
Stage 1 of the proposed framework would involve the identification of a 
relevant B-R assessment requiring the patients’ perspective. The FDA (2013) 
highlighted that not all B-R discussions would benefit from patient 
involvement, however this is perhaps an approach that will change with time. 
Some decision-making is straightforward, in that the evidence is clear about 
whether or not a drug should be licenced, for example when data shows a drug 
is clearly efficacious. A number of participants who completed the surveys 
highlighted that there are often cases where the decision would be greatly 
enhanced by the patients’ perspective, and it is more likely that borderline 
cases – examples where decision-making is perhaps not so simple – are 
probably the most appropriate examples of when the proposed framework 
could be applied. 
 
Stage 2 of the proposed framework highlighted the need for the identification 
of all relevant stakeholders – including representatives from industry, patient 
advocates and appropriately-selected patients. Topic 1 of the semi-structured 
interviews investigated the methods of involving patients in B-R analysis. 
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Participants recognised the difficulty in not only identifying and selecting the 
right patients to be involved, but they also had concerns about the methods 
utilised to include them.  As part of the stakeholder identification, an 
independent moderator should be employed.  
 
The independent moderator would be pivotal to the entire process, as they 
would be key to the way in which the proposed framework is employed. As a 
result, the recruitment of this individual would require careful consideration 
from all stakeholders. The moderator could potentially alter the direction of 
benefit-risk discussions due to the way in which they moderate, therefore they 
would need a specific set of skills and experience. Perhaps individuals without 
any previous healthcare experience would be the most appropriate to employ, 
in order to truly ensure independence. They would however need skills in 
undertaking interviews and focus groups, therefore individuals with a 
background in market research could be best placed for this role. 
 
The independent moderator would apply transparency to all levels of the 
process, including the methods used to identify stakeholders. Part of their 
responsibilities would be to ensure a wide range of patient advocacy group(s) 
and patient representative(s) are involved. After reviewing the PREFER 
consortium’s website (2018), it can be seen that they have recently taken a 
similar approach to the methods utilised within this thesis. Their programmes 
were recently commenced, verifying the research strategy which was 
implemented within this programme of PhD research. The PREFER 
consortium also consider stakeholder involvement essential as well as the 
education and training of patient advocates, patient representatives and 
patients. The commencement of this initiative is a positive development. Not 
only does verify the research strategy employed, but it sheds light on the 
enormity of the challenge at hand.  
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The only way to ensure an adequate framework for involving patients in B-R 
assessment is developed is with the engagement of multiple international 
stakeholders. As a result, this PhD research adds a unique contribution to the 
topic of patient involvement in benefit-risk assessment, but also to the 
literature surrounding patient and public involvement more generally. 
 
The involvement of patient advocacy groups and patient representatives has 
been shown to be valuable not only in benefit-risk considerations, especially 
from the standpoint of risk tolerability, but it has also aided the decision-
making process (Bernabe et al., 2014). Still, this research has discovered 
examples where patient advocates were perhaps not the most appropriate 
stakeholder to involve. There were examples identified during this 
programme of research where patient advocates and patient representatives 
perhaps no longer put the needs of patients first; where their motivation for 
participation may have even been self-serving. For the researcher, the term 
‘expert patient’ was a challenge. On one hand, examples were discovered of 
patient advocates who described themselves as ‘expert patients.’ They were in 
fact experts. Experts in their disease, experts in their treatment and an expert 
in ethics and with a high moral standing. They were clearly committed to 
ensuring the voice of others patients are heard. In these cases, the term ‘expert 
patient’ is appropriate. However, there were also examples where an ‘expert 
patient’ had perhaps demonstrated bias or possibly even had ulterior motives. 
This issue arose multiple times within the data, and it was the perspective of 
several participants - including those who represent patient advocacy groups 
- so it does raise the question about the motivations of some individuals.  This 
is a concern.  
 
Corrie and Finch (2015) described how the expert patient can add value to the 
process, but they rarely highlighted any potential risks of employing expert 
patients. The information gathered during the conduct of this programme of 
PhD research regarding ‘expert patients’ is a unique contribution to the wider 
topic of patient and public involvement. The literature rarely criticises expert 
patients and actively promotes their use. Corrie and Finch (2015) also 
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suggested that the popularity of using expert patients will only increase. This 
is inevitable, so it is argued that there must be an honest discussion about the 
issues that may become more prevalent as a result. All stakeholders, including 
expert patients, may introduce a level of bias. Thus, it is essential that this is 
recognised by all parties and it is documented, debated and eventually 
accepted as an inevitable consequence of involving different people within a 
process. 
 
Stage 3 of the proposed framework described the benefit-risk collaboration 
meeting. The data collected during all stages of this programme of research 
highlighted how education and training are essential for the proposed 
framework to be a success. The NIHR (2013) have demonstrated multiple 
examples of how PPI initiatives can be improved by not only training patient 
representatives but also the researchers conducting research. A training and 
educational element will therefore be necessary, in order for all stakeholders 
to positively contribute to benefit-risk discussions.  
 
Stage 4 of the proposed framework described the patient stakeholder focus 
groups. The independent moderator would be responsible for moderating the 
patient focus groups within this stage of the framework, in collaboration with 
patient advocacy group(s) and patient representative(s). The patient 
advocate, who would have already received training during the B-R 
assessment stakeholder collaboration meeting, would assist the moderator in 
explaining concepts to patients during the qualitative focus groups. In fact, it 
would be expected that information is shared between patient advocate and 
patient in advance of the patient focus group, to help with their training and 
awareness.  
 
As limited research had already been completed within this area, for example 
the project undertaken by Bernabe et al. (2014), in the research plan it was 
decided to expand the types of organisations involved, not only focusing on 
European organisations but also involving several international stakeholders.  
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Bernabe et al. (2014) reported how patient advocacy groups and patient 
representatives were involved at the EMA. However, there was no distinction 
between patient advocacy groups, charities or any examples of direct contact 
with patients. This was verified during the research, when direct telephone 
contact was made with the lead researcher of the paper. It was confirmed that 
only patient advocacy groups who were existing members of the EMA’s 
network were involved. It is understood that using pre-existing links are 
essential to aid new initiatives, however, any aspects where potential bias can 
be brought into the process must be limited.  
 
Hoos et al. (2015) recognised that improved patient involvement has the 
potential to drive medicines development, as more relevant and impactful 
patient outcomes will increase efficiency, whilst make the drug lifecycle more 
productive (Hoos et al., 2015). This research group also identified the barriers 
to patient participation, many of which were also highlighted within this 
programme of PhD research. Education and training, communication, 
perceptions and cultural barriers were all highlighted as important elements 
to consider (Hoos et al., 2015). All of these elements emerged within this 
thesis. Although Hoos et al. (2015) noted cultural differences as an important 
point, this was expanded further within this programme of PhD research, 
offering a unique contribution to this topic. Previously, demographics were not 
considered when selecting patient advocates and patient representatives.  
 
Furthermore, the data obtained in the surveys suggested that regulatory 
agencies, pharmaceutical companies and patient advocacy groups were 
notably staffed by white, educated, middle-class individuals. Is this a true 
representation of society? It is clearly not. Some specific diseases are more 
prevalent in ethnic minority groups, therefore, would these groups be engaged 
in B-R discussions which affect them? Indeed, they must.  
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Patient identification and selection must be considered to verify that those 
patients included were drawn from a range of backgrounds. Tokenism is still 
a challenge which must be addressed. It appears that patient involvement 
representing all patients, regardless of their age, gender, ethnicity, sexual 
orientation, and religion, is still not forthcoming. It is essential that this is 
addressed.  
 
The patient’s voice report on patients who had received organ donation 
highlighted how patients were willing to accept different treatments before 
and after transplant, as their risk profile changed (FDA, 2016b). These themes 
were also identified in Focus Group 1 (Renal), completed in December 2014. 
This acts as validation of the processes used within the focus groups in Phase 
III of the research as the FDA produced similar data, two years after the 
completion of Focus Group 1 (Renal).   
 
The objectively of patients involved in B-R discussions was a theme which 
arose multiple times during phase I of the research in particular. Yet, the 
objectivity of other stakeholders was also seen as inadequate. Examples of bias 
were identified. Moving forward this must be considered by all stakeholders. 
With regards to the objectivity of patients, evidence was provided for both 
sides of the argument. Patients can be influenced by other sources such as 
negative press, therefore adequate training and education is essential.  
 
Issues still remain, and further research must be undertaken before a 
proposed framework could be accepted by industry and the regulators. The 
question now is not whether patients should be involved, as this is 
unequivocal, but how they can be incorporated into a benefit-risk assessment 
framework. It is argued that patients should not be involved in B-R decision-
making at the current time, yet their voice must be heard. There are multiple 
ways in which this can occur.  
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Several potential methods have been considered and investigated by the IMI 
PROTECT consortium (IMI PROTECT, 2015) although a validated method for 
including patients has not yet been forthcoming. Quantitative benefit-risk 
preference-elicitation methods include discrete choice experiments, rating 
scales, threshold technique, standard gamble and conjoint-analysis (Hauber et 
al. 2013; Hiligsman et al., 2014).  
 
It is anticipated that the proposed framework would be implemented in 
addition to other projects, such as quantitative preference elicitation studies, 
which are most effective with large samples of patients. Any proposed semi-
quantitative framework requires testing and validation. As some of the stages 
are theoretical at the point of writing, they would require testing and 
validation by a pharmaceutical company. It is possible that this could be 
undertaken as a future research project in collaboration with industry. 
 
When this PhD research was commenced it was proposed that a quantitative 
benefit-risk preference elicitation was developed as part of this thesis. It was 
not until the semi-structured interviews when it became apparent that this 
was not feasible. One participant, responsible for B-R across a multinational 
pharmaceutical company, commented how the development of such a method 
within their organisation involved almost twenty members of staff, working 
on this method alone.  
 
It was therefore accepted that although B-R preference elicitation data should 
be collected within the bounds of a semi-quantitative framework, it must be 
undertaken by those individuals with expertise in preference elicitation 
techniques. It was at this point that the researcher recognised the element of 
the proposed framework which could be effectively applied and tested was the 
generation of qualitative focus groups to discuss the concept of benefits and 
risks.  
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Still, the process was challenging and the outcomes were not those which were 
anticipated. A large proportion of the focus groups were spent explaining the 
concept of B-R assessment to participants. However, participants did 
understand the concept after a short discussion, and there were no examples 
where patients were not able to comprehend the discussion. As part of a semi-
quantitative framework, this element should be transferred to a point before 
the focus group, to ensure the time spent in the focus group is focused on the 
important topics: the patients’ perspective, their insight into their condition 
and how the drug under investigation affected them. 
 
The data collected during Stage 4 would then be transcribed, coded and a 
thematic analysis would be undertaken. Representatives from industry in 
collaboration with the patient advocate(s) and patient(s), with oversight from 
the moderator, would then write up a report, which would then be presented 
as part of a regulatory submission. The FDA (2013) have already 
acknowledged the inclusion of the patients’ perspective within their 
assessments, but the lack of an approved method has limited this work to date.  
 
If a universal framework for patient involvement is ever to be adopted, a 
unique partnership will be required between all relevant stakeholders; who 
will need to implement a change of culture within their organisations (Smith 
et al., 2016) In the context of B-R assessment, these methods could be greatly 
enhanced when combined with a qualitative element, which would be 
essential in allowing patients the opportunity to communicate what is most 
important to them.   
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Study limitations 
 
Survey coverage  
It was accepted that study participants were limited to a number of regulatory 
agencies, pharmaceutical companies and patient advocacy groups. However, 
as one participant represented the EMA, they had a large remit. The companies 
that did participate also represented some of the largest from industry. 
 
Semi-structured interviews 
Participates who did agree to continue to phase II may have already had a 
positive bias about involving patients in benefit-risk, therefore a larger sample 
may indicate that patient involvement is less acceptable than these data 
suggest. 
 
Patient focus group sample size 
It was recognised that the number of participants who attended each patient 
focus was lower than would normally be deemed accepted. It was planned for 
Focus Group 1 (Renal) to have two participants, acting as a pilot session. 
However, the intention was for at least four patients to attend each of Focus 
Groups 2-4. However, on the morning of the focus groups patients cancelled 
their attendance. In future, the researcher would ensure at least eight 
participants have confirmed attendance, meaning that at least four would 
attend in the event that participants pull out. Yet, on the other hand, Brain and 
Clarke (2006) confirm that focus groups with less participants do generate 
richer data, and after analysis it is argued that all four focus groups generated 
rich data which contributed to the overall aim of this thesis.  
 
It should also be noted that Focus Group 2 (Cancer) had unique challenges. 
Four patients agreed to participate, yet, as all four were receiving 
chemotherapy treatment on the unit on the day of the focus group, their 
availability changed, depending on their current condition and prioritising 
their treatment (which could be variable depending on adverse events).  
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This indicates how involving patients with serious disease, offers its own 
unique challenges, in addition to those already described.   
 
Qualitative research tends to use much smaller sample sizes when compared 
to quantitative research (Braun and Clarke, 2013). Nevertheless, although the 
sample size is of less importance, the concept of ‘saturation’ is paramount. 
With regards to the study aim, it was concluded that saturation was achieved, 
as the same concepts emerged throughout all three phases of the research. Yet, 
within the disease-specific discussions, there was an opportunity to further 
delve into the differences between patient groups, yet, due to time limitations, 
this was not possible. Future work could investigate this concept further. 
 
Member checking 
It was proposed that participants be given the opportunity to review the 
transcript and the emerging themes, to ensure the data was an adequate 
representation of their opinions. This process, known as ‘member checking’ is 
a form of quality control. However, six participants were unable to review their 
transcripts, therefore this was a limitation. Yet, the remaining participants 
accepted the transcript and agreed with the themes which were highlighted, 
therefore it can be assumed that the level of transcription and thematic 
analysis was adequate, as the majority accepted the findings. 
 
Recommendations and future work 
 
It is hoped that further collaborations could be generated between industry, 
patient advocacy groups(s) and patient representative(s), including 
collaboration with the PREFER consortium. There is potential for 
implementing education and training initiatives with all stakeholders on 
patient involvement in B-R. Also, future work should consider expanding the 
type of stakeholder involvement. Perhaps clinicians, nurses, pharmacists, 
family members and carers would all contribute greatly to B-R discussions. In 
addition, paediatrics could also be considered, involving parents and their 
children in focus group discussions. It is hoped that a future collaboration 
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project could be implemented, enabling the researcher to fully test and 
validate the proposed framework. Although challenges remain, further 
research on this topic presents a genuine opportunity to significantly enhance 
the current regulatory framework, which ultimately has real potential to 
benefit patients. 
 
Conclusions 
 
The question was not whether patients should be involved in B-R assessment, 
as this was unequivocal, but how they could be incorporated into a benefit-risk 
assessment framework. Based on the findings from this research, it is argued 
that - at the current time - patients should not be involved in B-R decision-
making. However, their voice must be heard. As systems and processes 
develop their voice will undoubtedly become louder, but there is still much to 
do before patients are able to become an equal partner in B-R decision-making.  
Furthermore, it appears that patient involvement representing all patients, 
regardless of their age, gender, ethnicity, sexual orientation, and religion, is 
still not forthcoming. This must be considered going forward. 
 
However, involving patients is essential, and there are multiple ways for this 
to happen. There are already multiple examples of successful PPI initiatives in 
healthcare (Corrie and Finch, 2015), which could be considered as best 
practices by the stakeholders involved in benefit-risk decision-making.  
 
The aim of this research was to propose a semi-quantitative framework for 
involving patients in the benefit-risk assessment of medicines. The framework 
which was developed offers a unique contribution to the topic of involving 
patients in B-R assessment.  It is hoped that a future collaboration project 
could be implemented, enabling the framework to be fully tested and 
validated. This research, accomplished over a similar time period to those 
projects completed by the regulatory agencies of the US and Europe, has 
produced a distinctive contribution to information in this area of research, 
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while also adding to the wider topic of patient and public involvement. The 
general consensus published by the FDA and EMA was that patients must be 
incorporated in the clinical trial and subsequent review process. However, the 
current study has generated findings some of which may well throw doubt on 
this assumption.  
 
It is essential that patients are given the opportunity to contribute to B-R 
decision-making, even if it is concluded that they should not be directly 
involved in the decision-making. As one participant put it, ‘we are all patients.’ 
An important consideration when undertaking qualitative research is the 
concept of reflexivity: how the researcher affects the social construct and 
ultimately the data which is collected. For the final focus group, the thesis 
author recognised this important consideration, when faced with a unique 
situation: moderating a focus group of patients who have the same disease and 
same drug treatment as the researcher. After experiencing a similar diagnosis 
and treatment, this was an interesting situation for the thesis author. Yet, in 
fact, Focus Group 4 was the most successful. By having something in common 
with participants, including the same insight into the patient’s experience, the 
thesis author was able to fully connect with the participants, resulting in a 
richer experience for all involved. The researcher recognises the risk of bias 
with this situation, yet, bias exists everywhere. As another participant 
highlighted ‘where there are humans, there is bias.’ It just has to be recognised 
and avoided as much as possible. 
 
As patients, our insights into our conditions and how treatments affect us, offer 
unique experiences and information, which could, perhaps, swing the decision 
pendulum either way during B-R discussions. There could be no contest. For 
example, in the case of a new drug for psoriatic arthritis, which has the 
potential to change the life of many patients who receive it, the B-R balance of 
such a product is clear. On the other hand, there are examples where expensive 
life-extending drugs, which may have a negligible efficacy, could give a specific 
sub-group of patients an extra few months of life.  
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The statistics and the quantitative analysis are essential; however, we need the 
patients’ perspective in these cases, to help us remember that the numbers we 
are reviewing refer to real people. They are mothers, fathers, sisters, brothers 
and grandparents. We must remember why this industry exists: to help people 
live longer, healthier and happier lives. Thus, all people deserve a say in what 
could ultimately change their life for the better; and give them valuable extra 
days, weeks or months to spend with the people most important to them. 
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In his quest to ensure that he approaches his fieldwork as well informed as possible I understand 
that Paul has engaged with colleagues working in various fields including that of PPI; for example, 
discussing for his purposes, the optimum number of patients for a focus group and the techniques 
he might use. 
 
Overall, although there are aspects of Paul’s research I am not qualified to comment upon, I do 
consider that he has designed his qualitative research with care and consideration of his 
participants, whilst maintaining a clear focus on the purpose of his research. 
 
I believe Paul to be a most thoughtful and reflexive researcher, as such I am certain that during his 
proposed pilot study he will fully engage with any issues that emerge and produce the changes 
that will enhance the experience for participants whilst producing robust data to move the field 
forward.  
 
  
Jean Harrington 
Research Fellow – Social Science 
NIHR Biomedical Research Centre at Guy’s and St Thomas’ NHS Trust and King’s College London 
Division of Health and Social Care Research 
                                                                                                                          www.kcl.ac.uk 
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Developing a model for the benefit-risk 
assessment of medicines, incorporating patient 
views as key criteria in decision making
Paul Cross
BRC Quality Assurance Manager, Guy’s and St Thomas’ 
PhD Student at Cardiff University (part-time)
Background
• Benefit-risk (B-R) assessment is a pivotal stage of the drug approval
process and is integral to the activities of regulatory agencies.
• A detailed assessment is completed using all available pre-clinical and
clinical data; to ensure the benefits of the product are carefully balanced
against the risks.
• Several frameworks / models exist, however no industry standard:
– Framework – e.g. the Benefit Risk Action Team (BRAT) framework
– Quantitative model – e.g. multi-criteria decision analysis and B-R value trees
– Semi-quantitative model – combination of data review and expert opinion
– Qualitative – detailed discussions / expert opinion of all stakeholders
Background
• Benefit-risk assessment is about communicating and making
sense of large volumes of data from numerous sources
• Its about breaking down and understanding a problem
• There is a need to communicate issues in a transparent,
rational and consistent way to aid in decision making
In this context the decision 
is whether the drug  should 
be approved/licensed  or 
not
Why involve patients?
• Tysabri (natalizumab) approved by FDA in 2004 for treatment of relapsing
remitting multiple sclerosis (RRMS)
• 2005: Drug license was suspended because of associated incidence of PML, a rare
neurological disorder
• 2006: Reintroduced due to high patient demand, but with strict minimisation
measures
• 2009: Further cases of PML postmarketing, B-R was reassessed and Tysabri still has
approval.
• Current research about involving patients
– US Food and Drug Administration (FDA) first agency to highlight the need to
incorporate patients in regulatory B-R assessment
– European Medicines Agency via the ‘PROTECT consortium’: B-R methodology
and Patient-Public Involvement
– Utrecht University Medical Centre, The Netherlands: patient representative
involvement in benefit-risk assessment tasks of the EMA
Aim
• To develop and validate a semi-quantitative model for the benefit-risk
assessment of medicines, incorporating patient views as key criteria in
decision making
Decision
Study overview / methodology
Regulatory Agencies
Pharmaceutical Companies
Patient Advocate Groups
Patients
Online questionnaires Focus Groups
Semi-structured 
interviews
Development of a B-R assessment model Test and validate
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Questionnaire Recruitment 
• Pharmaceutical Companies and Regulatory Agencies
Questionnaire – Pharma/Regulator
• 19 participants completed to date
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Organisation Type
Questionnaire – Pharma/Regulator
• Which of the following best describes the system 
used by your organisation for assessing the B-R of a 
new medicine?
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Questionnaire – Pharma/Regulator
• Who is involved?
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Questionnaire – Pharma/Regulator
• There is a need to incorporate the views of patient representatives and/or 
patient advocate groups into benefit-risk analysis (i.e. they can answer 
questions, provide general information on conditions and treatments, 
state their opinions but no do anything more than this).
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Strongly disagree Disagree Neutral Agree Strongly agree
Patients in B-R analysis
Questionnaire – Pharma/Regulator
• Reasons for your answer:
• Disagree: “Patients are able to provide clear insight into patient reported 
outcomes and endpoints that can be utilised for this purpose”
• Neutral: “If there is no established procedure I would refrain from 
inclusion of patient representatives”
• Agree: “The decision pendulum swings both ways, patients could provide 
compelling testimony to keep a drug on market which they feel is worth 
the risk. Quantitatively it may not be”
• Strongly agree: “It’s important to understand which endpoints are 
important to patients” / “Experts cannot provide the needed trade-off 
between benefits and risks”
Questionnaire – Pharma/Regulator
• There is a need to incorporate the views of patients into benefit-risk 
analysis (i.e. they can answer questions, provide general information on 
conditions and treatments, state their opinions but no do anything more 
than this).
0
1
2
3
4
5
6
7
8
9
10
11
Strongly
disagree
Disagree Neutral Agree Strongly agree
Patients in B-R analysis
Questionnaire – Pharma/Regulator
• Reasons for your answer:
• Disagree: “Information from patients could be taken into account but the 
analysis should be made by specialists and be data driven”
• Neutral: “It is difficult to provide complex information, in ways that can be 
properly understood”
• Agree: “Depending on their conditions, e.g. cognitive issues, terminal 
state etc.), patients may be unable to exercise their rights, hence their 
caregivers should always be able to stand in for them”
• Strongly agree: “Patients’ subjective views on benefit-risk tradeoffs are a 
prerequisite to making a decision that is for their best interests”
Questionnaire – Pharma/Regulator
• What do you perceive are the barriers to involving patients in the benefit-
risk assessment process? Please provide reasons for your answer.
“Methodology of 
obtaining patient 
views”
“Structural and logistical 
challenges in doing 
something new in the 
pharmaceutical company.”
“Lack of internal expertise 
in preference elicitation 
methods and application. 
Acceptance of preference 
elicitation by regulators.”
“Lack of established 
best practice on how 
to do this”
“Some countries would have to 
deal with pre-existing structures 
such as insurance companies 
who might be resistant to a 
bigger involvement of patients 
making decisions”
“Identification of 
correct patients 
that are able to 
give input”
Questionnaire Recruitment 
• Patient Advocate Groups
Questionnaire – Patient Advocates
• 20 participants completed to date
0
2
4
6
8
10
12
14
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Questionnaire – Patient Advocates
• Do you feel there is a need to incorporate patient views into the benefit-
risk assessment of medicines? Please provide reasons for your answer.
“Of course, often the side effects 
are not taken in consideration and 
for the patient the quality of life is 
very important”
“Yes. Patients are often 
more willing to tolerate 
risks that non-patients 
would not.”
“Its important to understand what 
risks patients see as being 
important to them. What you may 
see as a minor risk may be crucial 
to patients.”
Questionnaire – Patient Advocates
• What is your personal opinion on the perceived risks/negatives of 
incorporating patient views in benefit-risk assessment?
“There is a possibility that patients 
could accept medicines with lower 
level of benefits due to absence of 
alternatives”
“Some patient views will be very 
personal and subjective – their 
experience may outweigh a 
perception of possible benefits 
to others from a treatment if 
theirs was inappropriately 
delivered and their experience 
was poor”“While many individuals can well represent 
their own views and experiences, unless 
they have contact with others living with 
the same condition/disability they may not 
be able to represent a wider experience”
Questionnaire - limitations
• Still awaiting completion of some 
questionnaires, response or non-response 
bias?
• Have not yet reached saturation – further 
data to collect and analysis still to undertake
Next steps
• Semi-structured interviews with pharma, 
regulators and patient advocates 
• Patient Focus Groups
– Oncology
– Rheumatology 
– Cardiovascular
– Allergy
– Renal (1 pilot focus group already completed)
– HIV
Summary
• In general, a cross-section of pharmaceutical 
companies and regulators who participated were 
generally supportive of involving patients in B-R 
assessment. 
• Patient advocates are supportive of becoming more 
aware of and involved in B-R assessment initiatives.
• However, a number of logistical and procedural 
challenges remain, which must be addressed before 
this can be realised.
References
• Bernabe, R. (2014), Patient representatives’ contributions to the benefit-risk 
assessment tasks of the European Medicines Agency scientific committees, British 
Journal of Clinical Pharmacology, 78:6, 1248-1256.
• Food and Drug Administration. (2013a). Structured Approach to Benefit-Risk 
Assessment in Drug Regulatory Decision-Making. Draft PDUFA V Implementation 
Plan – February 2013 (Fiscal Years 2013-2017). Available at: 
http://www.fda.gov/downloads/forindustry/userfees/prescriptiondruguserfee/uc
m329758.pdf last accessed, 28th April 2015.
• Mol. P. G. M. et al, (2014). Understanding drug preferences, different perspectives, 
British Journal of Clinical Pharmacology, 79:6, 978-987.
• Nixon, R. and the Pharmacoepidemiological Research on Outcomes of 
Therapeutics by a European Consortium (PROTECT), (2012). Benefit Risk Analysis, 
experience of using the BRAT framework. PSI conference.
Thank you for listening
Any questions?
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Developing and validating a semi-quantitative model for the benefit-risk 
assessment of medicines, 
incorporating patient views as key criteria in decision making 
Paul Ian Cross (Guy’s and St Thomas’, London, UK) and Robert D. Sewell (Cardiff University)
The authors acknowledge financial support from the Department of Health via the National Institute for Health Research (NIHR) Biomedical Research Centre and the 
NIHR Clinical Research Facility for Experimental Medicine awards to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London.
•Before new medicines are approved
for marketing, safety, quality and
efficacy must be assessed. A detailed
assessment is completed using all
available data; to ensure the benefits
of the product are carefully balanced
against the risks.
•Benefit-risk (B-R) assessment is a
vital stage of the drug approval
process.
•Involving patients in B-R assessment
is a recent innovation. Patients may
view benefits and risks very differently
when compared with the views of
pharmaceutical companies or
regulatory assessors. However, there
has been limited research in this area.
•The aim of this research is to develop
and validate a method to include
patients in this process.
•Scoping exercise - Questionnaires
were submitted to (1) - pharmaceutical
companies, E.U. and G20 country
regulatory agencies and (2) - patient
advocacy groups and charities across
Europe, using SurveyMonkey, to obtain
their opinions on involving patients in B-
R assessment.
•Data was collected on country (Fig. 1),
type of organisation (pharmaceutical
company or regulator, Fig. 2) and the
type of benefit-risk assessment model /
system used (qualitative, semi-
quantitative or quantitative; Fig. 3),
need for patient involvement (Fig. 4)
and who is currently involved (Fig. 5).
•Data is currently informing the
development of a semi-quantitative
model for including patients in B-R
assessment.
•This involves thematic analysis of
qualitative focus group data in
combination with quantitative ranking of
benefits and risks.
Introduction / Aim
Methodology
Results
Conclusions
Questionnaire to Pharmaceutical companies and Regulatory Agencies
Figure 1 – Global distribution of responders Figure 2 – Organisation Type Figure 3 – The majority of responders use 
a semi-quantitative approach
•Considering most participants agreed or strongly agreed that patients should be involved, only 9% responded that patients were currently
incorporated in the B-R assessment process at their organisation.
•Challenges included a deficiency of established best practice and a lack of validated methods. Patient identification and selection were also key
challenges and in addition, how the selected group could be representative.
•Patient Advocacy groups were very supportive of further patient involvement. Qualitative focus groups are currently underway with patients at
Guy’s and St Thomas’ Hospitals in London, UK. Therefore further research needs to be completed and the project is ongoing.
Figure 5 – Only 9% of responders involve patients at the current time
Decision
Question: What are the barriers to involving patients?
“Methodology of 
obtaining patient 
views”
“Lack of established 
best practice on how to 
do this”
“Structural and logistical 
challenges in doing 
something new in the 
pharmaceutical company”
“Some countries would 
have to deal with pre-
existing structures, such 
as insurance companies 
who might be resistant to 
a bigger involvement of 
patients making 
decisions”
“Identification of 
correct patients that 
are able to give input”
“Lack of internal expertise in preference elicitation 
methods and application. Acceptance of 
preference elicitation by regulators”
Figure 4 – The majority of responses agreed that patients 
should be involved
Questionnaire to Pharmaceutical companies and Regulatory Agencies: Responses
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Statement  
The Chief Investigator, Principal Investigator, Sponsor and representatives from the 
participating site have discussed this protocol. The Chief Investigator and Investigator Site 
Staff agree to adhere to this protocol at all times. 
 
Professor Robert Sewell 
Chief Investigator 
Date: 22/09/2014 
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2. Background  
Before a new medicine is approved for marketing, data must be available to demonstrate 
the safety and efficacy of the medicinal product. A detailed assessment is completed using 
all available pre-clinical and clinical data; to ensure the benefits of the product are carefully 
balanced against the risks. Benefit-risk assessment is a pivotal stage of the drug approval 
process and is integral to the activities of regulatory agencies (ICH, 2012). ‘The 
assessment of the benefit-risk in the context of a new drug application is a central element 
of the scientific assessment of a marketing authorisation’ (EMA, 2007).   
 
There are a number of different models and frameworks used by pharmaceutical 
companies and regulators for benefit-risk analysis. For example, the multi criteria decision 
analysis (MCDA) model ‘uses an algorithm that combines value judgements along multiple 
dimensions’ (EMA, 2007). ‘Decision analysis’ is widely used throughout the world of 
business as well as within various government departments. The MCDA model involves 
developing a list of relevant benefit and risk criteria that can then be used for determining a 
benefit-risk profile. These criteria are then organised depending on their importance in the 
overall decision (termed ‘weighting’). Each criterion can be scored, weighted and then a 
calculation can be undertaken using computer software (EMA, 2007).  
 
In their book, ‘Benefit-Risk Appraisal of Medicines, A systematic approach to decision-
making’ published in 2009, Mussen, Salek and Walker presented a detailed case for the 
reasons why a standardised model for benefit-risk assessment of medicines is required. 
Previously there was no standardised model for such an assessment and therefore 
regulatory agencies and industry conducted the benefit-risk assessment process using a 
variety of models (Mussen, Salek and Walker, 2007a, 2007b). By developing a 
standardised model it was hoped that a more reproducible system could be implemented, 
which may one day become the industry standard. This quantitative model, based around 
multi-criteria decision analysis, was devised and validated by the authors.  
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Regulators agree that there is a great deal of work to be done with regards to 
standardising benefit-risk analysis. The United States Food and Drug Administration (FDA) 
are also working on this issue and are in fact leading the way at the current time. In their 
recent publication ‘Structured Approach to Benefit-Risk Assessment in Drug Regulatory 
Decision-Making’ (FDA, 2013) they write their case for a complete review of their current 
systems and processes. The authors state that ‘in the past, some FDA stakeholders have 
indicated that there is room for improvement in the clarity and transparency of FDA’s 
benefit-risk assessment in human drug review’ (FDA, 2013).  
 
Although the FDA publish documentation related to their decision-making online, they also 
point out that ‘while FDA takes great care to clearly explain the reasoning behind a 
regulatory decision in these documents, the clinical analysis may not always be readily 
understood by a broad audience who may wish to understand FDA’s thinking’ (FDA, 
2013).  
 
The stakeholders involved in benefit-risk analysis include pharmaceutical companies, 
regulatory agencies as well as healthcare professionals such as prescribers (Mussen, 
Salek and Walker, 2009). One key area that is addressed by Mussen, Salek and Walker 
(2009) is the different perspectives of professionals involved in benefit-risk analysis. 
Different stakeholders have both different perspectives and different priorities depending 
on the nature of their work. ‘Since benefit-risk assessment is essentially a value 
judgement, it will inevitably be prone to a number of biases’ (Mussen, Salek and Walker, 
2009). These biases are informed by the nature of the work of the individual making the 
assessment. In addition, different individuals may give different views at different times, 
even when presented with the same data; which demonstrates the subjective nature of the 
assessment process (Mussen, Salek and Walker, 2009).   
 
The primary objective of pharmaceutical companies is to demonstrate sufficient efficacy of 
a product to receive regulatory approval (Mussen, Salek and Walker, 2009). In addition, 
the company would hope that healthcare professionals prescribe the medicine (Mussen, 
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Salek and Walker, 2009). A pharmaceutical company may accept a risk depending on how 
likely that risk will affect the chance of the product receiving a licence. They also consider 
the possibility of legal liability in the event of serious adverse events (Mussen, Salek and 
Walker, 2009).  ‘Regulatory agencies view the benefits and risks for the nation as a whole 
rather than for individuals’ (Spilker, 1994; Cromie, 1997). They require evidence for an 
established and favourable safety profile. They will also consider the cost of a treatment by 
comparing it to treatment alternatives; as the pharmacoeconomics of medicines also 
influence their decision-making. Regulators ‘usually focus on risks more than benefits due 
to their responsibility for ensuring public health’ (Mussen, Salek and Walker, 2009).  
 
In general, ‘regulators tend to view patients as incompetent to judge risks and benefits,’ 
(Mussen, Salek and Walker, 2009). However, this is unfounded and opinions are 
changing. Patient-Public Involvement (PPI) has become increasingly important in recent 
years. As patients become more informed, due to increased access to information such as 
via the internet, their well-informed opinions are increasingly important. The National 
Institute of Health Research (NIHR) explain that PPI ‘can lead to better research that is 
more focussed on the needs of patients and can accelerate the transfer of research 
evidence into practice’ (NIHR, 2013). Patients and the public can participate in research in 
a number of ways. Most often, their participation involves working with researchers, 
clinicians, research managers and health economists.  
 
Involving patients in the research process is not a new concept; however involving patients 
in the area of benefit-risk analysis is relatively new. It has been identified by several parties 
that patients have a vital role to play as they can offer a different and unique point of view. 
This is because patients, who are taking medications for their various conditions, may view 
benefits and risks very differently when compared against the views of pharmaceutical 
companies or regulatory assessors. Patients tend to ‘view benefits in terms of how their 
symptoms improve, by how much and for how long’ (Mussen, Salek and Walker, 2009). 
Patients view risks with respect to their chance of having an adverse reaction or a lack of 
effect resulting in a relapse of their underlying disease (Mussen, Salek and Walker, 2009). 
It is important to note that patients may sometimes ‘focus excessively on any risks to 
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which their attention is drawn’ (Mussen, Salek and Walker, 2009). The patients’ 
‘perception of risk may therefore be different from actual risk’ (Mussen, Salek and Walker, 
2009). However, patients’ opinions are ‘often very personal, subjective value judgements 
that can only be based on religious, philosophical, and social values’ (Veatch, 1993). It is 
therefore essential that a patient is given all the information and not only information on the 
benefits or side-effects, so that they can make an unbiased decision. 
 
Many factors influence how a patient views the benefit and risks of a particular treatment. 
They are ‘influenced by the media, by healthcare professionals and by friends and family’ 
(Mussen, Salek and Walker, 2009). This makes for a very complex picture, which can be 
unique to every individual. In addition, the way in which a patient makes their assessment 
is strongly influenced by the way in which the data is presented. For example, if side 
effects have been emphasised by a healthcare professional, when in fact the risk is low, 
the patient may still be influenced negatively.  
 
It is clear from recent developments that patient-focused drug development is going to 
continue to gain in popularity and will be used more widely. The FDA’s project aim’s to 
address how to use the patient’s perspective to inform their decision making but to also 
include their views in a benefit-risk assessment process. Mullard (2013) states that once 
patient opinions have been collected, using a variety of means (from meetings or from 
surveys), ‘the next challenge becomes turning anecdotal reports into structured and 
meaningfully [sic] data that can be incorporated into an assessment framework’ (Mullard, 
2013; FDA, 2013b). Involving patients in regulatory decision-making could greatly improve 
and enhance the benefit-risk assessment process.  Leong et al (2013) demonstrates that 
there is need for a universal benefit-risk assessment framework which incorporates a 
variety of different tools and methods, which could be the industry and regulatory standard.  
 
Leong (2013) also highlights the need to incorporate patients into any agreed process. It is 
on this basis that this research project will investigate how qualitative data obtained 
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directly from patients themselves can be incorporated into a benefit-risk assessment 
model. The model developed during this study will need to be tested and validated.  
 
3. Aim  
 
To develop and validate a semi-quantitative model for the benefit-risk assessment of 
medicines, to incorporate patient views as key criteria in decision-making. 
 
4. Objectives  
 
 Complete a literature review on the current models of benefit-risk assessment of 
medicines, focusing on the inclusion of patient views as key criteria. 
 
 Identify the current models/processes used by regulators to incorporate patient views 
into benefit-risk analysis (US, EU, UK). 
 
 Undertake patient focus groups to collect information directly from patients and analyse 
this data using NVivo to identify the key themes and issues.  
 
 Propose a method to incorporate this qualitative data into a model or framework for the 
benefit-risk assessment of medicines. 
 
 Test and validate the method. 
 
 Obtain further information from regulators, pharmaceutical companies and patient 
expert groups by collecting data via questionnaire. 
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5. Methodology - Qualitative Study - Patient Focus Groups 
 
Recruitment  
The study would be introduced to patients during their routine clinical appointments by 
doctors or nurses responsible for their care. The doctor or nurse will gain approval from 
the patient to be contacted. The researcher will send an invitation letter and Patient 
Information Sheet with a tear off slip (and prepaid stamped addressed envelope) to send 
back to the researcher, indicating whether they would like to participate or not. Patients will 
be given about ten days to think about participating before the researcher contacts them to 
confirm that they are happy to continue (except for those patients who have already 
informed the researcher that they do not wish to participate). Once the patient is happy to 
participate, the researcher will book the participant in to attend an appropriate patient 
focus group (depending on the condition that they have).  
 
Patient Focus Groups 
Initially, a pilot group will be developed which will help to determine how the patient focus 
groups will be run and also to gain insight into how this type of meeting will progress. In 
addition, work will be undertaken to determine the optimum number of participants in each 
group. Patient focus groups will be formed in several different indications including:  
 
 Cancer 
 Rheumatology 
 Cardiovascular 
 Inflammatory and Immune System 
 Renal and Urogenital 
 
Patient Focus Group Logistics 
The researcher will arrange for a taxi if the patient requests it, otherwise patients will visit 
the hospital at an arranged time. The patient focus group will consist of up to five people at 
a time. Refreshments will be served during the meeting. 
 
 
 
Consent  
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All patients will be asked to sign a consent form before the start of the patient focus group 
and the researcher will check that all patients are happy to continue and for their 
conversation to be recorded. 
 
Demographics Questionnaire 
Patients will be asked to complete a demographics questionnaire which may help the 
researcher in the subsequent data analysis. 
 
Group Discussion 
A list of prompts will be used by the researcher which will be followed when asking 
questions. By following the same standard it can be ensured that the conversation follows 
a similar agenda for each meeting, however the make-up of each group will be inherently 
unique, which is an important element in this type of qualitative study.  
 
Follow-up 
Patients may be contacted by telephone during the data analysis phase to confirm some 
aspects of their views/opinions if this becomes necessary. 
 
6. Selection of Subjects 
 
Inclusion Criteria 
 Male and female patients  
 Aged at least 18 years old 
 Prescribed medications and taking medicines for their conditions or patients who 
have previously taken medications for their conditions.  
 
Exclusion Criteria 
 Patients not willing to be recorded as part of a patient focus group meeting. 
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7. Data Collection 
 
The Trust has strict confidentiality policies which the researcher will adhere to at all times. 
The patient focus groups will be recorded and therefore it may be possible to identify 
patients from such recordings. All recordings will therefore be stored in a locked cabinet in 
a secure office. This data will be anonymised at the point of transcription to ensure 
confidentiality is maintained. Study data will be stored in a the Study Master File located in 
the Clinical Research Facilities at Guy's and St Thomas' NHS Foundation Trust for a 
minimum of fifteen years after the study is completed, in line with Cardiff University’s Data 
Retention Policy. 
 
8.  Data Analysis 
 
The qualitative data collected from the patient focus groups will be analysed using the 
'NVivo' software. This software will assist the researcher in interrogating the data, 
identifying both common themes and more subtle connections. A method will be 
developed after the focus group meeting stage of the study to incorporate this data into a 
benefit-risk assessment model or framework. 
 
9.  Statistics 
 
As this is a qualitative study, the sample size will be dependent on the point at which 
saturation occurs. There will be several patient focus groups of different indications 
included in this research study.   
 
10.  Informed Consent, Patient Confidentiality and Ethical Implications 
 
Patients may need to divulge sensitive, embarrassing or upsetting information to the 
researcher during the focus group meeting. Patients will be informed at the start of the 
meeting that they only need to provide as much information as they feel comfortable with. 
If they do not wish to answer a question, or discuss a topic any further, they are free to say 
so at any time. The researcher will ensure patients feel comfortable to continue by 
regularly checking on all individuals in the group. In the event that a patient becomes 
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distressed, they can discontinue at any time. Patients will be directed to the Guy’s and St 
Thomas’ NHS Foundation Trust Patient Advice and Liaison Service (PALS) in the event 
that they need further advice or guidance. 
 
Informed consent will be taken before commencing the patient focus group. However, the 
rights of patients will be respected at all times and it will be made clear to patients that 
their participation is voluntary and that  they are free to withdraw at any time, without giving 
a reason and without their medical care or legal rights being affected.  
 
Data will be anonymised at the point of transcription to ensure patient confidentiality is 
maintained at all times. Although there will be no direct benefit to those patients that are 
included, it is hoped that the findings from this study may help improve current processes 
and procedures, which may improve the care of patients in future. 
 
11. Research Study – second phase 
The second phase of this research will involve the development of a questionnaire which 
will be sent to patient advocate groups, regulators and pharmaceutical companies. This 
aspect of the research will be reviewed and approved by the Cardiff University Ethics 
Committee before it commences. 
 
12. Quality Assurance  
The study may be selected for monitoring or audit by the research Sponsor, Cardiff 
University or by the host organisation, Guy's and St Thomas' NHS Foundation Trust, in 
line with their research governance monitoring processes. 
 
13. Research Governance  
 
Research Ethics Committee (REC) and Research &Development (R&D) Approval 
The study will be reviewed and approved by an appropriate REC and by the R&D 
department at Guy’s and St Thomas’ NHS Foundation Trust.  
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The Research Governance Framework for Health and Social Care 
The study will be carried out in accordance with the NHS Research Governance 
Framework for Health and Social Care 2005.  
 
Insurance 
The Sponsor, Cardiff University, will provide trial Insurance and Indemnity. 
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Appendix VI: Semi-structured 
interview schedule   
 
 
 
 
 
 
 
 
Study Title: Developing a model to assess the benefits and risks of new medicines to 
incorporate patients’ views 
Semi-Structured Interview Schedule 
Version 1.0 dated 10th June 2015 
1. Welcome
• What is this research about?
• What will I do with the information collected?
2. Consent
3. Demographics Questionnaire
• Why do I need to collect this information?
4. Introductions
5. Interview Topics
Topic 1 – Benefit-risk (B-R) Assessment 
• Methods to include patients.
• What are the benefits of including patients?
• What are the challenges/negatives of including patients?
Topic 2 – Education 
• Should a patient’s level of education influence if they should be involved in B-R
analysis?
Topic 3 – Is there potential for bias? 
• Could patient involvement bias regulatory decisions?
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Appendix VII: Focus group 
schedule 
 
 
 
 
 
 
 
 
Version 1.0 – 14th July 2014 
Study Title: Developing a model to assess the benefits and risks of new 
medicines to incorporate patients’ views 
 
Patient Focus Group Schedule 
Version 1.0 dated 14th July 2014 
 
1. Welcome 
 
• What is this research about? 
• What will I do with the information collected? 
 
2. What is a focus group? 
 
• All views welcome to gather a diverse set of information. 
• We expect views to be different. 
 
3. Consent  
 
4. Demographics Questionnaire 
 
• Why do I need to collect this information? 
 
5. Rules  
 
• All members should be given the opportunity to give their views. 
• The meeting will be recorded, but this will be kept confidential. 
 
 
6. Introductions 
 
7. Focus Group Topics 
 
Topic 1 - Disease overview 
• Which symptoms have the most significant impact on your daily life? 
 
• Depending on what is raised, ask about particular symptoms in detail. 
 
• How do these symptoms impact on your daily life?  
 
• Are there specific activities that are important to you but that you cannot do 
because of these signs or symptoms?   
 
• How have your signs or symptoms changed over time? 
Version 1.0 – 14th July 2014 
Topic 2 - Patient Perspectives on Current Approaches to Treating 
• What are you currently doing to help treat the condition or its 
signs/symptoms?  
 
• How well does this current treatment regimen treat these symptoms?  
 
 
Topic 3 – Scenario for Discussion 
• Imagine that you had the opportunity to consider participating in a clinical trial 
for an experimental therapy. What are you views on taking a new medicine? 
 
Topic 4 – Benefit / Risk Assessment 
• Discussion on the different ways that patient views could be incorporated.  
• How would you like this to happen e.g. visual (graphs, images)? 
 
 
Food and Drug Administration. (2013b). Patient-focused drug developed: Disease Area 
Meetings Planned for Fiscal Years 2013-2015. Available at: 
http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm347317.htm last 
accessed, 20th November 2013. 
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Appendix VIII: Research 
approvals  
 
 
 
 
SPPS Ethics Approval Notification (EAN) 8/9/14 v12 
 
 1 
 
Cardiff School of Pharmacy and Pharmaceutical Sciences,  
Research Ethics Approval  
 
This form has been signed by the School Research Ethics Officer as evidence that approval 
has been granted by the Cardiff School of Pharmacy and Pharmaceutical Sciences 
Research Ethics Committee for the following study:  
 
Project title: Developing and validating a semi-quantitative model for the benefit-
risk assessment of medicines, incorporating patient views as key 
criteria in decision making 
 
This is a/an: Undergraduate project  
 ERASMUS project  
 Postgraduate project  X 
 Staff project  
 
Name of researcher: 
(PG/Staff projects only) 
Paul Cross 
 
Name of supervisor(s): Prof R Sewell 
 
 
 
 
STATEMENT OF ETHICS APPROVAL  
 
This project has been considered and has been approved by the Cardiff 
School of Pharmacy and Pharmaceutical Sciences Research Ethics 
Committee 
Signed                     Name   R Price-Davies      Date _18/2/15__                 
(Chair, School Research Ethics Committee) 
 
 
 
NRES Committee South East Coast - Surrey 
Bristol Research Ethics Committee Centre 
Whitefriars 
Level 3, Block B 
Lewins Mead 
Bristol 
BS1 2NT 
 
Telephone: 0117 342 1380 
30 September 2014 
 
Professor Robert Sewell 
Professor of Pharmacology and Director of Dip Clinical Research 
Cardiff University 
Redwood Building 
King Edward VII Avenue 
Cardiff, Wales 
CF10 3NB 
 
 
Dear Professor Sewell  
 
Study title: Developing and validating a semi-quantitative model for 
the benefit-risk assessment of medicines, incorporating 
patient views as key criteria in decision making  
REC reference: 14/LO/1589 
Protocol number: N/A 
IRAS project ID: 143944 
 
Thank you for your letter of 08 September 2014, responding to the Committee’s request for 
further information on the above research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Chair. 
 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the 
date of this opinion letter.  Should you wish to provide a substitute contact point, require 
further information, or wish to make a request to postpone publication, please contact the 
REC Manager, Miss Gemma Oakes, nrescommittee.secoast-surrey@nhs.net. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation 
as revised, subject to the conditions specified below. 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of the 
study. 
 
Management permission or approval must be obtained from each host organisation prior to the 
start of the study at the site concerned. 
 
Management permission ("R&D approval") should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements. 
 
Guidance on applying for NHS permission for research is available in the Integrated Research 
Application System or at http://www.rdforum.nhs.uk.   
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites ("participant identification centre"), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation.  
 
Sponsors are not required to notify the Committee of approvals from host organisations 
 
Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on the IRAS filter page) must be registered 
on a publically accessible database within 6 weeks of recruitment of the first participant (for 
medical device studies, within the timeline determined by the current registration and publication 
trees).   
 
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g when submitting an amendment.  We will audit the registration details as part of 
the annual progress reporting process. 
 
To ensure transparency in research, we strongly recommend that all research is registered but 
for non-clinical trials this is not currently mandatory. 
 
If a sponsor wishes to contest the need for registration they should contact Catherine Blewett 
(catherineblewett@nhs.net), the HRA does not, however, expect exceptions to be made. 
Guidance on where to register is provided within IRAS.  
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
 
Ethical review of research sites 
 
NHS sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see 
"Conditions of the favourable opinion" below). 
 
Approved documents 
 
The final list of documents reviewed and approved by the Committee is as follows: 
Document   Version   Date   
Covering letter on headed paper  1  08 August 2014  
Covering letter on headed paper [Covering Letter ]  1  22 September 2014  
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only) [Certificate Number: Y016458QBE0114/165]  
  01 August 2014  
GP/consultant information sheets or letters  1  22 September 2014  
Interview schedules or topic guides for participants  1  14 July 2014  
IRAS Checklist XML [Checklist_18082014]    18 August 2014  
IRAS Checklist XML [Checklist_24092014]    24 September 2014  
Letter from sponsor  1  30 July 2014  
Letters of invitation to participant  2  22 September 2014  
Non-validated questionnaire [Demographics Questionnaire]  1  14 July 2014  
Other [Participant Consent Form - TRACKED CHANGES]  2  22 September 2014  
Other  2  22 September 2014  
Other [PhD Protocol TRACKED CHANGES]  2  22 September 2014  
Other [PIS - TRACKED CHANGES]  2  22 September 2014  
Participant consent form  2  22 September 2014  
Participant information sheet (PIS)  2  22 September 2014  
REC Application Form [REC_Form_18082014]    18 August 2014  
Referee's report or other scientific critique report  1  14 July 2014  
Research protocol or project proposal  2  22 September 2014  
Research protocol or project proposal  1  14 July 2014  
Summary CV for Chief Investigator (CI) [Prof Robert Sewell]  1  30 July 2014  
Summary CV for student [Paul Cross]  1  30 July 2014  
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK. 
 
After ethical review 
 
Reporting requirements 
 
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
 Notifying substantial amendments 
 Adding new sites and investigators 
 Notification of serious breaches of the protocol 
 Progress and safety reports 
 Notifying the end of the study 
 
The HRA website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures. 
 
User Feedback 
 
The Health Research Authority is continually striving to provide a high quality service to all 
applicants and sponsors. You are invited to give your view of the service you have received and 
the application procedure. If you wish to make your views known please use the feedback form 
available on the HRA website: 
http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/    
 
HRA Training 
 
We are pleased to welcome researchers and R&D staff at our training days – see details at 
http://www.hra.nhs.uk/hra-training/   
 
14/LO/1589                          Please quote this number on all correspondence 
 
With the Committee’s best wishes for the success of this project. 
 
Yours sincerely 
 
pp Prof David Russell-Jones 
Chair 
 
Email: nrescommittee.secoast-surrey@nhs.net 
 
Enclosures:  “After ethical review – guidance for researchers” [SL-AR2] 
 
Copy to: Mrs K Ignatian, karen.ignatian@gstt.nhs.uk 
 
 
 
   
 
 
 
 
 
 
 
 



